Last updated: Apr 29, 2020 - 02:00 BST

Title Indication Intervention Actions PatientSelection Sponsor Collaborator Country StartDate EndDate Identifiers Phase Recruitment Status Sites Trial Duration Enrollment Count Contacts LastChanged
Collection of Biological Samples With Clinical Characterization of Covid-19 Patients Coronavirus disease 19 infection blood sampling alone Centre Hospitalier Intercommunal Creteil France 2020-05-01 2020-12-01 COVIGENET, NCT04363385 Phase Not Applicable Not yet recruiting 0 7 Months 500 Bernard MAITRE, Ph D, Bernard Maitre, Ph D, Isabelle HAU, MD 2020-04-28
CEDiD: COVID-19 Early Diagnosis in Doctors Coronavirus disease 19 infection Empatica E4 alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) King's College London Empatica Srl UK 2020-04-27 2020-05-27 CEDID STUDY STH, CEDiD, NCT04363489 Phase Not Applicable Not yet recruiting 0 1 Month 30 Dr Alexander Zargaran 2020-04-28
FatCovid-19: Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability Chronic fatigue syndrome, Coronavirus disease 19 infection actigraphy alone, blood test alone, electromyography alone, ergometer alone, magnetic resonance imaging alone, maximal effort test alone, neuromuscular evaluation alone, peripheral nerve stimulation alone, transcranial magnetic stimulation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Centre Hospitalier Universitaire de Saint Etienne Universite Jean Monnet France 2020-04-30 2021-12-31 2020-A00982-37, 20CH085, FatCovid-19, NCT04363606 Phase Not Applicable Not yet recruiting 0 20 Months 52 Guillaume THIERY, MD PhD, Jérome MOREL, MD PhD, Jérôme MOREL, MD PhD, Laurent GERGELE, MD, Lydia OUJAMAA, MD, Léonard FEASSON, MD PhD, Pascal GIRAUX, MD, Pierre CROISILLE, MD PhD 2020-04-28
MARIPOSA: A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia standard of care alone, tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Roche Holding AG 2020-05-04 2020-08-03 CA42481, MARIPOSA, NCT04363736 Phase 2 Clinical Not yet recruiting 0 3 Months 100 Clinical Trials 2020-04-28
COMBAT-COVID19: The COMBAT-COVID-19 Pilot Study Coronavirus disease 19 infection, Respiratory distress syndrome colchicine alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Maimonides Medical Center US 2020-04-23 2021-06-30 2020-04-12, COMBAT-COVID19, NCT04363437 Phase 2 Clinical Recruiting 0 14 Months 70 Antonios Likourezos, MA, MPH, Antonios Likourezos, MPH, Felix Yang, MD 2020-04-28
Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19 Coronavirus disease 19 infection, Respiratory failure anakinra alone Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Alabama at Birmingham US 2020-05-31 2020-12-31 CHATHAM-CYTOKINE COVID-19, NCT04362111 Phase 3 Clinical Not yet recruiting 0 7 Months 20 Angela Kendrach, Walter W Chatham, MD 2020-04-28
GETAFE: Lenalidomide Covid-19 Trial Coronavirus disease 19 infection lenalidomide plus low molecular weight heparin (LMWH) Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Universitario de Getafe Spain 2020-04-27 2020-12-31 COVID19-EC01, GETAFE, NCT04361643 Phase 4 Clinical Not yet recruiting 0 8 Months 120 Joaquin De Haro, MD 2020-04-28
Tocilizumab Treatment in Patients With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Nacional de Cancerologia de Mexico Roche Pharma (Schweiz) AG Mexico 2020-04-01 2020-08-01 INF-3343-20-22-1, NCT04363853 Phase 2 Clinical Recruiting 0 4 Months 200 Diana Flores Estrada, Oscar G Arrieta, MD M Sc., Oscar G Arrieta, Oncologist, Oscar Gerardo Arrieta Rodríguez 2020-04-28
The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection Coronavirus disease 19 infection Variable regimens including azithromycin , ceftriaxone , colchicine , lopinavir + ritonavir , omega-3 , selenium , tiamine , vitamin A , vitamin C , vitamin D HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-03-20 2020-05-30 NCT04360980, SBMU.IR.REC.165423 Phase 2 Clinical Recruiting 0 2 Months 80 CKDRC,SBMU, MD, Nooshin Dalili, Dr, Nooshin Dalili, MD, SBMU, nooshin dalili 2020-04-28
COVID 19 Biomarkers Coronavirus disease 19 infection, Respiratory distress syndrome University of British Columbia Canada 2020-03-30 2021-09-30 H20-00971, NCT04363008 Phase Not Applicable Recruiting 0 18 Months 150 Cheryl Wellington, PhD, Mypinder Sekhon, Mypinder Sekhon, MD 2020-04-28
The Impact of COVID-19 Pandemic on the Smoking Behavior of Young Smokers and the Youth Quitline Service in Hong Kong Coronavirus disease 19 infection, Nicotine dependence Telephone survey alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) The University of Hong Kong Hong Kong 2020-04-24 2020-06-30 NCT02758028_1, NCT04360863 Phase Not Applicable Recruiting 0 2 Months 150 Ho Cheung William Li, PhD, Long Kwan Ho, MPhil 2020-04-28
Psychological Impact of Corona Virus Among Doctors in Assiut University Hospitals Acute stress disorder, Coronavirus disease 19 infection, Psychiatric disorder Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assiut University Egypt 2020-05-31 2021-06-30 NCT04363229, PSHYCOLOGICAL IMPACT OF CORONA Phase Not Applicable Not yet recruiting 0 13 Months 250 Mariam Roshdy Elkhayat, mariam elkhayat, MD, shimaa abdelsameaa, MD 2020-04-28
Clinical Impact of Bactek-R in Subject With Mild Pneumonia Due to COVID-19 Infection Coronavirus disease 19 infection, Viral pneumonia MV-130 alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Inmunotek SL BioClever 2005 SL 2020-05-10 2020-07-31 MV130-SLG-35, NCT04363814 Phase 3 Clinical Not yet recruiting 0 2 Months 100 Guillermo Ángeles, Guillermo Ángeles, MD, M. Polanco, Martín Martín, MD, Miguel Casanovas, PhD, MD, Natalia García, Nicolas Batlle, MD, Raymundo Hernández 2020-04-28
ANACONDA: Anakinra for COVID-19 Respiratory Symptoms Coronavirus disease 19 infection anakinra alone, optimized standard of care alone Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Tours INSERM CIC-P 1415, Swedish Orphan Biovitrum AB 2020-04-27 2020-09-24 2020-001734-36, ANACONDA, ANACONDA-COVID-19, DR200111, NCT04364009 Phase 3 Clinical Not yet recruiting 0 4 Months 240 Alexandra AUDEMARD-VERGER, MD-PhD, Elodie MOUSSET 2020-04-28
A multicenter, randomized, double-blind, placebo-controlled, proof-of-concept, phase II trial of Metablok for lung and kidney inflammation in patients with COVID-19 Coronavirus disease 19 infection, Lung inflammation, Nephritis Metablok alone Dehydropeptidase-1 modulator Arch Biopartners Inc Phase 2 Clinical Planned 0 2020-04-28
LEAD COVID-19: The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Blood clotting disorder, Coronavirus disease 19 infection, Vitamin D deficiency aspirin alone, aspirin plus vitamin D Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Louisiana State University Health Sciences Center New Orleans US 2020-05-31 2020-12-31 20-063, LEAD COVID-19, NCT04363840 Phase 2 Clinical Not yet recruiting 0 7 Months 1080 Frank H Lau, MD 2020-04-28
Alterations in inflammatory and coagulation variables in COVID-19 patients Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum der Universität München, Klinik für Anaesthesiologie Germany 2020-04-27 20-296, DRKS00021581 Phase Not Applicable Recruiting 1 100 Tobias Nitschke 2020-04-28
AziA: Azithromycin + Amoxicillin/clavulanate versus Amoxicillin/clavulanate in COVID-19 Patients With Pneumonia in Non-intensive Unit Coronavirus disease 19 infection, Viral pneumonia Variable regimens including amoxicillin + clavulanate , azithromycin , cephalosporin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) CHU De Nantes France 2020-04-30 2020-07-30 AziA, NCT04363060, RC20_0168 Phase 3 Clinical Not yet recruiting 3 3 Months 104 Blandine RAMMAERT, MD, PhD, Emmanuel MONTASSIER, Romain DECOURS, MD, PhD, Vincent DUBEE, MD, PhD 2020-04-28
Identification of predictive biomarkers for severe progression of COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bundeswehrkrankenhaus Berlin Germany 2020-05-03 DRKS00021591, Eth-10/20 Phase Not Applicable Not yet recruiting 4 100 Christian Zobel, Maximilian Schreiner 2020-04-28
CytoResc: CytoSorb Rescue for COVID-19 Cytokine Storm Coronavirus disease 19 infection CytoSorb therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Charité Campus Virchow-Klinikum Germany 2020-05-01 CytoResc, DRKS00021447, EA1/069/20, U1111-1250-8875 Phase 2b Clinical Not yet recruiting 4 100 Philipp Enghardt, Torsten Slowinski 2020-04-28
Local Thermotherapy for Patients With Moderate Symptoms of COVID-19 Coronavirus disease 19 infection electric chest pad alone, electric cushion therapy alone, thermotherapy alone National Institute of Perinatology Directorate for Quality and Health Education, Juarez de Mexico Hospital, Laboratorios Silanes SA De CV Mexico 2020-04-30 2020-11-30 CONACYTF0005-2020-01S311971, NCT04363541 Phase Not Applicable Not yet recruiting 1 7 Months 298 Gabriela Ibañez Cervantes, PhD, Norma del Carmen Galindo Sevilla, PhD, Norma del Carmen Galindo-Sevilla 2020-04-28
COVID.PPI: The influence of proton pump inhibitor therapy on the clinical course of COVID-19 Coronavirus disease 19 infection proton pump inhibitors therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum der Albert-Ludwigs Universitaet Freiburg Germany 2020-05-01 254/20, COVID.PPI, DRKS00021523 Phase Not Applicable Not yet recruiting 1 200 Dominik Bettinger 2020-04-28
COVID-AGE: Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults Coronavirus disease 19 infection glucocorticoids alone, Variable regimens including anakinra , azithromycin , baricitinib , ceftriaxone , emtricitabine + tenofovir , hydroxychloroquine , lopinavir + ritonavir HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Type I IL-1 receptor antagonist Aged Adults (65-79 yrs), Elderly Adults (80 and over) Complejo Hospitalario Universitario de Albacete Spain 2020-04-20 2020-07-31 COVID-AGE, NCT04362943, PAS-BAR-2020-04 Phase 4 Clinical Recruiting 2 3 Months 576 Almudena Avendaño Céspedes, RN, PhD, Pedro Abizanda Soler, MD,PhD 2020-04-28
Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure clazakizumab alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Johns Hopkins University US 2020-04-30 2020-07-31 IRB00247932, NCT04363502 Phase 2 Clinical Not yet recruiting 0 3 Months 30 Nada Alachkar, MD, Russell Wesson, MD 2020-04-28
PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL Universita di Bologna Italy 2020-05-31 2021-03-31 IRST100.47, NCT04363827, PROTECT Phase 2 Clinical Not yet recruiting 1 10 Months 2300 Giovanni Martinelli, Prof., Oriana Nanni, Pierluigi Viale, Prof. 2020-04-28
Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19) Coronavirus disease 19 infection, Psychiatric disorder Face-to-face consultation alone, Phone consultation alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) Sun Yat-Sen University National Natural Science Foundation of China China 2020-03-18 2021-03-18 ChiCTR2000032095 Phase 0 Clinical Recruiting 1 12 Months 130 Peijia Liu 2020-04-28
The Danish Pre-HCQ COVID19 Dialysis Study: Hydroxychloroquine for prevention of COVID-19 in patients on chronic dialysis Coronavirus disease 19 infection Plaquenil alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rigshospitalet, Denmark Denmark 2020-04-15 2020-001257-51, The Danish Pre-HCQ COVID19 Dialysis Study Phase 3 Clinical Recruiting 1 568 Department of Nephrology 2132 2020-04-28
A Study for Efficacy and Safety of Live Biotherapeutic MRx-4DP0004 to Treat COVID-19 Coronavirus disease 19 infection MRx-0004 alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) 4D pharma plc UK 2020-05-31 2020-09-30 MRX-4DP0004-II-001, NCT04363372 Phase 2 Clinical Not yet recruiting 1 4 Months 90 Clinical Operations, Dinesh Saralaya, MBBS, MD, MRCP, FRCP 2020-04-28
Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill Coronavirus disease 19 infection Mycobacterium w alone, standard care therapy alone Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cadila Pharmaceuticals Ltd Council of Scientific and Industrial Research (India) 2020-04-30 2021-04-30 CRSC20006, NCT04358809 Phase 3 Clinical Not yet recruiting 0 12 Months 480 Anil Avhad, MBBS, Sanjay Patel, MBBS 2020-04-28
Comparison of VieScope versus Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions Coronavirus disease 19 infection, Edema Vie Scope laryngoscope alone, intubation alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Lazarski University Medical University of Bialystok, Poznan University of Medical Sciences, Wroclaw Medical University Poland 2020-01-20 2020-02-25 INT_PPE_2020_1, NCT04363775 Phase Not Applicable Completed 1 1 Month 35 Łukasz Szarpak 2020-04-28
Effect of plasma of patients recovered from Covid-19 versus control group on treatment of Covid-19 Coronavirus disease 19 infection Variable regimens including chloroquine , lopinavir , plasma , ritonavir Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Hamadan University of Medical Sciences Iran 2020-05-14 IR.UMSHA.REC.1399.037, IRCT20120215009014N353 Phase 2 Clinical Not yet recruiting 1 100 Dr. Ebrahim Jalili, Dr. Jalal Poorolajal, Dr. Saeid Bashirian, Samereh Ghelichkhani 2020-04-28
CAN-COVID: Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia Coronavirus disease 19 infection, Viral pneumonia standard of care alone, 5% dextrose plus canakinumab Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Novartis AG 2020-04-30 2020-10-05 2020-001370-30, CACZ885D2310, CAN-COVID, NCT04362813 Phase 3 Clinical Not yet recruiting 0 5 Months 450 Novartis Pharmaceuticals 2020-04-28
Dose-Finding Study of Ivermectin in the Treatment of COVID-19 Coronavirus disease 19 infection ivermectin alone, standard regimen therapy alone Chloride channel modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chistasazan notash fartak Iran 2020-05-04 IR.QUMS.REC.1399.017, IRCT20200408046987N1 Phase 3 Clinical Not yet recruiting 2 100 Dr Abbas Allami, Dr. Aliakbar Karami, Nematollah Gheibi, dr. morteza shakhs niaee 2020-04-28
COVIDAM: An open-label, single-center, randomized, controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Institute of Tropical Medicine Belgium 2020-04-12 2020-001417-21, COVIDAM, ITM202004 Phase 2 Clinical Recruiting 1 206 Yven Van Herrewege 2020-04-28
ONCOVID-19: Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection Coronavirus disease 19 infection, Hematological neoplasm, Solid tumor medical treatment alone Centre Leon Berard France 2020-04-02 2020-06-30 ET20-069, NCT04363632, ONCOVID-19 Phase Not Applicable Recruiting 0 2 Months 150 Julien GAUTIER, Souad ASSAAD, Dr 2020-04-28
ROCOCO: Serology COVID-19 From the Cornwall Hospital Union Coronavirus disease 19 infection immunoglobulin (IgG) Dia-Pro serological test alone, serum test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier de Cornouaille Centre Hospitalier Regional Universitaire de Brest France 2020-05-04 2020-11-04 29BRC20.0122, NCT04363593, ROCOCO Phase Not Applicable Not yet recruiting 1 6 Months 3200 Marie-Sarah FANGOUS, PH 2020-04-28
RESPIRE: Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia ruxolitinib alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) L'Azienda USL Nord Ovest Azienda Ospedaliera Universitaria Senese, Azienda Ospedaliero, Universitaria Pisana, Fondazione Toscana Gabriele Monasterio Italy 2020-04-25 2020-05-31 2020.COVID-19.RUXO106, NCT04361903, RESPIRE Phase Not Applicable Not yet recruiting 1 1 Month 13 Barbara Dr Meini, Pharmacist, Enrico Dr Capochiani, hematologist 2020-04-28
SJTRC: St. Jude Tracking of Viral and Host Factors Associated With COVID-19 Coronavirus disease 19 infection blood sampling alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) St Jude Children's Research Hospital US 2020-04-23 2025-03-20 NCT04362995, SJTRC, SJTRC Phase Not Applicable Recruiting 0 58 Months 1517 Aditya H. Gaur, MD, Jeremie H. Estepp, MD, Joshua Wolf, MBBS, PhD, FRACP, Paul G. Thomas, PhD 2020-04-28
COPEP: Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland Coronavirus disease 19 infection Plaquenil alone, lopinavir + ritonavir alone HIV protease inhibitor Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires De Geneve Switzerland 2020-04-30 2020-10-31 CCER 2020-00864, COPEP, NCT04364022 Phase 3 Clinical Recruiting 2 6 Months 420 Alexandra Calmy, Prof, Niklaus Labhardt, Prof 2020-04-28
OSACOVID-19: Obstructive Sleep Apnea and Covid-19 Outcomes Coronavirus disease 19 infection, Obstructive sleep apnea, Viral pneumonia polysomnography alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Koc University Turkey 2020-04-20 2020-12-31 2020.140.IRB1.030, NCT04363333, OSACOVID-19 Phase Not Applicable Not yet recruiting 1 8 Months 275 The OSACOVID-19 Study Group, Yeliz Celik, MSc, Yuksel Peker, MD, PhD 2020-04-28
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program Coronavirus disease 19 infection convalescent plasma alone, acetaminophen plus diphenhydramine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Arkansas 260944, NCT04363034 Phase Not Applicable Suspended 0 2020-04-28
A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) Coronavirus disease 19 infection, Viral pneumonia hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Oregon Health Sciences University OHSU Knight Cancer Institute US 2020-05-31 2021-06-30 NCT04363866, STUDY00021303 Phase 4 Clinical Not yet recruiting 0 13 Months 40 Brett Rodgers, Marcel Curlin, MD 2020-04-28
Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19 Coronavirus disease 19 infection, Rheumatoid arthritis Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Manchester UK 2020-05-01 2021-05-01 282566, NCT04363047 Phase Not Applicable Not yet recruiting 1 12 Months 125 Anne C Barton, Dr. Sebastien Viatte, Lynne Macrae 2020-04-28
AdoPro-Cov19: Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine Coronavirus disease 19 infection Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) Hôpital Cochin INSERM France 2020-05-31 2020-12-31 AdoPro-Cov19, NCT04363671, P20-670 Phase Not Applicable Not yet recruiting 1 7 Months 30 Carretier Emilie, Emilie Carretier, MD, Jonathan Lachal, PhD 2020-04-28
Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection Coronavirus disease 19 infection, Cough, Fever, Viral pneumonia Female Fundacion Infant Argentina 2020-05-01 2020-09-30 NCT04362956, PERINATAL COVID-19 Phase Not Applicable Not yet recruiting 1 5 Months 200 Gaston Ofman, Head of Perinatal Research, Gaston Ofman, MD 2020-04-28
A medical records based study for epidemiological characteristics of 88 patients with new coronavirus pneumonia (COVID-19) and its impact on severe disease Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) China 2020-01-29 2020-03-16 ChiCTR2000032239 Phase Not Applicable Recruiting 1 1 Month 88 Gu Xue 2020-04-28
CoCo-Neuro: Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders Coronavirus disease 19 infection, Neurological disease, Psychiatric disorder Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris 2020-04-24 2022-04-24 APHP200525, CoCo-Neuro, NCT04362930 Phase Not Applicable Not yet recruiting 0 24 Months 2000 CECILE DELORME, MD, Jean-Christophe CORVOL, MD,PHD 2020-04-28
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection Coronavirus disease 19 infection blood sampling alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National Cancer Institute National Institutes of Health Clinical Center US 2020-04-30 2024-12-01 20-C-0103, 200103, NCT04362865 Phase Not Applicable Recruiting 0 55 Months 150 Leah E Hoffman, R.N., Robert J Kreitman, M.D. 2020-04-28
A trial to evaluate plasma therapy for the treatment of COVID-19 patients Coronavirus disease 19 infection plasma therapy alone Korea Center for Disease Control & Prevention South Korea Phase 2 Clinical Recruiting 1 2 2020-04-28
A clinical trial of a plasma therapy for the treatment of patients with Covid-19 Coronavirus disease 19 infection plasma therapy alone Korea Center for Disease Control & Prevention South Korea 2020-07-31 Phase Not Applicable Planned 1 2020-04-28
Comparison of suspected or negative cases with confirmed cases of COVID-19 at Max Hospital Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Max Healthcare Institute Ltd, India India 2020-04-28 CTRI/2020/04/024772 Phase Not Applicable Not yet recruiting 1 90 Samreen Siddiqui, Sujeet Jha 2020-04-28
A trial to remotely monitor the cardiac safety of patients with COVID-19 via data gathered from Withings Move ECG Watch Cardiotoxicity drug-induced, Coronavirus disease 19 infection Withings Move ECG Watch alone Cardiologs Technologies France Phase Not Applicable Status not specified 1 Jean-Claude Deharo 2020-04-28
Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects Coronavirus disease 19 infection VPM-1002 alone Listeriolysin stimulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Serum Institute of India Privated Ltd India 2020-04-21 CTRI/2020/04/024749, SII-rBCG/COVID-19/IN-01 Phase 3 Clinical Not yet recruiting 5 5946 Dr Hitt Sharma, Dr Pradeep Dcosta, Dr Sanjay Lalwani, Dr Savita Verma, Dr Umesh Shaligram, Dr Vasudev Rajapantula, Dr Venkat Rao 2020-04-28
A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence Coronavirus disease 19 infection, Dyspepsia, Viral pneumonia Xiang-Sha-Liu-Jun pill alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Ezhou Hospital of traditional Chinese Medicine in Hubei Province State Administration of Traditional Chinese Medicine People's Republic of China China 2020-04-01 2020-06-30 ChiCTR2000032237, ChiMCTR2000003234 Phase Not Applicable Recruiting 1 3 Months 200 Hong Ying, Shao Xianzhi 2020-04-28
Clinical study for the potential impact of novel coronavirus pneumonia (COVID-19) on endocrine system Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shanghai Jiao Tong University China 2020-04-23 2020-05-06 ChiCTR2000032233 Phase Not Applicable No longer recruiting 2 28 Jiang Lai, Mao Yanfei 2020-04-28
COVASE: Nebulized Dornase Alfa for Treatment of COVID-19 Coronavirus disease 19 infection, Inflammatory disease dornase alfa alone, standard of care alone Deoxyribonuclease I stimulator, Deoxyribonuclease stimulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of London UK 2020-05-01 2020-11-01 132333, COVASE, NCT04359654 Phase 2 Clinical Not yet recruiting 0 6 Months 50 Donna Basire, Joanna Porter, MD PhD, Misha Ladva, Novin Fard 2020-04-28
BCG-Denmark versus no-BCG for COVID 19 prevention Coronavirus disease 19 infection BCG-Denmark alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Jawaharlal Institute of Postgraduate Medical Education Research India 2020-05-01 CTRI/2020/04/024833 Phase 3 Clinical Not yet recruiting 1 1826 Narayanan Parameswaran 2020-04-28
Imatinib in COVID-19 infection Coronavirus disease 19 infection imatinib alone Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) All India Institute of Medical Sciences India 2020-04-26 CTRI/2020/04/024806 Phase 2 Clinical Recruiting 1 100 Akash Kumar 2020-04-28
Impact of Covid-19 pandemic on practice pattern of Indian urologists Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry Sanjay Gandhi Postgraduate Institute of Medical Sciences India 2020-04-24 CTRI/2020/04/024805 Phase Not Applicable Not yet recruiting 1 160 Sanjoy Kumar Sureka 2020-04-28
Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients Anxiety disorder, Coronavirus disease 19 infection, Depression, Insomnia, Viral pneumonia shumian capsule alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Hubei province hospital of Traditional Chinese Medicine Ministry of Science and Technology of the People´s Republic of China China 2020-04-01 2020-07-10 ChiCTR2000032214, ChiMCTR2000003233 Phase Not Applicable Not yet recruiting 3 3 Months 200 Ba Yuanming, Li Li 2020-04-28
Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients Coronavirus disease 19 infection convalesecent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) International Stemcell Services Limited India 2020-04-30 CTRI/2020/04/024804, F. No. X. 11026/71/2020-BD, IMD/CoV/003/2020 Phase 2 Clinical Recruiting 1 Dr Jyothnsa Rao, Dr Vishal Rao, Meena Dalal 2020-04-28
A medical records based study for the impact of wearing medical masks on oxygen saturation in adult surgical patients after general anesthesia during novel coronavirus pneumonia (COVID-19) pandemic Coronavirus disease 19 infection medical masks alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) First Affiliated Hospital of Chongqing Medical University China 2020-04-23 2020-05-23 ChiCTR2000032213 Phase Not Applicable Recruiting 1 1 Month 151 Feng Lv, Su Min 2020-04-28
Effectiveness to Manage Covid 19 Pandemic by Teaching Ventilatory Management to Non-anesthesiology Residents Coronavirus disease 19 infection ventilatory management teaching alone Young Adults (18-44 yrs) GSL Medical College India 2020-01-01 CTRI/2020/04/024747 Phase Not Applicable Not yet recruiting 1 26 TATIKONDA CHANDRA MOULI 2020-04-28
A medical records based retrospective study for the effectiveness and safety of Xi-Yan-Ping injection combined with conventional protocol in the treatment of common type novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Xiyanping alone, conventional treatment alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shanghai Public Health Clinical Center China 2020-05-15 2020-08-22 ChiCTR2000032412 Phase Not Applicable Not yet recruiting 1 3 Months 426 Hongzhou Lu, Lin Wenjun 2020-04-27
The efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomized, controlled trial Coronavirus disease 19 infection, Viral pneumonia High Dose Intravenous Vitamin C alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rui Jin Hospital Science and Technology Commission of Shanghai Municipality China 2020-01-01 2020-06-01 ChiCTR2000032400 Phase 2 Clinical Recruiting 1 5 Months 120 Bing Zhao, Enqiang Mao 2020-04-27
A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19) Anxiety disorder, Coronavirus disease 19 infection, Viral pneumonia xiaoyao capsule alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Xiaogan Traditional Chinese Medicine Hospital Ministry of Science and Technology of the People´s Republic of China China 2020-04-01 2020-07-01 ChiCTR2000032399, ChiMCTR2000003249 Phase not specified Recruiting 3 3 Months 200 Yang Guiping, Zhou Jing 2020-04-27
TRONCHER: Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia Coronavirus disease 19 infection usual standard treatment alone, enoxaparin sodium plus tocilizumab Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Abderrahmane Mami Hospital Datametrix AG, Eshmoun Clinical Research Centre Tunisia 2020-05-04 2020-10-04 ECC2020-06, NCT04361032, TRONCHER Phase 3 Clinical Not yet recruiting 1 5 Months 260 Chokri Jeribi, Dr, Dr Jalila Ben Khelil, Eshmoun Clinical Research Centre 2020-04-27
Physical Activity in University Students Around COVID-19 Confinement Coronavirus disease 19 infection, Pain online survey alone Healthy volunteers accepted Universidad del Pais Vasco Universidad De Cantabria, Universidad De Castilla-La Mancha, Universidad De Las Palmas De Gran Canaria, Universidad Miguel Hernandez de Elche, Universidad Politecnica de Madrid, Universidad Publica De Navarra, Universidad de Extremadura, Universidad de Sevilla, Universidad de Zaragoza, Universitat Jaume I de Castelló, Universitat de les Illes Balears, University of Cadiz, University of Granada, University of León, University of Valencia Spain 2020-04-16 2020-10-20 COVID_PA2020, NCT04361019 Phase Not Applicable Recruiting 1 6 Months 25000 Ana Rodriguez, PhD, Ander Espin, MSc, Ander Espin, Ph D, Diego Jimenez, PhD, Diego Moliner, PhD, Domingo Gonzalez, PhD, Francisco B Ortega, PhD, Francisco J Vera, PhD, Idoia Labayen, PhD, Ignacio Ara, PhD, Jon Irazusta, PhD, Jonatan Ruiz, PhD, Jose Antonio Casajus, PhD, Jose Antonio Serrano, PhD, Jose Castro, PhD, Josep Tur, PhD, Luis Carrasco, PhD, Marcela Gonzalez, PhD, Mari Carmen Gomez, PhD, Maria Jose Cuevas, PhD, Maria Jose Noriega, PhD, Narcis Gusi, PhD, Pedro J Benito, PhD, Susana Aznar, PhD 2020-04-28
PSY-CO-CHU: Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: an Online Survey Anxiety disorder, Coronavirus disease 19 infection, Insomnia, Pain Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Nimes France 2020-04-09 2020-04-22 LOCAL COVID 2019/JYL-01), NCT04358640, PSY-CO-CHU Phase Not Applicable Recruiting 1 2000 Jean-Yves LEFRANT, Jean-Yves LEFRANT, MD,PhD, Jean-Yves Lefrant, MD,PhD 2020-04-27
COVID-19 Mortality Prediction Model Coronavirus disease 19 infection, Viral pneumonia COViage alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Dascena US 2020-04-01 2020-04-17 04202001, NCT04358510 Phase Not Applicable Completed 0 114 2020-04-27
COSA: Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter Coronavirus disease 19 infection, Respiratory failure Seraph 100 Microbind affinity blood filter alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hannover Medical School Academic Teaching Hospital Brunswick Germany 2020-04-15 2021-10-01 COSA, COSA-8998, NCT04361500 Phase Not Applicable Recruiting 2 17 Months 100 Bernhard MW Schmidt, Jan T Kielstein, Prof, Julius J Schmidt, Julius J Schmidt, Dr 2020-04-28
KICC-COVID19: Keto-diet for Intubated Critical Care COVID-19 Coronavirus disease 19 infection, Respiratory failure Ketogenic diet alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Johns Hopkins University US 2020-04-20 2020-08-01 IRB00247383, KICC-COVID19, NCT04358835 Phase Not Applicable Not yet recruiting 0 3 Months 15 Mackenzie Cervenka, MD, Tanya McDonald, MD PhD 2020-04-28
Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for COVID-19 Pneumonia Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires de Strasbourg France 2020-04-09 2020-04-17 7773, NCT04362345 Phase Not Applicable Recruiting 1 100 Antonin HUGEROT, MD, Charlotte KAEUFFER, MD, Coralie LE HYARIC, MD, François DANION, MD, Joy MOOTIEN, MD, Nicolas LEFEBVRE, MD, Nicolas MEYER, MD, PhD, Olivier HINSCHBERGER, MD, Saïd CHAYER, PhD, HDR, Yves HANSMANN, MD, PhD, Yvon RUCH, MD 2020-04-28
MARNEVO-Covid: Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection Coronavirus disease 19 infection, Epilepsy, Viral encephalitis blood sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier de PAU 2020-05-05 2021-01-05 CHPAU2020/02, MARNEVO-Covid, NCT04361344 Phase Not Applicable Not yet recruiting 0 8 Months 30 2020-04-28
START: START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19) Coronavirus disease 19 infection standard care alone, Brammanandha bairavam plus Kabasura kudineer Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Eminentlabs GmbH India 2020-04-17 2020-06-26 ISRCTN13311119, NV-05-943-2020, START Phase 2 Clinical Recruiting 0 2 Months 116 Mr Thanicakachalam 2020-04-28
RAPID COVID COAG: Coagulopathy of COVID-19: A Pragmatic, Randomized, Controlled Trial of Therapeutic Anticoagulation Versus Standard Care Blood clotting disorder, Coronavirus disease 19 infection dalteparin sodium alone, enoxaparin sodium alone, tinzaparin sodium alone, unfractionated heparin alone Antithrombin III, Factor IIa antagonist, Factor Xa antagonist, Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) St Michaels Hospital University of Vermont Medical Center US, Canada 2020-04-30 2020-12-31 NCT04362085, RAPID COVID COAG, RAPID COVID-COAG Phase 3 Clinical Not yet recruiting 1 8 Months 462 Mary Cushman, MD, Michelle Sholzberg, MD, FRCPC, Peter Jüni, MD, FESC 2020-04-28
A phase IIb/III, multinational, adaptive pilot to pivotal trial design of NP-120 in COVID-19 infected patients from progressing to mechanical ventilation with intubation and death Coronavirus disease 19 infection ifenprodil (injectable/intravenous, COVID-19/acute lung injury), Nash Pharmaceuticals alone, standard of care alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals US Phase Not Applicable Not yet recruiting 0 100 2020-04-27
COVSurf: A Clinical Trial of Nebulized Bovactant (Alveofact) for the Treatment of Moderate to Severe COVID-19 Coronavirus disease 19 infection AeroFact-COVID drug delivery system alone, bovactant alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Southampton NHS Foundation Trust Bill & Melinda Gates Foundation, University College London UK 2020-04-27 2020-11-02 COVSurf, NCT04362059, RHM CRI0399 Phase 2 Clinical Not yet recruiting 1 6 Months 24 Danny B Pratt, Michael P Grocott, MD 2020-04-27
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 Coronavirus disease 19 infection, Viral pneumonia anti-SARS-CoV-2 convalescent plasma cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tulane University School of Medicine US 2020-595, NCT04358211 Phase Not Applicable Recruiting 0 Nakhle Saba, MD 2020-04-28
Evaluation of Antibody Tests for COVID-19 Coronavirus disease 19 infection rapid-format, point-of-care antibody test kit alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Washington University School of Medicine, US US 2020-04-27 2020-10-27 202004088, NCT04360954 Phase Not Applicable Recruiting 0 6 Months 1000 Gary Weil, MD, Peter Fischer, PhD, Teresa Tufte, MPH 2020-04-28
STOP COVID 19: Sequencing and Tracking of Phylogeny in COVID-19 Study Coronavirus disease 19 infection Nanopore-based whole genome sequencing alone, phylogenetic analysis alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Portsmouth Hospitals University of Portsmouth UK 2020-05-31 2022-09-30 NCT04359849, PHT/2020/34, STOP COVID 19 Phase Not Applicable Recruiting 1 28 Months 500 Alice Mortlock, Samuel Robson 2020-04-28
A clinical study of atexakin alfa for the treatment in patients with COVID-19-induced ARDS Coronavirus disease 19 infection, Respiratory distress syndrome atexakin alfa alone IL-6 receptor agonist Real Relief Holding ApS NeuroRx Inc US Phase Not Applicable Not yet recruiting 0 2020-04-27
Plasma Therapy of COVID-19 in Critically Ill Patients Coronavirus disease 19 infection anti-SARS-CoV-2 convalescent plasma cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Columbia University New York Blood Center US 2020-04-30 2021-04-30 AAAS9924, NCT04359810 Phase 2 Clinical Not yet recruiting 0 12 Months 105 Andrew Eisenberger, MD, Max O'Donnell, MD, Walter I. Lipkin, MD 2020-04-27
CHEER: Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Shaheed Zulfiqar Ali Bhutto Medical University Islamabad Pakistan 2020-04-25 2020-09-25 CHEER, F.1-1/2015/ERB/SZABMU/549, NCT04359537 Phase 2 Clinical Not yet recruiting 1 5 Months 200 Fibhaa Syed, FRCP, Mohammed Ali Arif, FRCP, Rauf Niazi, FRCP 2020-04-28
Treatment Of Coronavirus Disease 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) Coronavirus disease 19 infection Anti-Sars-CoV-2 convalescent plasma alone US Army Medical Research and Development Command NCT04360486, S-20-02 Phase Not Applicable Recruiting 0 Andrew P Cap, MS, MD, PhD, FACP 2020-04-28
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) Coronavirus disease 19 infection, Systemic inflammatory response syndrome standard of care alone, tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Emory University National Cancer Institute US 2020-05-30 2022-05-30 NCI-2020-02314, NCT04361552, P30CA138292, STUDY00000419, WINSHIP4998-20 Phase 3 Clinical Recruiting 0 24 Months 180 Ajay K Nooka, Ajay K. Nooka, Shondolyn D. Richburg 2020-04-27
COVID19 LTFU: Long-Term Outcomes of Patients With COVID-19 Coronavirus disease 19 infection physical disability assessment tool alone, psychological Sequelae assessment tool alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-08 2021-12-30 20-0538, COVID19 LTFU, NCT04360538 Phase Not Applicable Recruiting 0 20 Months 500 Anne Pohlman, MSN, Bhakti Patel, MD, John Kress, MD, Krysta Wolfe, MD 2020-04-27
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19 Coronavirus disease 19 infection nitric oxide (inhaled, INOpulse), Bellerophon alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bellerophon Therapeutics LLC NCT04358588, PULSE-EAP-001 Phase Not Applicable Recruiting 0 Hunter Gilles, MD, Michelle Alamo, Valerie Parker 2020-04-28
THROMBOVID: Study of Hemostasis in Case of Severe COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital of Strasbourg 2020-04-17 2021-05-01 7774, NCT04359992, THROMBOVID Phase Not Applicable Not yet recruiting 0 12 Months 50 Charles TACQUARD 2020-04-27
LIINC: Long-term Impact of Infection With Novel Coronavirus (COVID-19) Coronavirus disease 19 infection biological sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of California San Francisco US 2020-04-17 2024-12-21 20-30479, LIINC, NCT04362150 Phase Not Applicable Not yet recruiting 0 56 Months 800 Michael J Peluso, MD, Rebecca Hoh, Rebecca Hoh, MS, RD, Steven Deeks, MD, Steven G Deeks, MD 2020-04-27
Efficacy of tenofovir in covid-19 Coronavirus disease 19 infection hydroxychloroquine plus tenofovir disoproxil fumarate DNA polymerase inhibitor, HIV-1 reverse transcriptase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ardabil University of Medical Sciences Iran 2020-04-29 IR.AUMS.REC.1399.051, IRCT20200421047155N1 Phase 3 Clinical Not yet recruiting 0 86 Shahab Bohlooli, Shahram Habibzadeh, Sina Parsay 2020-04-28
A 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells for the treatment of COVID-19 associated with lung inflammation Coronavirus disease 19 infection, Lung inflammation umbilical cord-derived mesenchymal stem cells (intravenous, COVID-19/lung inflammation/acute lung injury/acute respiratory distress syndrome), University of Miami alone KCNQ2 Cure Alliance Foundation, University of Miami Miller School of Medicine US Phase Not Applicable Not yet recruiting 0 24 Camillo Ricordi, M.D 2020-04-28
CV-COVID-19: Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System Cardiac failure, Coronavirus disease 19 infection, Heart arrhythmia, Myocardial infarction, Stroke, Sudden cardiac death real-time reverse transcriptase-polymerase chain reaction alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Clinic of Barcelona Spain 2020-04-20 2025-08-31 CV-COVID-19, HCB/2020/0457, NCT04359927 Phase Not Applicable Recruiting 1 64 Months 10000 Luis Ortega Paz, MD, PhD, Luis Ortega, MD, PhD, Manel Sabaté, MD, PhD, Salvatore Brugaletta, MD, PhD 2020-04-28
FIC: Favipiravir in Hospitalized COVID-19 Patients Coronavirus disease 19 infection favipiravir alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-20 2020-05-05 FAVIPIRAVIR IN COVID-19, FIC, NCT04359615 Phase 4 Clinical Not yet recruiting 1 40 Mehran Lack, MD, Mohammad Fathi, MD, Nader Markazi, MD, Nasser Malekpour Alamdari, MD, Sanaz Zargar Balaye Jam, MD, Sasan Tavana, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA 2020-04-27
Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19 Coronavirus disease 19 infection convalescent immune plasma alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National Institutes of Health Clinical Center US 2020-04-30 2030-04-14 20-CC-0092, 200092, NCT04360278 Phase Not Applicable Recruiting 0 119 Months 1500 Kamille A West, M.D. 2020-04-28
Ivermectin and Nitazoxanide Combination Therapy for COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure ivermectin plus nitazoxanide Chloride channel modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tanta University Egypt 2020-05-31 2020-12-31 IVR/NTZ, NCT04360356 Phase 2/Phase 3 Clinical Not yet recruiting 1 7 Months 100 Kamal Okasha, Md, PhD, Nahla Elashmawy, Md, PhD 2020-04-27
VTE COVID: Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 Coronavirus disease 19 infection, Thromboembolism fondaparinux sodium alone, low-molecular-weight heparin alone Factor Xa antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Quovadis Associazione Azienda Ospedaliera di Padova Italy 2020-05-31 2020-06-30 NCT04359212, VTE COVID, VTE COVID Phase Not Applicable Not yet recruiting 1 1 Month 80 Giuseppe Camporese, MD, Paolo Simioni, MD 2020-04-28
Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19 Coronavirus disease 19 infection herbal extract (Glycyrrhiza glabra, Mentha pulegium and Urtica) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Baqiyatallah University of Medical Sciences Iran 2020-03-30 2020-05-31 IR.BMSU.REC.1399.054, IRCT20080901001165N49 Phase Not Applicable Recruiting 1 2 Months 80 Ali Ghazivini, Dr. Rezaeiyan, Hossein Biganeh, Parisa Kianpour, Siamak Mohammadi, Yunes Panahi 2020-04-27
The effect of Naproxen in recovery and reducing mortality in patients with COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Iran University of Medical Sciences Iran 2020-04-13 2020-07-15 IR.IUMS.REC.1399.001, IRCT20200410047009N1 Phase 4 Clinical Recruiting 1 3 Months 101 Maryam Esghaei 2020-04-27
effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections Coronavirus disease 19 infection Arbidol plus hydroxychloroquine, Amin Pharmaceutical Company Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-22 IR.MUMS.REC.1399.103, IRCT20200325046859N2 Phase 2/Phase 3 Clinical No longer recruiting 1 40 Rozita Khodashahi 2020-04-28
Evaluation of the colchicine tablet efficacy as an adjuvant therapy for patients with mild to moderate COVID-19 Coronavirus disease 19 infection colchicine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mashhad University of Medical Sciences Iran 2020-04-29 IR.MUMS.REC.1399.096, IRCT20200408046990N2 Phase 3 Clinical Not yet recruiting 1 40 Sepideh Elyasi 2020-04-27
Atrium COVID-19 Syndromic and Serological Surveillance Coronavirus disease 19 infection daily syndromic surveillance alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Atrium Health US 2020-04-30 2021-12-31 04-20-11A, NCT04361123 Phase Not Applicable Not yet recruiting 0 20 Months 450000 Melanie Hogg, MS, Michael Runyon, MD, MPH 2020-04-27
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) Coronavirus disease 19 infection, Lung disease, Sepsis, Viral pneumonia Reuquinol alone, Reuquinol plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Apsen Farmaceutica SA Hospital São Paulo Brazil 2020-05-04 2020-11-04 APS001/2020, NCT04361461 Phase 3 Clinical Not yet recruiting 1 6 Months 500 Dr. Eduardo Alexandrino Servolo de Medeiros, M.D, Fernanda Martinez, B.Sc. 2020-04-27
Precision Immunology to Determine the Immune Response in Patients With COVID-19 Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Bonn Germany 2020-04-20 2022-09-30 BOST-03, NCT04360733 Phase Not Applicable Recruiting 1 29 Months 200 Chrisitan Bode, MD, Christian Bode, MD, Dr. Christian Bode, Folkert Steinhagen, MD 2020-04-27
Effect of lithium carbonate on COVID-19 Coronavirus disease 19 infection lithium carbonate alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-05-02 IR.MUMS.REC.1399.145, IRCT20081019001369N5 Phase 2 Clinical Not yet recruiting 1 40 Hossein Hosseinzadeh, Javad Dehghan Nayyeri 2020-04-27
Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients Coronavirus disease 19 infection telmisartan alone Angiotensin II receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Hawaii US 2020-07-01 2021-06-30 H051, NCT04360551 Phase 2 Clinical Not yet recruiting 0 12 Months 40 Cecilia M Shikuma, MD, Debra Ogata-Arakaki, RN 2020-04-27
COVIDORL: Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Coronavirus disease 19 infection, Olfaction disorder budesonide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fondation Ophtalmologique Adolf De Rothschild Assistance Publique Hopitaux de Paris France 2020-04-25 2021-05-25 COVIDORL, MDL_2020_10, NCT04361474 Phase 3 Clinical Not yet recruiting 1 13 Months 120 Amélie Yavchitz, Mary DAVAL, Mary Daval 2020-04-27
NCoV: Neurocognitive Impairment in Patients With COVID-19 Cognitive disorder, Coronavirus disease 19 infection, Delirium delirium test alone, short blessed test alone University of Rostock Ludwig-Maximilians University of Munich, University College London Germany 2020-04-15 2021-04-01 COVID-BRAIN, NCT04359914, NCoV Phase Not Applicable Recruiting 1 11 Months 80 Gerd Klinkmann, MD, Johannes Ehler, MD 2020-04-28
STOP-COVID19: A multicenter, investigator-initiated, prospective, randomized, double-blind, placebo-controlled trial of brensocatib in patients with severe COVID-19 Coronavirus disease 19 infection brensocatib alone Dipeptidyl peptidase I inhibitor University of Dundee Insmed Inc UK STOP-COVID19 Phase 2 Clinical Status not specified 1 300 Professor James Chalmers 2020-04-27
AVINALI: Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19 Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome aviptadil alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) NeuroRx Inc 2020-06-01 2020-10-01 AVINALI, NCT04360096, RLF-100-002 Phase 2/Phase 3 Clinical Not yet recruiting 0 4 Months 144 Jonathan C Javitt, MD, MPH, Robert E Besthof, MIM 2020-04-28
Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study Coronavirus disease 19 infection ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Zealand University Hospital Denmark 2020-04-22 2020-001459-42, 26223678Hans Phase 2 Clinical No longer recruiting 1 40 Hans Hasselbalch 2020-04-28
Isotretinoin in Treatment of COVID-19 (Randomized) Coronavirus disease 19 infection isotretinoin alone, Variable regimens including ascorbic acid , azithromycin , clarithromycin , cyanocobalamin , hydroxychloroquine , isotretinoin , lopinavir + ritonavir , oseltamivir , paracetamol Exo-alpha sialidase inhibitor, HIV protease inhibitor, Retinoic acid receptor agonist Young Adults (18-44 yrs) Tanta University Egypt 2020-04-21 2020-09-30 9469305C, NCT04361422 Phase 3 Clinical Not yet recruiting 1 5 Months 300 Lamia Elgarhy 2020-04-27
UHID-COVID19: Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab Coronavirus disease 19 infection, Viral pneumonia tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital for Infectious Diseases Croatia 2020-04-16 2021-04-15 NCT04359667, UHID-04, UHID-COVID19 Phase 2 Clinical Recruiting 1 12 Months 30 Arijana Pavelic, BA, Marko Kutlesa, MD, PhD, Miroslav Mayer, MD, PhD, Rok Civljak, MD, PhD 2020-04-27
COVID-19 PREVENTION: Medication for prevention of Corona-virus for Danish nursing home residents Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , vitamin D , zinc Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) Odense University Hospital Denmark 2020-04-23 2020-001363-85, 60152610‬, COVID-19 PREVENTION Phase 3 Clinical No longer recruiting 1 206 Clinical Trial Information 2020-04-28
CQOTE: Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 Coronavirus disease 19 infection, HIV infection chloroquine alone, hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Cape Town South Africa 2020-05-01 2021-07-31 CQOTE, HIV-COVID-19 CQOTE, NCT04360759 Phase 3 Clinical Not yet recruiting 2 15 Months 560 Amy Ward, MBBCh, Bianca Sossen, MBChB, Bianca Sossen, MBChB, MSc, Bianca Sossen, MBChB, MSc), Graeme Meintjes, PhD, Jacob Standler, MBChB, Mpumi Maxebengula, BCom, Nompumelelo Maxebengula, Sean Wasserman, MBChB, Trevor Ayanda Mnguni, MBChB, FCP(SA) 2020-04-28
A Study to Explore the Role of Gut Flora in COVID-19 Infection Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) ProgenaBiome US 2020-04-16 2021-07-31 NCT04359836, PRG-041 Phase Not Applicable Recruiting 0 15 Months 250 Jordan Daniels, MS, Sabine Hazan, MD 2020-04-28
Leflunomide in Mild COVID-19 Patients Coronavirus disease 19 infection leflunomide alone Dihydroorotate dehydrogenase inhibitor, Protein tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-30 2020-07-31 IRB20-0622, NCT04361214 Phase 1 Clinical Not yet recruiting 0 3 Months 20 Laurencia Perea, Michael Millis, Michael Millis, MD 2020-04-27
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 Coronavirus disease 19 infection favipiravir alone, standard of care alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fujifilm Pharmaceuticals USA, Inc US 2020-04-17 2020-12-31 FAVI-COV-US201, NCT04358549 Phase 2 Clinical Recruiting 0 8 Months 50 FPHU Study Coordinator 2020-04-27
PassItOn II: Passive Immunity Trial of Nashville II Coronavirus disease 19 infection, Respiratory tract infection pathogen reduced SARS-CoV-2 convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Vanderbilt University Medical Center, US US 2020-04-24 2021-04-30 200738, NCT04362176, PassItOn II Phase 3 Clinical Not yet recruiting 0 12 Months 500 Amanda J Bistran-Hall, Todd Rice, MD 2020-04-27
A phase I trial to evaluate AlloRx Stem Cells for the treatment of patients with COVID-19 infection Coronavirus disease 19 infection AlloRx Stem Cells alone Vitro Diagnostics Inc US Phase 1 Clinical Planned 0 2020-04-27
Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients Coronavirus disease 19 infection, Dysgeusia, Dysomia Centre Hospitalier Universitaire De Nice France 2020-03-20 2020-05-31 20ODONTOCOVID.06, NCT04361565 Phase Not Applicable Recruiting 1 2 Months 50 2020-04-28
Acral Cutaneous Thrombotic Vasculopathy and COVID-19 Infection Acrocyanosis, Coronavirus disease 19 infection, Necrosis, Purpura, Raynauds disease, Vascular disease University Hospital, Montpellier Assistance Publique Hopitaux De Marseille, Lyon-Sud Hospital Center, Marseille University Hospital France 2020-04-01 2020-10-30 NCT04361786, RECHMPL20_0211 Phase Not Applicable Recruiting 1 6 Months 10 Didier BESSIS, PhD, Léo-Paul Secco, Student 2020-04-27
PRECOVIA: Longitudinal Study of SARS-Cov2 Infection Among HCW in a French University Hospital Coronavirus disease 19 infection SARS-Cov2 testing alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille Fondation Santé Roquette France 2020-04-30 2020-09-30 2020-A00950-39, 2020_34, NCT04362267, PRECOVIA Phase Not Applicable Not yet recruiting 1 5 Months 150 Annie SOBASZEK, MD, Annie SOBASZEK, MD,PhD 2020-04-27
CytokCOVID19: Pilot Study on Cytokine Filtration in COVID-19 ARDS Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia cytokine adsorption alone, sodium heparin alone, standard intensive care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Clinic of Barcelona Spain 2020-04-17 2020-07-31 CytokCOVID19, HCB/2020/0464, NCT04361526 Phase 2 Clinical Recruiting 1 3 Months 40 Manuel Castellà, MD PhD 2020-04-27
A multicenter, randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia Coronavirus disease 19 infection, Viral pneumonia shengmai decoction alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Wuhan 7th Hospital, Wuhan Hospital of Traditional Chinese Medicine, Xiaogan Traditional Chinese Medicine Hospital China 2020-04-15 2020-07-15 ChiCTR2000032205, ChiMCTR2000003235 Phase Not Applicable Not yet recruiting 3 3 Months 200 Mao Lina, Xia Ping 2020-04-27
A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period Coronavirus disease 19 infection, Viral pneumonia Qi-Mai-Fei-Luo-Ping mixture alone, rehabilitation education guidance alone, respiratory training alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Hubei province hospital of Traditional Chinese Medicine China 2020-04-01 2021-03-31 ChiCTR2000032165, ChiMCTR2000003230 Phase Not Applicable Not yet recruiting 3 12 Months 60 Xiao Mingzhong 2020-04-27
MICROVID: Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With SARS-CoV2 Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-09-30 2020-A01042-37, 2020_28, MICROVID, NCT04359706 Phase Not Applicable Not yet recruiting 1 5 Months 30 Saad Nseir, MD,PhD 2020-04-27
COVID19-SETH: COVID-19 in Liver Transplant Recipients Coronavirus disease 19 infection Hospital Clinic of Barcelona Sociedad Española de Trasplante Hepático Spain 2020-03-01 2021-03-31 COVID19-SETH, HCB/2020/0384, NCT04361591 Phase Not Applicable Recruiting 1 13 Months 200 Jordi Colmenero, Jordi Colmenero, MD PhD, SETH Scientific Committee 2020-04-27
Estrogen Patch for COVID-19 Symptoms Coronavirus disease 19 infection, Viral pneumonia estradiol (transdermal patch, vasomotor symptoms/ osteoporosis), Bayer Schering alone Estradiol agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stony Brook University Hospital US 2020-04-20 2020-11-15 NCT04359329, SBU-ESTROGENPATCH-COVID19 Phase 2 Clinical Recruiting 0 6 Months 110 Alison Stopeck, MD, Andrew Handel, MD, Antonio Gasparis, MD, Christina Preece, Christina Preece, MD, Jie Yang, PhD, Patricia Thompson, Patricia Thompson, PhD, Sharon Nachman, MD 2020-04-27
A medical records based study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients Coronavirus disease 19 infection, Viral pneumonia ECMO alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) BaYi Brain Hospital, Children's Hospital of Chongqing Medical University China 2020-04-22 2020-05-21 ChiCTR2000032162 Phase Not Applicable Not yet recruiting 1 1 Month 80 Cao Huiling, Feng Zhichun 2020-04-27
Study for evolution and clinical outcomes study of novel coronavirus pneumonia (COVID-19) patients: a retrospective, cohort study Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital, Tongji Medical College National Natural Science Foundation of China China 2020-02-01 2020-06-30 ChiCTR2000032161 Phase Not Applicable Recruiting 1 5 Months 2000 Gao Qinglei, Wang Ya 2020-04-27
CORTICOVIDHUGO: Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia Standard of care alone, hydrocortisone hemisuccinate alone, prednisone alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Tours France 2020-05-31 2020-09-30 CORTI-COVID-19-HUGO, CORTICOVIDHUGO, DR200136, NCT04359511 Phase 3 Clinical Not yet recruiting 12 4 Months 210 BAZIN YANN, MD, GOUPIL FRANCOIS, MD, GUY TIPHAINE, MD, JOUNEAU STEPHANE, MD, PhD, LEMMENS BRUNO, MD, LIOGER BERTRAND, MD, LOUIS BERNARD, MD, PhD, MAILLOT FRANCOIS, MD, MEURICE JEAN CLAUDE, MD, MOREL HUGUES, MD, PECQUERIAUX OLIVIER, MD, POPA Mihai, MD, RABUT Thi- Tuyet Hong, MD, ROY XAVIER, MD, pascal magro, MD, sylvain marchand-adam, MD, PhD 2020-04-27
Efficacy and safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia ulinastatin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Shanghai Public Health Clinical Center China 2020-04-22 2020-12-31 ChiCTR2000032135 Phase 4 Clinical Not yet recruiting 1 8 Months 50 Hongzhou Lu, Yun Ling 2020-04-27
HBOTCOVID19: Hyperbaric Oxygen Therapy Effect in COVID-19 RCT Coronavirus disease 19 infection, Respiratory insufficiency hyperbaric oxygen therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assaf-Harofeh Medical Center 2020-04-26 2020-07-30 120-20-ASF, HBOTCOVID19, NCT04358926 Phase Not Applicable Not yet recruiting 0 3 Months 30 Amir Hadanny, MD, Shai Efrati, MD 2020-04-27
The effect of pomegranate tea on symptom relief of COVID-19 patients: a double-blind, randomized clinical trial study Coronavirus disease 19 infection, Viral pneumonia pomegranate tea alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shahrekord University of Medical Sciences and Health Services Iran 2020-04-20 IR.SKUMS.REC.1399.017, IRCT20200416047104N1 Phase Not Applicable Recruiting 1 66 Dr. Fereidoun Rahmani, Dr. Mehraban Sadeghi, Dr. Zahra Lorigooini, Dr. Zohreh Abolhassanzadeh, Vahid Reisi-Vanani 2020-04-27
TX-COVID: Solid Organ Transplant Recipients With Covid-19 French Registry Coronavirus disease 19 infection Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires de Strasbourg France 2020-04-08 2021-04-08 7766, NCT04360707, TX-COVID Phase Not Applicable Recruiting 1 12 Months 300 Gabriela GAUTIER, MD, Samira FAFI-KREMER, MD, PhD, Saïd CHAYER, PhD, HDR, Sophie CAILLARD, MD, PhD 2020-04-27
COVID-DEX: Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients Coronavirus disease 19 infection, Pulmonary edema, Respiratory distress syndrome, Respiratory insufficiency Variable regimens including dexmedetomidine , propofol, AstraZeneca/Fresenius , remifentanil Alpha 2 adrenoceptor agonist, Opioid receptor mu agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Clinic of Barcelona Spain 2020-04-15 2020-06-30 COVID-DEX, NCT04358627, SPEC-M, SPEC-M COVID-19 Phase Not Applicable Not yet recruiting 1 2 Months 80 Pedro L Gambus, PhD MD, Xavier Borrat, PhD MD 2020-04-27
CIPOLLINI: Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Medical Center Groningen Netherlands 2020-06-30 2022-06-30 CIPOLLINI, CIPOLLINI, NCT04359459 Phase Not Applicable Not yet recruiting 1 24 Months 150 Daan Pouwels, PhD, Dirk-Jan Slebos, MD PhD, Janesh Pillay, MD PhD, Maarten van den Berge, Maarten van den Berge, MD PhD 2020-04-28
Examination of test accuracy of COVID-19 rapid antibody kit Coronavirus disease 19 infection rapid antibody kit alone Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ja Akita Koseiren Omagari Kosei Medical Care Center Japan 2020-04-23 UMIN000040235 Phase Not Applicable Recruiting 1 20 Toshiki Horii 2020-04-27
COCARDE: Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients Coronavirus disease 19 infection, Myocardial disease transthoracic echocardiography alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Toulouse France 2020-04-04 2020-11-04 2020-A00852-37, COCARDE, NCT04358952, RC31/20/0117 Phase Not Applicable Recruiting 1 7 Months 50 Olivier LAIREZ, PU-PH, Vincent MINVILLE, PU PH, Vincent MINVILLE, PU-PH 2020-04-27
Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot, Randomized Clinical Trial Adult respiratory distress syndrome, Coronavirus disease 19 infection, Viral pneumonia dexamethasone alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Colorado at Denver and Health Sciences Center 2020-05-01 2020-12-31 20-0811, NCT04360876 Phase 2a Clinical Not yet recruiting 0 8 Months 90 2020-04-27
Database for diagnosis and therapy of COVID-19 infected patients Coronavirus disease 19 infection data collection alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The Institute for Research in Operative Medicine Germany 2020-04-26 75/2020, DRKS00021514 Phase Not Applicable Not yet recruiting 1 150 Sarah Schwarz, Tim Mathes 2020-04-27
Quercetin in COVID-19 Coronavirus disease 19 infection quercetin alone, routine drug therapy alone Ahvaz University of Medical Sciences Iran 2020-04-29 IR.AJUMS.REC.1399.087, IRCT20200419047128N2 Phase 3 Clinical Not yet recruiting 1 60 Ali khodadadi, Mohamad Badavi, َAli Khodadadi 2020-04-27
Evaluation of the effects of Sitagliptin administration in patients with COVID-19 Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , lopinavir + ritonavir , sitagliptin (Dr. Abidi Pharmaceuticals) HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-05-04 IR.SBMU.NRITLD.REC.1399.029, IRCT20200420047147N1 Phase 2/Phase 3 Clinical Not yet recruiting 1 84 Afshin Zarghi, Ahad Zare, Dr. Atefe Abedini, Farzaneh Dastan 2020-04-27
Effect of NK cell therapy in COVID-19 Coronavirus disease 19 infection, Viral pneumonia allogeneic natural killer cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Middle East Gene Therapy corporation Iran 2020-04-27 IR.TUMS.VCR.REC.1399.069, IRCT20200417047113N1 Phase 1/Phase 2 Clinical Recruiting 1 70 Minoo Mohraz, Sahar Shojaei 2020-04-27
Performance Evaluation of BCG versus COVID-19 Coronavirus disease 19 infection vaccine BCG alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universidad de Antioquia Colombia 2020-04-30 2021-11-30 NCT04362124, PEC03_2020 Phase 3 Clinical Not yet recruiting 0 19 Months 1000 Juan C Cataño, MD.MI.ID, Juan C cataño, MD.MI.ID, Liliana Lopez, BSc.MSc 2020-04-28
Classification of COVID-19 Infection in Posteroanterior Chest X-rays Coronavirus disease 19 infection DenseNet121 alone, PCX images (chest X-rays) alone, VGG16 alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Dascena US 2020-04-01 2020-04-17 04202002, NCT04358536 Phase Not Applicable Completed 0 230 2020-04-28
Baricitinib Therapy in COVID-19 Coronavirus disease 19 infection, Viral pneumonia baricitinib plus lopinavir + ritonavir HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ospedale Misericordia e Dolce Italy 2020-03-16 2020-04-07 HPRATO-4, NCT04358614 Phase 2/Phase 3 Clinical Completed 0 12 Fabrizio Cantini 2020-04-28
A clinical study of CLBS-119 for repair of COVID-19 induced lung damage in patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure Coronavirus disease 19 infection, Lung injury, Respiratory failure CLBS-119 alone Caladrius Biosciences Inc US Phase Not Applicable Not yet recruiting 0 2020-04-28
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone, Variable regimens including autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences , azithromycin , hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation US 2020-05-15 2020-10-31 ALLOGENEIC TREATMENT COVID-19, NCT04362189 Phase 2 Clinical Not yet recruiting 0 5 Months 110 Joseph Gathe, MD, FACP, Katherine Ruppert, PhD, Mariann England, Rajiv Thakur, MD, Sherry Diers, RN, Thinh Vo, MD 2020-04-27
A clinical trial of Mitotech-19 for the treatment of acute respiratory distress syndrome in patients with COVID-19 infection Coronavirus disease 19 infection, Respiratory distress syndrome Mitotech-19 alone Mitotech SA Phase Not Applicable Planned 0 2020-04-28
RUXCOVID: Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm Coronavirus disease 19 infection, Viral pneumonia ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone, standard-of-care alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Novartis AG Incyte Corp Germany 2020-04-30 2020-06-29 2020-001662-11, CINC424J12301, INCB 18424-368, NCT04362137, RUXCOVID Phase 3 Clinical Recruiting 1 2 Months 402 Medizinischer Infoservice (MCC), Novartis Pharmaceuticals 2020-04-28
Adaptive, multicenter, randomized, open, comparative clinical trial of the efficacy and safety of the drug favipiravir in patients hospitalized with COVID-19 Coronavirus disease 19 infection favipiravir alone RNA polymerase inhibitor Kromis LLC Russian Federation 2020-04-23 2020-12-31 COVID-FPR-01 Phase 3 Clinical Status not specified 17 8 Months 390 2020-04-25
CORONA: A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 Coronavirus disease 19 infection BCD-089 alone IL-6 receptor antagonist Biocad Ltd Russian Federation 2020-04-22 2022-12-30 BCD-089-4, CORONA Phase 3 Clinical Status not specified 4 32 Months 250 2020-04-25
A clinical trial of convalescent plasma for the treatment of COVID-19 infection Coronavirus disease 19 infection onvalescent plasma alone Healthy volunteers accepted Viravaxx AG Phase Not Applicable Not yet recruiting 0 600 2020-04-24
Study of Shreepad Shree Vallabh SSV Formulation to improve immunity in quarantine patients of COVID-19 Coronavirus disease 19 infection, Immunization SSV Formulation tablet alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) SSV Phytopharmaceuticals India 2020-04-27 CTRI/2020/04/024659, Protocol No. SSV-SF-04/2020 Phase 3 Clinical Not yet recruiting 1 30 Dr Samadhan Patil, Dr Yogesh Dound 2020-04-28
RTLS Technology Study Coronavirus disease 19 infection Real Time Location System alone The Royal Wolverhampton Hospitals Nhs Trust Cornell University, La Trobe University UK 2020-01-06 2020-12-31 2019SUR107, NCT04114110 Phase Not Applicable No longer recruiting 1 11 Months 2000 2020-04-27
CONCOR-1: Convalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness Coronavirus disease 19 infection Convalescent plasma alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hamilton Health Sciences Corp, Hema-Quebec Canadian Blood Services, Universite De Montreal, University of Toronto Canada 2020-04-27 2020-12-31 CONCOR-1, CONCOR-1, NCT04348656 Phase 3 Clinical Not yet recruiting 27 8 Months 1200 Andrew Shih, Anne-Sophie Lemay, Arjuna Ponnampalam, Benjamin Rioux-Masse, Brian Berry, Christine Cserti, Danielle Talbot, David Welbourne, Donald M Arnold, MD, Erin B Jamula, MSc., Jacob Pendergrast, Julie Rousseau, Katerina Pavenski, Luigina Mollica, Menaka Pai, Michelle Zeller, Nadine Shehata, Patrice Beauregard, Patricia Pelletier, Shuoyan Ning, Stephen Caplan, Susan Nahirniak, Tony Giulivi, Valerie Arsenault, Vincent Laroche, Yulia Lin, Ziad Solh 2020-04-27
PRA-001: Plasma Rich Antibodies From Recovered Patients From COVID19 Coronavirus disease 19 infection Variable regimens including Antibody-Rich Plasma , azithromycin , hydroxychroquine , oseltamivir Exo-alpha sialidase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ain Shams University Egypt 2020-04-20 2020-12-31 FMASU P15/ 2020, NCT04348877, PRA-001 Phase 2 Clinical Not yet recruiting 1 8 Months 20 Hossam Fahmy, Professor of Faculty of Medicine 2020-04-27
WAVES: Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study Coronavirus disease 19 infection Airway pressure release ventilation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sir Charles Gairdner Hospital Australia 2020-04-27 ACTRN12620000474954p, WAVES Phase Not Applicable Not yet recruiting 8 100 A/Prof Matthew Anstey 2020-04-27
COVID RASP: Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM-85 Coronavirus disease 19 infection, Respiratory disease OM-85 alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Queensland Australian Government Australia 2020-06-01 2020-07-31 ACTRN12620000473965p, BV-2020/19, COVID RASP, U1111-1250-2920 Phase 3 Clinical Not yet recruiting 3 2 Months 1000 Mrs Sharon Brabon, Prof Peter Sly 2020-04-28
An investigator initiated study to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections Bacterial infection, Coronavirus disease 19 infection, Viral pneumonia Unyvero system alone Karolinska Institutet OpGen Inc Sweden 2020-04-21 Phase Not Applicable Recruiting 1 2020-04-24
Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) Coronavirus disease 19 infection Measles Mumps and Rubella vaccine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Misr University for Science and Technology Kasr Alainy School of Medicine Egypt 2020-04-15 PACTR202004693933092 Phase 2 Clinical Not yet recruiting 1 200 Ahmed Mukhtar, Mahmoud Nassar, Mostafa Alfishawy 2020-04-27
COVIPOC: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial Coronavirus disease 19 infection, Respiratory insufficiency senicapoc alone KCNN potassium channel-4 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Aarhus University Denmark 2020-04-14 0001, 2020-001420-34, COVIPOC Phase 2 Clinical Recruiting 1 www.Clinicaltrials.gov 2020-04-27
A phase I clinical study to assess ABL novel prophylactic COVID-19 vaccine and to analyze biomarker to characterize the immune profile of subjects participating in the study Coronavirus disease 19 infection ABL novel prophylactic COVID-19 vaccine alone Advanced BioScience Laboratories Inc Institut Merieux SA Phase 1 Clinical Planned 0 2020-04-27
Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial Coronavirus disease 19 infection IHP Detox Tea alone, conventional therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Neimeth International Pharmaceuticals Plc Nigeria 2020-05-01 PACTR202004761408382 Phase Not Applicable Not yet recruiting 2 72 Charles Esimone, George Eleje, Jude Duru 2020-04-26
A diagnostic study IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 coronavirus) through ZEUS's lateral flow test Coronavirus disease 19 infection ZEUS's lateral flow test alone Healthy volunteers accepted Zeus Scientific Inc China, US Phase Not Applicable Status not specified 1 2020-04-24
A medical records based study for 'Guangdong Pneumonia NO.1' in the Treatment of Novel Coronavirus Pneumonia (COVID-19) Coronavirus disease 19 infection, Pneumonia Guangdong Pneumonia NO.1 alone, basic treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Guangzhou Hospital China 2020-02-11 2020-11-30 ChiCTR2000031888, ChiMCTR2000003208 Phase Not Applicable Recruiting 3 9 Months 300 Liansheng Lin, Luping Lin 2020-04-27
A phase II clinical study of stem cells to treat hospitalized patients with COVID-19 infection Coronavirus disease 19 infection stem cells alone Personalized Stem Cells Inc Phase 2 Clinical Planned 0 2020-04-24
A study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 Coronavirus disease 19 infection Wondfo SARS-CoV-2A point of care test alone Guangzhou Wondfo Biotech Co Ltd Phase Not Applicable Status not specified 0 2020-04-24
A validation study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 Coronavirus disease 19 infection Wondfo SARS-CoV-2A point of care test alone National Institute of Virology Cellmid Ltd, World Health Organization India 2020-04-22 Phase Not Applicable Completed 1 36 2020-04-24
A phase IIa, multicenter clinical trial of Cannabidiol-Steroid formulation for the treatment of COVID-19 infection Coronavirus disease 19 infection cannabidiol-steroid alone Stero Biotechs Ltd Phase 2a Clinical Planned 0 40 2020-04-25
An IP Protected Cliniacl Trial of Cannabidiol- steroid formulation for the treatment of COVID-19 infection Coronavirus disease 19 infection cannabidiol- steroid alone Stero Biotechs Ltd Mor Research Applications Ltd Israel 2020-04-30 Phase Not Applicable Planned 1 10 2020-04-25
Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Mútua Terrassa University Hospital Spain 2020-04-18 2020-001536-98, PREPSARS Phase 3 Clinical Recruiting 1 300 HOSPITAL UNIVERSITARI MUTUA TERRASSA, INTERNAL MEDICINE DEPARTMENT 2020-04-27
Study to investigate the safety and effects of vaccines in healthy adults Coronavirus disease 19 infection BNT-162a1 alone COVID19 Spike glycoprotein modulator Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) BioNTech SE Pfizer Inc Germany 2020-04-20 2020-001038-36, BNT162-01, U1111-1249-4220 Phase 1/Phase 2 Clinical Recruiting 1 196 Clinical Study Management 2020-04-28
A trial to evaluate BNT-162 for the prevention of COVID-19 infection Coronavirus disease 19 infection BNT-162a1 alone COVID19 Spike glycoprotein modulator BioNTech SE Pfizer Inc US Phase Not Applicable Planned 0 2020-04-27
CIGB-2020 in contacts and suspects of SARS-CoV-2 infection Coronavirus disease 19 infection CIGB-2020 alone, conventional treatment alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Center for Genetic Engineering and Biotechnology Instituto Pedro Kouri Cuba 2020-03-27 2020-06-30 CIGB 2020-01, RPCEC00000306 Phase 1/Phase 2 Clinical Recruiting 1 3 Months 80 Julia Cuesta Diéguez, Zurina Cinza Estévez 2020-04-27
PrevenCOVID-19: Study for the prevention of COVID-19 infection in healthcare personnel Coronavirus disease 19 infection hydroxychloroquine (Dolquine) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Spain 2020-04-19 2020-001440-26, PrevenCOVID-19, PrevenCOVID-19 Phase 3 Clinical Recruiting 1 184 CTU-HUVR, Clinical trial information 2020-04-27
TAC-COVID19: Outpatient Treatment Of Covid-19 With Early Pulmonary Corticosteroids As An Opportunity To Modify The Course Of The Disease Coronavirus disease 19 infection Variable regimens including azithromycin , hydroxychloroquine , paracetamol , prednisone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Hospital San Juan de Dios Burgos Hospital Universitario de Burgos Spain 2020-04-19 2020-001622-64, TAC-COVID19, TAC-COVID19 Phase 4 Clinical Recruiting 1 200 María Jesús Coma 2020-04-28
COVID-Aging: Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19: A Randomized, Multicenter, Adaptive, Blinded Study Coronavirus disease 19 infection Variable regimens including azithromycin , curcumin , hydroxychloroquine , telmisartan Angiotensin II receptor antagonist Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires de Strasbourg France 2020-04-11 2020-001303-16, 7747, COVID-Aging Phase 3 Clinical Recruiting 1 1600 Eric DEMONSANT 2020-04-28
CAPACoV19: Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation Coronavirus disease 19 infection data record alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Reims France 2020-05-01 2022-02-01 CAPACoV19, NCT04356378, PO20055 Phase Not Applicable Not yet recruiting 1 21 Months 300 Francois BOYER, François BOYER 2020-04-27
Efficacy of Tocilizumab on Patients With COVID-19 Coronavirus disease 19 infection, Hypoxia, Respiratory failure tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital Genentech Inc US 2020-04-27 2020-08-30 2020P001159, NCT04356937 Phase 3 Clinical Not yet recruiting 0 4 Months 300 Ana D Fernandes, MA, John H Stone, MD, John H Stone, MD,MPH 2020-04-27
CORONA-SHIELD: Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19 Coronavirus disease 19 infection radiation therapy alone, telehealth alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University US 2020-04-14 2021-04-30 CORONA-SHIELD, NCT04357574, PRO00105266 Phase Not Applicable Recruiting 0 12 Months 1000 Manisha Palta, MD 2020-04-24
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Coronavirus disease 19 infection, Respiratory failure best supportive care alone, nivolumab alone Programmed cell death protein 1 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Queen Mary Hospital The University of Hong Kong Hong Kong 2020-04-14 2021-08-31 NCT04356508, UW20213 Phase 2 Clinical Not yet recruiting 1 16 Months 15 Gerry Gin Wai Kwok, MBBS 2020-04-23
A phase II, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and preliminary efficacy of ATYR-1923 in confirmed COVID-19 positive patients with severe respiratory complications Coronavirus disease 19 infection ATYR-1923 alone Neuropilin 2 inhibitor aTyr Pharma Inc US Phase 2 Clinical Not yet recruiting 0 30 2020-04-23
A single-blinded, randomized, placebo-controlled phase II trial of prophylactic treatment with oral azithromycin versus placebo in cancer patients undergoing antineoplastic treatment during the covid-19 pandemic Coronavirus disease 19 infection azithromycin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Vienna Austria 2020-04-14 2020-001327-13, OnCoVID19Trial Phase 2 Clinical Recruiting 1 200 Matthias Preusser 2020-04-23
A clinical study evaluate the safety and efficacy of combination of chloroquine with azithromycin and interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19 Coronavirus disease 19 infection Variable regimens including azithromycin , chloroquine , interferon beta-1b, Bayer Interferon beta ligand Bayer Inc, Population Health Research Institute Canada Phase Not Applicable Planned 1 2020-04-23
MV-COVID19: Measles Vaccine in HCW Coronavirus disease 19 infection measles, mumps, rubella vaccine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Kasr El Aini Hospital Egypt 2020-05-01 2020-11-01 MV-COVID19, N-20-2020, NCT04357028 Phase 3 Clinical Not yet recruiting 2 6 Months 200 Abeer Ahmed, MD, Ahmed M Mukhtar, M.D, Doaa Ghaith, MD, Marwa Rashad, MD, Mostafa Alfishawy, MD 2020-04-24
A pilot study to assess the effect of beta-nicotinamide mononucleotide (NMN) in the prevention/treatment of patients with Covid-19 Coronavirus disease 19 infection beta-nicotinamide mononucleotide alone Shinkowa Pharmaceutical Co Ltd Phase Not Applicable Planned 0 2020-04-23
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Sciensano Jessa Hospital Belgium 2020-04-30 2020-07-30 JESSA300, NCT04356586 Phase Not Applicable Recruiting 2 3 Months 300 Maria Goossens, MD, PhD 2020-04-24
Feasibility, early intervention, chinese herbal treatment, addition to standard of care, COVID-19 Coronavirus disease 19 infection Chinese herbal treatment alone, standard care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sunway TCM Centre Malaysia 2020-05-01 2020-10-30 54625, NMRR-20-759-54625 Phase Not Applicable Status not specified 1 5 Months 100 Dr LIM REN JYE, Dr Lee Yee Leng 2020-04-24
PACA: Nebulized Rt-PA for ARDS Due to COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome invasive mechanical ventilation alone, nebulized recombinant tissue-plasminogen activator (rt-PA) alone, non-invasive ventilation alone, standard of care alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) University College London 2020-04-14 2021-01-14 132151, NCT04356833, PACA Phase 2 Clinical Not yet recruiting 0 9 Months 24 Mark Phillips 2020-04-23
SCout: Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections Coronavirus disease 19 infection, Viral pneumonia CT-imaging alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jena University Hospital Germany 2020-04-15 2020-04-30 IDIR-001-2020, NCT04357938, SCout Phase Not Applicable No longer recruiting 1 145 Ulf Teichgräber, Prof. Dr. 2020-04-23
RISC-19-ICU: The Risk Stratification in COVID-19 Patients in the ICU Registry Coronavirus disease 19 infection standard of care alone University of Zurich Switzerland 2020-03-13 2022-03-31 KEK-ZH-REQ-2020-00322, NCT04357275, RISC-19-ICU Phase Not Applicable Recruiting 1 24 Months 10000 Dorothea Heuberger, PhD, Jonathan Montomoli, MD, PhD, Matthias P Hilty, MD, Pedro D Wendel Garcia, MSc, Philippe Guerci, MD, Reto A Schüpbach, MD, Theirry Fumeaux, MD 2020-04-23
MODIF: Myocardial Infarction Rates Overview During COVID-19 Pandemic In France Coronavirus disease 19 infection, Myocardial infarction Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Société Française de Cardiologie INSERM France 2020-04-27 2020-07-31 2020-03, MODIF, NCT04357314 Phase Not Applicable Not yet recruiting 1 3 Months 80 Guillaume BONNET, MD, Guillaume CAYLA, MD, Tessa BERGOT 2020-04-23
COVIP: Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 Coronavirus disease 19 infection, HIV-1 infection, HIV-2 infection antiretroviral therapy alone, protease inhibitor therapy alone, usual care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Intercommunal Creteil Centre Hospitalier Intercommunal Villeneuve Saint Georges, Service des Urgences France 2020-04-30 2020-10-31 COVIP, COVIP, NCT04357639 Phase Not Applicable Not yet recruiting 5 6 Months 794 Alice RAFFETIN, MD, GARRAIT Valérie, MD, Gallien Sebastien, MD, Raffetin Alice, MD, SALMON Dominique, MD, Vignier Nicolas, MD 2020-04-27
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease Coronavirus disease 19 infection, Viral pneumonia azithromycin plus hydroxychloroquine (JWT-629) Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Novartis AG 2020-04-30 2020-07-21 CJWT629A12301, NCT04358081 Phase 3 Clinical Not yet recruiting 0 2 Months 444 Novartis Pharmaceuticals 2020-04-23
AVoCaDO: Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation Coronavirus disease 19 infection, Hypoxia, Respiratory distress syndrome, Respiratory failure ascorbic acid alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hunter Holmes Mcguire Veteran Affairs Medical Center Mcguire Research Institute Inc US 2020-04-16 2020-08-01 AVoCaDO, DAVIS 001, NCT04357782 Phase 1/Phase 2 Clinical Recruiting 0 3 Months 20 Brian C Davis, MD 2020-04-23
COVID-19 Among Egyptian Health Care Providers Coronavirus disease 19 infection online self-administered questionnaire alone Assiut University Egypt 2020-04-30 2020-05-31 COVIDQ, NCT04357431 Phase Not Applicable Not yet recruiting 1 1 Month 600 Ahmed Mohamed Abbas 2020-04-23
WAVE: Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories Coronavirus disease 19 infection smartwatch alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Inselspital, Berne ETH Zurich Switzerland 2020-05-01 2020-07-31 NCT04357834, WAVE, WAVE Phase Not Applicable Not yet recruiting 1 3 Months 100 Aristomenis Extradaktylos, Prof. MD, David D Srivastava, MD, MBA, David Srivastava, MD, MBA 2020-04-25
COPLASCOV19: Convalescent Plasma For Ill Patients By COVID-19 Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia convalescent plasma alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto De Seguridad Y Servicios Sociales De Los Trabajadores Del Estado ANGELES DE CHIHUAHUA HOSPITAL, GENERAL HOSPITAL OF THE STATE OF SONORA, HOSPITAL CENTRAL NACIONAL PEMEX NORTE, HOSPITAL DE ZONA No. 2 IMSS, HOSPITAL DE ZONA No.14 IMSS, SECRETARIA DE SALUD DEL ESTADO DE SONORA Mexico 2020-05-31 2020-12-31 COPLASCOV19, NCT04356482, TERAPLASCOV2 Phase 1/Phase 2 Clinical Not yet recruiting 5 7 Months 90 CARLOS BEST, MD, Carlos Martinez-Murillo, MD, Diego Espinoza, MD, FERNANDO PEREZ-JACOBO, MD, LUIS villela, MD, Luis M Villela, MD, Luis Villela, MD,MSc, Melani Otañez, MD 2020-04-28
Sarilumab treatment in cytokine storm caused by infection with COVID-19 Coronavirus disease 19 infection, Respiratory failure sarilumab alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Clinica Universidad de Navarra Spain 2020-04-16 2020-001255-40, STRIKE-SARS-CoV2 Phase 2 Clinical No longer recruiting 1 60 UCEC 2020-04-23
Covid-Thelium: Assessment of Endothelial and Hemostatic Changes During Severe SARS-CoV-2 Infection Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Boisguillaume France 2020-04-09 2020-08-31 2020/097/OB, Covid-Thelium, NCT04357847 Phase Not Applicable Recruiting 1 4 Months 100 EBESNIER, emmanuel besnier, MD, thomas clavier, MD, PhD 2020-04-27
SARICOR: Clinical Trial of Sarilumab in Adults With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome best available treatment alone, sarilumab alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Maimonides Biomedical Research Institute of Cordoba Consejeria de Salud. Junta de Andalucia Spain 2020-04-18 2020-07-27 2020-001531-27, NCT04357860, SARICOR, SARICOR Phase 2 Clinical Recruiting 1 3 Months 120 Antonio Luque, José Carlos Garrido Gracia, Julián de la Torre Cisneros, MD, Rafael León López, MD 2020-04-28
COVID-TGT: Analysis of the Coagulopathy Developed by COVID-19 Infected Patients Coronavirus disease 19 infection fibrin generation markers assays alone, thrombin generation test assay alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Nimes France 2020-04-30 2021-01-31 COVID-TGT, NCT04356950, PHRC-I/2020/JCG-01 Phase Not Applicable Not yet recruiting 4 9 Months 175 Albert Sotto, Anissa Megzari, Antonia Perez Martin, Catherine Lechiche, Charles Cazenave, Claire Roger, Claudine Barbuat, Didier Laureillard, Isabelle Quere, Jean-Christophe Gris, Jean-François Faucher, Jean-Marc Mauboussin, Jean-Yves Lefrant, Kada Klouche, Laurent Muller, Paul Loubet, Saber D Barbar, Vincent Le Moing 2020-04-24
Plasma Adsorption in Patients With Confirmed COVID-19 Coronavirus disease 19 infection D2000 plasma adsorption cartridge alone, Optia secondary plasma device alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Marker Therapeutics AG 2020-04-27 2020-12-01 MH-007/B, NCT04358003 Phase Not Applicable Not yet recruiting 0 7 Months 2000 Eeke Romo, MD 2020-04-25
Registry of Hospitalized Pediatric Patients with SARS-CoV-2 Infection (COVID-19) Coronavirus disease 19 infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) University Hospital Carl Gustav Carus Germany 2020-03-18 BO-EK-110032020, DRKS00021506 Phase Not Applicable Recruiting 1 1000 Jakob Armann 2020-04-24
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National Institute of Allergy and Infectious Diseases Teva Pharmaceutical Industries Ltd 2020-05-01 2021-03-05 38720, ACTG A5395, NCT04358068 Phase 2b Clinical Not yet recruiting 0 10 Months 2000 Davey Smith, MD 2020-04-24
ICOS: Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives Anxiety disorder, Coronavirus disease 19 infection, Depression, Psychiatric disorder survey alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre hospitalier de Ville-Evrard France 2020-04-01 2020-06-30 10477M-ICOS, ICOS, NCT04357418 Phase Not Applicable No longer recruiting 1 3 Months 1320 Clemence ISAAC, PhD, Dominique JANUEL, Pr 2020-04-25
Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections Coronavirus disease 19 infection thrombin generation assay alone, thrombomodulin-modified thrombin generation assay alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Vienna Medizinisch-Wissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt Wien Austria 2020-04-17 2020-12-01 NCT04356144, TGA-TM-CRITICAL-2019 Phase Not Applicable Not yet recruiting 1 7 Months 60 Lukas Infanger, Lukas Infanger, MD, Marion Wiegele, MD 2020-04-24
Dysosmia and Dysgeusia in COVID-19 patients Coronavirus disease 19 infection, Dysgeusia, Dysomia smell and taste test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kantonsspital Aarau Switzerland 2020-04-22 2020-00666, DRKS00021516 Phase Not Applicable Recruiting 1 100 Thirza Singer-Cornelius 2020-04-27
Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome Coronavirus disease 19 infection methylprednisolone pulse therapy alone, hydroxychloroquine plus methylprednisolone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Artesh University of Medical Sciences Iran 2020-03-30 IR.AJAUMS.REC.1399.008, IRCT20200406046963N1 Phase 3 Clinical Recruiting 1 40 Ebrahim Hazrati, Ebrahim hazrati, Ramin Hamidi Farahani, Reza Mosaed 2020-04-24
A prospective, single-center, parallel-group, open-label, randomized clinical trial to assess the efficacy of CPAP in 200 COVID-19 confirmed or suspected patients within the Mount Sinai Health System with respiratory symptoms Coronavirus disease 19 infection, Obstructive sleep apnea CPAP alone, WatchPAT ONE alone Itamar Medical (Cm) 1997 Ltd US Phase 2 Clinical Status not specified 0 200 Neomi Shah 2020-04-27
What’s the STORY?: A pilot, multi-site, UK immunization program to assess novel coronavirus infection (COVID-19) rates in children and teenagers across the UK Coronavirus disease 19 infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) University of Oxford United Kingdom Research & Innovation UK What’s the STORY? Phase Not Applicable Recruiting 1 1200 Professor Matthew Snape 2020-04-23
A compassionate use program of Ruconest in hospitalized patients with confirmed COVID-19 infections suffering from related severe pneumonia who did not improve despite standard treatment, including hydroxychloroquine and lopinavir/ritonavir Coronavirus disease 19 infection, Viral pneumonia conestat alfa alone Complement C1s subcomponent inhibitor, Kallikrein modulator, Mannan-binding lectin serine protease inhibitor Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Pharming Group NV Switzerland Phase 2 Clinical Status not specified 1 5 2020-04-23
Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19) Coronavirus disease 19 infection rapid salivary test alone Healthy volunteers accepted Università degli Studi dell'Insubria Italy 2020-04-16 2020-07-31 68/2020, NCT04357327 Phase Not Applicable Recruiting 1 3 Months 100 Lorenzo Azzi, Lorenzo Azzi, DDS 2020-04-27
Comparison of New Coronavirus (Covid-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey Coronavirus disease 19 infection Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istanbul University-Cerrahpasa Turkey 2020-05-31 2020-06-30 60350273-605.99-, NCT04357886 Phase Not Applicable Not yet recruiting 1 1 Month 1000 Aysenur Erekdag, Student, Ipek Yeldan, PhD, Saliha Gurdal Karakelle, MSc 2020-04-27
CoVS: COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being Coronavirus disease 19 infection staying home alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Illinois Institute of Technology US 2020-04-17 2021-04-30 CoVS, IRB-2020-91, NCT04357041 Phase Not Applicable Recruiting 0 12 Months 500 Britt Burton-Freeman, Ph.D, Di Xiao, MAS, Indika Edirisinghe, Ph.D 2020-04-23
PSYCHIC: Psychiatric Disorders and Covid-19 Coronavirus disease 19 infection, Post traumatic stress disorder, Psychiatric disorder Brief Psychiatric Rating Scale alone, Connor-Davidson Resilience Scale 10 items (CD-RISC 10) alone, Impact of Event Scale-Revised alone, depression, Anxiety and Stress Scale alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) CHU De Nantes France 2020-04-25 2023-01-01 NCT04358042, PSYCHIC, RC20-0165 Phase Not Applicable Not yet recruiting 1 32 Months 250 Gaelle CHALLET, Marie GRALL-BRONNEC 2020-04-27
A prospective, multicenter, randomized, placebo-controlled, double-blind, phase II clinical study to assess the efficacy, safety and tolerability of IMU-838 in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection standard-of-care antiviral therapy alone, vidofludimus alone Dihydroorotate dehydrogenase inhibitor, IL-17 antagonist Immunic Inc Europe, US Phase 2 Clinical Planned 0 2020-04-23
A multinational, randomized, controlled, investigator-initiated clinical trial in patients with confirmed COVID-19 infections Coronavirus disease 19 infection conestat alfa alone Complement C1s subcomponent inhibitor, Kallikrein modulator, Mannan-binding lectin serine protease inhibitor Pharming Group NV Switzerland Phase Not Applicable Planned 1 150 Michael Osthoff 2020-04-23
A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device Coronavirus disease 19 infection RBA-2, Kaligia Biosciences alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kaligia Biosciences LLC University of South Florida US 2020-04-30 2020-12-31 KBS005, NCT04357977 Phase Not Applicable Not yet recruiting 0 8 Months 300 Asa Oxner, MD, Elsie Medina, MS, Fazal Fazlin, Janice Shirley, MPH MBA PA-C, Jose Tirado, Rachel Karlnoski, PhD 2020-04-24
Etoposide in Patients With COVID-19 Infection Coronavirus disease 19 infection, Respiratory failure etoposide phosphate alone Topoisomerase II inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Boston Medical Center Corp US 2020-04-30 2021-12-31 H-40102, NCT04356690 Phase 2 Clinical Not yet recruiting 0 20 Months 134 John Mark Sloan, MD, Sally A Fennessey, BS 2020-04-24
COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department Coronavirus disease 19 infection, Upper respiratory tract infection COVID-19 test alone, polymerase chain reaction alone Healthy volunteers accepted Rigshospitalet, Denmark Denmark 2020-03-23 2020-12-31 DT P-2020-353, NCT04356560 Phase Not Applicable Recruiting 1 9 Months 300 Inge J Knudsen, MD, Nikolai S Kirkeby, MSc, Ramon G Jensen, MD 2020-04-25
Cell therapy in patients with coronavirus19 Coronavirus disease 19 infection mesenchymal stem cells alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Barakat Pharmaceutical Group, Tehran University of Medical Sciences Iran 2020-04-20 IR.TUMS.VCR.REC.1399.203, IRCT20190717044241N2 Phase 1 Clinical Recruiting 1 10 Dr Javad Verdi- Dr Neda Alijani, Dr Mohammad Ali Sahraian, Dr Neda Alijani, Dr. Akbar Borandegi, Mahshid Saleh 2020-04-24
KONS-COVID-19: Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19 Coronavirus disease 19 infection, Upper respiratory tract infection Kerecis Oral and Nasal Spray device (Kerecis Ehf) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kerecis Ehf Iceland 2020-04-30 2020-07-31 KONS-COVID-19, KS-0470, NCT04357990 Phase Not Applicable Not yet recruiting 1 3 Months 81 2020-04-27
TRAPSAH: Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse Coronavirus disease 19 infection, Diabetes mellitus, Respiratory failure angiotensin receptor blocker (ARB) therapy alone, angiotensin-converting enzyme (ACE) therapy alone, chloroquine alone, hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris GIS EPI-PHARE France 2020-04-30 2020-06-30 APHP200412, NCT04356417, TRAPSAH Phase Not Applicable Not yet recruiting 1 2 Months 6000000 Emilie SBIDIAN, Pr, Emilie Sbidian, Pr 2020-04-26
STARS: Study of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19) Coronavirus disease 19 infection, Respiratory failure alteplase plus unfractionated heparin Tissue plasminogen activator stimulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Denver Health and Hospital Authority Beth Israel Deaconess Medical Center, Genentech Inc, Long Island Jewish Med Center, National Jewish Health, University of Colorado, Denver, US US 2020-04-30 2020-10-31 20-0880, NCT04357730, STARS Phase 2a Clinical Not yet recruiting 0 6 Months 60 Arsen Ghasabyan, MPH, Ernest "Gene" Moore, MD, Ernest E Moore, MD 2020-04-26
A new clinical trial to significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives using D'OXYVA (deoxyhemoglobin vasodilator) Coronavirus disease 19 infection D'OXYVA (deoxyhemoglobin vasodilator) alone Circularity Healthcare LLC US Phase Not Applicable Planned 0 2020-04-23
Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19) Coronavirus disease 19 infection, Heart arrhythmia Mount Sinai School of Medicine US 2020-04-09 2021-12-31 GCO 20-0931, NCT04358029 Phase Not Applicable Recruiting 0 20 Months 10000 Betsy Ellsworth, MSN, Martin Goldman, MD, Stephanie Harcum, MS, Vivek Reddy, MD 2020-04-27
PsyCOVID: COVID-19 Pandemic Burden in Severe Mental Disease Patients Acute stress disorder, Anxiety disorder, Bipolar disorder, Coronavirus disease 19 infection, Major depressive disorder, Psychotic disorder, Schizophrenia GAD-7 (7-item Generalized Anxiety Disorder) alone, PHQ-9 (9-item Patient Health Questionnaire) alone, PSS (Perceived Stress Scale) alone, SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales alone, Zaritt Burden Interview alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universita degli Studi di Napoli Federico II Italy 2020-04-10 2020-04-25 152/20, NCT04357769, PsyCOVID Phase Not Applicable Recruiting 1 400 Felice Iasevoli, Felice Iasevoli, M.D., Ph.D. 2020-04-26
COVeR: COVID-19 Epidemic Response Study Coronavirus disease 19 infection Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centogene Gmbh Germany 2020-04-20 2020-10-30 COVER-2020, COVeR, NCT04357496 Phase Not Applicable Not yet recruiting 1 6 Months 400 Arndt Rolfs, Prof., Volha Skrahina, PhD 2020-04-26
The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's) Anxiety disorder, Coronavirus disease 19 infection, Depression Non-pharmacological interventions alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Oslo Modum Bad Norway 2020-03-31 2020-04-07 NCT04356365, REK125510 Phase Not Applicable Completed 1 10084 Asle Hoffart, PhD, Omid V. E Ebrahimi, Double PhD Candidate, Sverre Urnes Johnson, PhD 2020-04-27
Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection Coronavirus disease 19 infection, Respiratory failure AirGo respiratory monitor alone, non-invasive monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital US 2020-04-15 2020-12-31 2020P000881, NCT04356443 Phase Not Applicable Recruiting 0 8 Months 500 Jeanine Wiener-Kronish, MD, M. Brandon Westover, MD, PhD, Omar Hyder, Omar Hyder, MD, MS 2020-04-27
Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives Cardiac failure, Coronary artery disease, Coronavirus disease 19 infection, Diabetes mellitus, Hypertension, Respiratory distress syndrome angiotensin II receptor blocker therapy alone, angiotensin-converting enzyme inhibitor therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) King Faisal Specialized Hospital & Research Center Saudi Arabia 2020-04-12 2020-09-30 2210061, NCT04357535 Phase Not Applicable Recruiting 1 5 Months 226 Abir H Omer, Hakeam A Hakeam, MS Pharm, Hakeam A Hakeam, MSPharm BCPS, Muhannad A Alsemari, MBBS 2020-04-27
SCHIZOVID-19: COVID-19 and Psychotic Symptoms in France Coronavirus disease 19 infection, Hallucination, Paranoia, Psychotic disorder survey alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) University Hospital, Montpellier Centre référent de réhabilitation psychosociale de Grenoble, Epsylon Laboratory, Universite Grenoble Alpes France 2020-04-01 2020-08-01 NCT04356885, RECHMPL20_0225, SCHIZOVID-19 Phase Not Applicable Recruiting 1 4 Months 600 Stephane Raffard, PhD, Stéphane RAFFARD, PhD 2020-04-24
COPLA: Treatment of Severe Forms of Coronavirus Infection With Convalescent Plasma Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centro de Hematologia y Medicina Interna Laboratorios Clinicos de Puebla, Laboratorios Ruiz Mexico 2020-04-13 2020-08-31 CHMI-030420-01, COPLA, NCT04357106 Phase 2 Clinical Recruiting 1 4 Months 10 Guillermo J Ruiz-Arguelles, MD, FRCP, MACP, DSc, Guillermo J. RUIZ-ARGÜELLES, José Manuel Priesca-Marin, MD, Juan Carlos Olivares-Gazca, MD, MPH, Juan Carlos Olivares-Gazca, MD,MPH 2020-04-27
Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19 Coronavirus disease 19 infection Zofa alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Baqiyatallah University of Medical Sciences, Niak Pharmaceutical Company Iran 2020-03-30 IR.BMSU.REC.1399.027, IRCT20080901001165N48 Phase 3 Clinical Recruiting 1 100 Ali Ghazvini, Parisa Kianpour, Yunes Panahi 2020-04-27
Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure, Viral pneumonia antivirals alone, convalescent plasma alone, mechanical ventilation alone, oxygen therapy alone, supportive care therapies alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-05-04 IR.TBZMED.REC.1399.018, IRCT20200406046968N2 Phase 2/Phase 3 Clinical Not yet recruiting 1 30 Haleh Mikaeili 2020-04-27
A prospective, cohort study to follow the health status of medical staff engage in COVID-19 Coronavirus disease 19 infection medical staff followup alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Yokohama City University Japan 2020-04-23 UMIN000040219 Phase Not Applicable Recruiting 1 30 Takuma HIGURASHI 2020-04-27
IMAGE-19: Imatinib In COVID-19 Disease In Aged Patients Coronavirus disease 19 infection imatinib alone Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Aged Adults (65-79 yrs), Elderly Adults (80 and over) Versailles University Hospital France 2020-05-01 2020-12-01 IMAGE-19, NCT04357613, P20/05_IMAGE19 Phase 2 Clinical Not yet recruiting 2 7 Months 99 Laure Morisset, Malvy, Philippe Rousselot 2020-04-27
Tranilast in COVID19 Coronavirus disease 19 infection, Viral pneumonia Tranilast ( TAIYO ) alone, routine treatment alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ahvaz University of Medical Sciences Iran 2020-05-04 IR.AJUMS.REC.1399.050, IRCT20200419047128N1 Phase 3 Clinical Not yet recruiting 1 60 Ali khodadadi, َAli Khodadadi 2020-04-27
LILIADE-COVID: Low Dose of IL-2 In Acute Respiratory Distress Syndrome Related to COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome aldesleukin (subcutaneous, autoimmune/inflammatory disorders/allergy/spontaneous abortion), ILTOO Pharma alone Interleukin-2 ligand Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris ILTOO Pharma France 2020-04-30 2020-07-31 2020-001571-32, APHP200406, LILIADE-COVID, NCT04357444 Phase 2 Clinical Not yet recruiting 1 3 Months 30 Jean-Michel CONSTANTIN, Jean-Michel CONSTANTIN, MD, PhD 2020-04-24
A Phase II Study of DN-TNF to treat patients with pulmonary complications from COVID-19 infection Coronavirus disease 19 infection, Hypoxia, Lung disease, Respiratory distress syndrome anti-TNF therapy, (pulmonary complications/COVID-19), INmune Bio alone ICAM-1 stimulator, TNF antagonist, Vascular cell adhesion protein 1 agonist INmune Bio Inc Phase 2 Clinical Not yet recruiting 0 2020-04-27
AIRVM-COVID: Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to COVID-19-related Pneumonia Coronavirus disease 19 infection, Hypoxia, Respiratory failure, Viral pneumonia almitrine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Assistance Publique Hopitaux de Paris Centre Hospitalier of Chartres France 2020-04-30 2020-07-31 2020-001909-22, AIRVM-COVID, APHP200461, NCT04357457 Phase 3 Clinical Not yet recruiting 1 3 Months 212 Pierre KALFON, PU-PH, Yonathan FREUND, PU-PH, Yonathan Freund, PU-PH 2020-04-27
Clinical trial of RLS-0071 for inflammatory disorders, such as acute lung injury, caused by an inflammatory response, such as due to COVID-19 infection Coronavirus disease 19 infection, Inflammatory disease, Lung injury PIC1-01 alone Complement C1s subcomponent inhibitor ReAlta Life Sciences Inc Phase Not Applicable Planned 0 2020-04-27
TOC-COVID: A prospective, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia Coronavirus disease 19 infection, Viral pneumonia conventional treatment alone, tocilizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum der Albert-Ludwigs Universitaet Freiburg Germany 2020-04-27 2020-001408-41, 203/20 (FF-MC), DRKS00021238, TOC-COVID Phase 2 Clinical Not yet recruiting 2 200 Mr PD Dr Tobias Wengenmayer 2020-04-24
Biomarker COVID-19: Local and systemic markers of inflammation and circadian rhythmicity in COVID-19 disease and their role in the prediction of clinical outcome Coronavirus disease 19 infection, Respiratory failure intensive care therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum der Albert-Ludwigs Universitaet Freiburg Germany 2020-04-21 225/20, Biomarker COVID-19, DRKS00021522 Phase Not Applicable Recruiting 1 50 Nils Schallner 2020-04-24
COVID-19 BaWu: Prevalence of COVID-19 in children aged 1 to 10 years in Baden-Wurttemberg Coronavirus disease 19 infection Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs) Zentrum für Infektionskrankheiten Germany 2020-04-22 COVID-19 BaWu, DRKS00021521, S-294/2020 Phase 0 Clinical Recruiting 5 2000 Georg Friedrich Hoffmann, Hanna Renk, Hans-Georg Kräusslich, Klaus-Michael Debatin, Philipp Henneke 2020-04-24
COVID-19 Data-bank Project Coronavirus disease 19 infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mahajan Imaging Center India 2020-04-17 CTRI/2020/04/024697 Phase Not Applicable Not yet recruiting 3 100000 Dr Anurag Agarwal, Dr Sushila Kataria, VIdur Mahajan 2020-04-27
A phase II clinical trial to evaluate the safety and efficacy of ArtemiC on patients diagnosed with COVID-19 Coronavirus disease 19 infection ArtemiC alone MGC Pharma Swiss PharmaCan AG Israel Phase 2 Clinical Not yet recruiting 1 50 2020-04-23
A clinical study on side effects of hydroxychloroquine in health care workers Coronavirus disease 19 infection hydroxychloroquine alone Indian Council of Medical Research Phase Not Applicable Status not specified 0 2020-04-24
A clinical trial to evaluate the efficacy of hydroxychloroquine as a preventive medicine for COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Indian Council of Medical Research Phase 3 Clinical Recruiting 0 480 2020-04-24
A large, multi-arm study to assess the effect of SARS-CoV-2 vaccine in the prevention of patients with Covid-19 Coronavirus disease 19 infection SARS-CoV-2 vaccine (Dynavax adjuvant CpG1018, COVID-19), CEPI/ University of Queensland alone University of Queensland Netherlands 2020-09-30 Phase Not Applicable Planned 1 2020-04-27
Use of UC-MSCs for COVID-19 Patients Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome standard of care alone, umbilical cord-derived mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Miami US 2020-04-17 2021-05-01 20200370, NCT04355728 Phase 1/Phase 2 Clinical Recruiting 0 12 Months 24 Camillo Ricordi, MD, David A Baidal, M.D., Khemraj Hirani, MPharm PhD RPH, Rodolfo Alejandro, M.D. 2020-04-25
Gut Microbiota, 'Spark and Flame' of COVID-19 Disease Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universidade Nova De Lisboa CINTESIS - Centre for Health Technology and Services Research, CUF Academic and Research Medical Center, Centro Hospitalar Lisboa Ocidental, Centro Hospitalar Sao Joao, Centro de Medicina Laboratorial Germano de Sousa, S.A., Hospital CUF Infante Santo, S.A., Nova Medical School Portugal 2020-04-30 2020-12-31 COVID19_MICROBIOTA, NCT04355741 Phase Not Applicable Not yet recruiting 3 8 Months 60 André Rosário, PhD, Conceição Calhau, PhD, Cristina Granja, PhD, Gonçalo Marcelino, José Leal, PhD, Maria JR Sousa, PhD, Pedro Póvoa, PhD 2020-04-24
Convalescent Plasma versus Placebo in Emergency Room Patients With COVID-19 Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stanford University US 2020-05-31 2022-12-31 56249, NCT04355767 Phase 2 Clinical Not yet recruiting 0 31 Months 206 Kevin Schulman, MD, Study Team 2020-04-23
TARUS: The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic Anxiety disorder, Coronavirus disease 19 infection survey alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ariel University Israel 2020-03-31 2020-05-31 AU-HEA-VKS-20200329, NCT04353934, TARUS Phase Not Applicable Recruiting 1 2 Months 3000 Mona Boaz, RD, PhD, Vered Kaufman-Shriqui, RD, PhD 2020-04-23
URGDENTCOVID: Evaluation of Dental Emergency Treatments During COVID19 Crisis Coronavirus disease 19 infection, Tooth disease survey alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris 2020-04-13 2020-06-20 APHP200464, NCT04354272, URGDENTCOVID Phase Not Applicable Not yet recruiting 0 2 Months 840 Isabelle Rodriguez, Yves Boucher, MD, PhD 2020-04-23
ENVIROREA: Study of the Dissemination of SARS-COV-2 in the Environment of Infected Patients Admitted to Intensive Care Unit Coronavirus disease 19 infection, Lower respiratory tract infection Coriolis system alone, RT-PCR alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-30 2020-12-31 2020-A00897-32, APHP200411, ENVIROREA, NCT04355481 Phase Not Applicable Recruiting 3 8 Months 150 Guillaume Voiriot, Dr, Lila Bouadma, Dr, Nacira DARGHAL, Yacine TANDJAOUI-LAMBIOTTE, Dr 2020-04-28
An investigator-initiated clinical trial of valsartan in patients with COVID-19 infection Coronavirus disease 19 infection valsartan alone Angiotensin I receptor antagonist, Angiotensin II receptor antagonist Novartis AG Phase Not Applicable Planned 0 2020-04-22
Assessment of Seroprevalence and Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil Coronavirus disease 19 infection IgG/IgM SARS-CoV-2 rapid test alone, blood sampling alone Healthy volunteers accepted Instituto Butantan Brazil 2020-05-15 2022-05-15 COV-01-IB, NCT04355338 Phase Not Applicable Not yet recruiting 1 24 Months 4030 Ricardo Palacios, MD, PhD 2020-04-23
An investigator-initiated clinical study of secukinumab for the treatment in patients with COVID-19 infection Coronavirus disease 19 infection secukinumab alone IL-17 antagonist Novartis AG Phase Not Applicable Planned 0 2020-04-22
An investigator-initiated clinical study of imatinib mesylate for the treatment in patients hospitalized with COVID-19 Coronavirus disease 19 infection imatinib alone Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Novartis AG Phase Not Applicable Planned 0 2020-04-22
A clinical study of canakinumab for the treatment in patients hospitalized with COVID-19 infection Coronavirus disease 19 infection canakinumab alone Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor Novartis AG Phase Not Applicable Planned 0 2020-04-22
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection Coronavirus disease 19 infection, Respiratory distress syndrome ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Incyte Corp US INCB 18424-MA-COVID-19-301, NCT04355793 Phase Not Applicable Recruiting 0 Incyte Corporation Call Center (US) 2020-04-25
CORIA: Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia Cancer, Coronavirus disease 19 infection, HIV infection, Immune deficiency blood sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National Centre in HIV Epidemiology and Clinical Research Blacktown Hospital, Cancer Council New South Wales, Cancer Institute New South Wales, Garvan Institute of Medical Research, Gilead Sciences Inc, Holdsworth House Medical Practice, Melanoma Institute Australia, Positive Life NSW, Prince of Wales Hospital foundation, Royal North Shore Hospital, St Vincents Hospital Sydney Ltd, Westmead Hospital Australia 2020-04-27 2022-04-27 2020-04-CORIA, CORIA, NCT04354818 Phase Not Applicable Not yet recruiting 1 24 Months 1000 Griselda Buckland, Mark Polizzotto, MD 2020-04-23
COSTA: Open-label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to 'no Treatment' in SARS CoV 2 Virus Coronavirus disease 19 infection, Viral pneumonia camostat mesylate plus hydroxychloroquine Serine protease inhibitor, Trypsin inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sheba Medical Center Israel 2020-04-11 2020-12-11 7092-20-SMC, COSTA, NCT04355052 Phase 3 Clinical Recruiting 1 8 Months 250 Irit Avisar, RN, Itsik Levy Dr, Itzchak Levy, MD 2020-04-22
A randomized, double-blind, placebo-controlled Phase IIa study to evaluate the safety and efficacy of opaganib in adult patients hospitalized with positive SARS-CoV-2 and pneumonia Coronavirus disease 19 infection, Viral pneumonia opaganib alone Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor RedHill Biopharma Ltd US Phase 2a Clinical Planned 0 60 2020-04-22
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection Coronavirus disease 19 infection, SARS coronavirus infection anti-SARS-CoV-2 convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical College of Wisconsin Froedtert Hospital US 2020-05-01 2023-05-01 NCT04354831, PRO00037712 Phase 2 Clinical Not yet recruiting 0 36 Months 106 Mary Beth Graham, Mary Beth Graham, MD, Sonija Parker 2020-04-22
Soliris (Eculizumab) Treatment of Participants With COVID-19 Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia eculizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Alexion Pharmaceuticals Inc France ECU-COV-401, NCT04355494 Phase Not Applicable Recruiting 5 Alexion Pharmaceuticals Inc. 2020-04-26
Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of coronavirus disease Coronavirus disease 19 infection Herbal supplement alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jahrom University of Medical Iran 2020-05-04 IR.JUMS.REC.1399.003, IRCT20200415047082N1 Phase 2/Phase 3 Clinical Not yet recruiting 1 10 Alireza hashemi shiri, Esmail Rayat dost, Rahim raufi 2020-04-23
HyPreC: Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women Coronavirus disease 19 infection hydroxychloroquine (Plaquenil) alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Sir Mortimer B Davis Jewish General Hospital 2020-05-31 2020-11-30 1, MARCH 30, 2020, HyPreC, NCT04354441 Phase 2 Clinical Not yet recruiting 0 6 Months 600 Haim Abenhaim 2020-04-23
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm Coronavirus disease 19 infection methylprednisolone  alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Auxilio Mutuo Cancer Center Puerto Rico 2020-04-14 2021-04-30 CCAM 20-01, NCT04355247 Phase 2 Clinical Recruiting 2 12 Months 20 Carmelo Santana-López, MD, Fernando Cabanillas, MD, Idalia Liboy, MD, James Bryan, MD, José Abreu-Arbelo, MD, Juan Arraut, MD, Luis Cotto, MD, Margarita Bruno, MD, Mirelis Acosta-Rivera, MD 2020-04-24
CovidAmiens20: French Single-center Experience of Critically Ill Patients With COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire D Amiens France 2020-04-30 2021-04-30 CovidAmiens20, NCT04354558, PI2020_843_0026 Phase Not Applicable Not yet recruiting 1 12 Months 200 Osama Abou Arab, MD 2020-04-22
COVIPREG: Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns Coronavirus disease 19 infection PCR test alone, serology test alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-24 2021-08-31 APHP 200448, COVIPREG, NCT04355234 Phase Not Applicable Not yet recruiting 1 16 Months 2200 Christelle Vauloup Fellous, Vassilis Tsatsaris 2020-04-28
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Headache, Lower respiratory tract infection, Myalgia, Respiratory distress syndrome selinexor alone Exportin 1 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Karyopharm Therapeutics Inc 2020-04-30 2020-08-30 NCT04355676, XPORT-COV-1002 Phase 2 Clinical Not yet recruiting 0 4 Months 80 Dayana Michel, Jatin Shah Chief Medical Officer, Sharon Shacham President and CSO 2020-04-23
ILIAD: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis Coronavirus disease 19 infection peginterferon lambda-1a alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University Health Network Canada 2020-04-21 2020-11-30 ILIAD, JF-4-2020, NCT04354259 Phase 2 Clinical Not yet recruiting 1 7 Months 140 Jordan Feld, MD, Josh Booth 2020-04-23
Study to Evaluate Preventive Effect of Ayurveda and Homeopathy Treatment in COVID-19 Coronavirus disease 19 infection Variable regimens including Aesenic Album , Khadiradi Vat , Murrchhita Tila Taila , Samshamani Vati , Sudarshan Ghana Vati Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Parul Institute of Ayurved India 2020-04-24 CTRI/2020/04/024731 Phase 3 Clinical Not yet recruiting 1 50 Dr Harish Daga, Dr Hemant Toshikhane, Dr Shailesh Deshpande 2020-04-24
Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia Coronavirus disease 19 infection, Lung infection, Viral pneumonia bromhexine plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) General Hospital Celje Slovenia 2020-04-10 2020-07-31 NCT04355026, SBCEBROMHEXINCOVID-19 Phase 4 Clinical Recruiting 1 3 Months 90 Matej Podbregar, Miha Mežnar, matej Podbregar 2020-04-24
COVID19@Spain: Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain Coronavirus disease 19 infection chest x-ray alone, oxygen therapy alone, real-time polymerase chain reaction (RT-PCR) alone, systemic corticosteroids therapy alone, tocilizumab alone Fundacion SEIMC-GESIDA Spain 2020-03-18 2020-04-17 COVID-19/SEIMC-FSG, COVID19@Spain, NCT04355871 Phase Not Applicable No longer recruiting 6 1 Month 3000 Jerónimo Pachón, MD, Jesús Rodriguez Baños, MD, Jordi Carratala, MD, Jose Ramón Arribas, MD, Juan Berenguer, MD, Pablo Ryan, MD 2020-04-23
DEFEAT COVID-19: A Multicenter, Retrospective Study to Evaluate the Efficacy of Systemic Gluco-corticoid Against COVID-19 Coronavirus disease 19 infection systemic Gluco-corticoid therapy alone Kanagawa Cardiovascular and Respiratory Center Japan 2020-05-01 DEFEAT COVID-19, UMIN000040211 Phase Not Applicable Recruiting 12 500 Satoshi Ikeda, Takashi Ogura 2020-04-24
Asymptomatic COVID-19 Infection Among Healthcare Workers Coronavirus disease 19 infection blood sampling alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Kasr El Aini Hospital Egypt 2020-04-25 2020-07-10 N-18-2020, NCT04354792 Phase Not Applicable Not yet recruiting 2 2 Months 1000 Ahmed M Mukhtar, M.D, Ahmed Mukhtar, Mohamed Elayashy Mohamed Ahmed Hassan, M.D, FCAI 2020-04-23
A clinical study to assess convalescent plasma in the treatment of patients with COVID-19 Coronavirus disease 19 infection convalescent plasma alone Froedtert & Medical College of Wisconsin US Phase Not Applicable Recruiting 0 Mary Beth Graham, MD 2020-04-22
CoVID-19 Plasma in Treatment of COVID-19 Patients Coronavirus disease 19 infection convalescent COVID 19 plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Christ Hospital US 2020-04-30 2020-08-31 20-23, NCT04355897 Phase 0 Clinical Recruiting 0 4 Months 100 Belinda Frakes, RN, Dean J Kereiakes, MD 2020-04-28
A randomized, placebo-controlled study to evaluate the use hydroxychloroquine for the prevention of COVID-19 amongst exposed healthcare workers and household contacts, as well as evaluates the use of hydroxychloroquine for the early treatment of mild cases Coronavirus disease 19 infection hydroxychloroquine alone St Josephs Healthcare Hamilton Mint Pharmaceuticals Inc Canada Phase Not Applicable Status not specified 1 Dr. Zain Chagla 2020-04-23
Ruxolitinib to Combat COVID-19 Coronavirus disease 19 infection ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Washington University School of Medicine, US Incyte Corp US 2020-06-30 2021-12-31 04-13-20-DUBBERKE, 04-13-20-DiPersio, NCT04354714 Phase 2 Clinical Not yet recruiting 0 18 Months 25 Erik Dubberke, M.D., MSPH, John DiPersio, M.D., Ph.D., Mark Fiala, MSW, Scott Goldsmith, M.D. 2020-04-28
COVID-19 PrEP HCW HCQ Study Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) NYU Langone Health US 2020-04-03 2020-09-01 NCT04354870, S20-00390 Phase 2 Clinical Recruiting 0 4 Months 350 Emily Beato, Lisa Zhao, Michael Belmont, MD 2020-04-23
PED-COVID: Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19 Coronavirus disease 19 infection, Immune disorder Classic test (Institut Pasteur) alone, Immunoprotection (neutralizing Ab, Institut Pasteur) alone, Rapid test (NGBiotech / CEA) alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) Assistance Publique Hopitaux de Paris Commissariat a l`Energie Atomique, INSERM, Institut Pasteur, NG Biotech France 2020-04-30 2021-07-31 2020-A00999-30, APHP200467, NCT04355533, PED-COVID Phase Not Applicable Not yet recruiting 3 15 Months 1920 Isabelle SERMET-GAUDELUS, MD, PhD, Isabelle SERMET-GAUDELUS, MD,PhD, Nelly BRIAND, PhD 2020-04-28
COVID-Scan: Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia Coronavirus disease 19 infection RT-PCR Test alone, chest CT scan alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Montpellier France 2019-04-01 2020-10-20 COVID-Scan, NCT04355715, RECHMPL20_0223 Phase Not Applicable No longer recruiting 1 18 Months 200 Philippe Gaudard, MD 2020-04-28
A clinical study to evaluate the efficacy of tPA in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection, Respiratory failure tPA alone Mount Sinai Medical Center US Phase 2 Clinical Status not specified 0 5 2020-04-23
CAPTOCOVID: Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia captopril alone ACE inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-13 2020-08-31 APHP200410, CAPTOCOVID, NCT04355429 Phase 2 Clinical Not yet recruiting 8 4 Months 230 Alexandre BLEIBTREU, MD, Anne-Lise LECAPITAINE, MD, Gilles PIALOUX, Pr, Laurent PLANTIER, Pr, Louis BERNARD, MD, Mohammed RAHAOUI, PM, Nunes HILARIO, MD, Olivier BOUCHAUD, Pr, Pascale LONGUET, MD, Sylvain DIAMANTIS, MD, Yacine TANDJAOUI-LAMBIOTTE, MD 2020-04-24
Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia Coronavirus disease 19 infection, Viral pneumonia Standard of care alone, budesonide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Fundacion Clinic per a la Recerca Biomédica AstraZeneca plc Spain 2020-04-18 2020-10-18 2020-001616-18, NCT04355637, TACTIC-COVID Phase 4 Clinical Not yet recruiting 8 6 Months 300 ALVAR AGUSTI, ALVAR AGUSTI, MD, PhD, Alicia Marin, Alvar Agusti, Daniel Ross Monserrate, Jaume Ferrer Sancho, Joaquim Gea Giralt, Jordi Dorca Sargatal, ROSA FANER, Rosa Faner, Salud Santos, Sara Varea, Sergi Pascual, Vicente Plaza, Xavier Muñoz 2020-04-23
DAS-181 for STOP COVID-19 Coronavirus disease 19 infection DAS-181 alone, standard local care alone Exo-alpha sialidase modulator, Muscarinic receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ansun BioPharma Inc Italy 2020-04-25 2020-07-31 2020-001874-30, DAS181-3-02-EU, NCT04354389 Phase 2/Phase 3 Clinical Not yet recruiting 2 3 Months 82 Andrea Gori, Cristina Mussini, Jennifer Ho, MD, PhD, Liz Dewaghe, Sylvie Lu 2020-04-23
COVKID: Kidney Involvement in COVID-19 Disease Coronavirus disease 19 infection, Renal injury Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Nice France 2020-04-15 2020-07-30 20REAMEDCOVID.05, COVKID, NCT04355624 Phase Not Applicable Recruiting 4 3 Months 80 Hajar Ouahmi, Philippe DESWARDT, Pierre-Marie BERTRAND, Sonia BOYER-SUAVET, Sonia Boyer-Suavet, Sonia Boyer-Suavet, 2020-04-23
CCC19: COVID-19 and Cancer Consortium Registry Coronavirus disease 19 infection web-based REDCap survey alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Vanderbilt-Ingram Cancer Center US 2020-03-17 2022-12-31 CCC19, NCT04354701, VICC MD 2032 Phase Not Applicable Recruiting 0 33 Months 1000 Jeremy Warner, MD, Teresa Melton, Vanderbilt-Ingram Service for Timely Access 2020-04-23
COLHEART-19: Colchicine to Reduce Myocardial Injury in COVID-19 Coronavirus disease 19 infection, Heart injury Current care alone, colchicine (oral, gout/familial Mediterranean fever), Takeda alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of California Los Angeles US 2020-04-25 2021-04-25 20-000685, COLHEART-19, NCT04355143 Phase 2 Clinical Not yet recruiting 0 12 Months 150 Amir B Rabbani, MD, Reza Ardehali, MD, PhD 2020-04-23
A clinical trial of efficacy of BCG vaccine in preventing Covid-19 Coronavirus disease 19 infection BCG vaccine, ICMR alone Indian Council of Medical Research 2020-04-30 Phase Not Applicable Planned 0 2020-04-22
Plasma therapy in patient with COVID-19 Coronavirus disease 19 infection, Viral pneumonia convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Shahid Beheshti University Iran 2020-04-05 IR.SBMU.RETECH.REC.1399.047, IRCT20200416047099N1 Phase 2 Clinical Recruiting 1 10 Abbas hajifathali, Elham Roshandel, Haniyeh Ghaffari-nazari, َAbbas Hajifathali 2020-04-23
A phase III, randomized, open-label study to assess the safety and efficacy of Ultomiris in adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS) Coronavirus disease 19 infection, Lung injury, Respiratory distress syndrome, Viral pneumonia ravulizumab alone Complement C5 factor inhibitor, IgG receptor FcRn large subunit p51 modulator Alexion Pharmaceuticals Inc 2020-05-31 Phase 3 Clinical Not yet recruiting 0 270 2020-04-22
Covid-19 in Lupus Patients Coronavirus disease 19 infection, Systemic lupus erythematosus hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Montpellier France 2020-03-01 2020-05-30 NCT04355702, RECHMPL20_0219 Phase Not Applicable Recruiting 1 2 Months 130 Christian JORGENSEN, Christian JORGENSEN, PUPH, Christian JORGENSEN, Resident, Jan HOLUBAR 2020-04-28
Anosmie-COVID: Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection Coronavirus disease 19 infection, Dysomia gustatory test alone, olfactory test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Nimes France 2020-03-27 2020-11-30 Anosmie-COVID, IRB: 20.04.09, NCT04354857 Phase Not Applicable Recruiting 1 8 Months 454 Albert Sotto, Anissa Megzari, Benjamin Lallemant, Caroline Alovisetti, Didier Laureillard, Gaelle Regnier, Jean-Philippe Lavigne, Marie-José Carles, Paul Loubet, Robin Stephan 2020-04-23
Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID-19) Survivors Coronavirus disease 19 infection cardiac assessment alone, echocardiography alone, standard 12-lead ECG alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University of Hong Kong Hong Kong 2020-04-20 2020-05-01 COVID_LVD_SCREEN, NCT04355884 Phase Not Applicable Not yet recruiting 1 100 Chung Wah SIU, MD, Venus HO, BSc 2020-04-27
MOPHYDA: Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID-19 Patients Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) King Hussein Cancer Center Jordan 2020-04-15 2020-10-15 20 KHCC 67, MOPHYDA, NCT04354597 Phase 2 Clinical Not yet recruiting 1 6 Months 200 Amal Al Omari, PhD, Dalia Al Rimawi, MDS, Hikmat Abdel-Razeq, MD, Iyad Al-Ammouri, MD, Iyad Sultan, Iyad Sultan, MD, Lama Nazer, PharmD, Nedal Al-Rawashdeh, MPH, Osama Abu Ata, MD, Rana Damsees, MPH 2020-04-23
ANTI-COV-2: COVID-19: Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2 Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospices Civils De Lyon Eurobio scientific France 2020-04-27 2020-07-31 2020-A01038-31, 69HCL20_0340, ANTI-COV-2, NCT04354766 Phase Not Applicable Not yet recruiting 1 3 Months 10 Frédéric COUTANT, MD, Tristan FERRY, MD 2020-04-23
COVAC-TP: COVID-19 Anticoagulation in Children - Thromboprophlaxis Trial Coronavirus disease 19 infection, Thromboembolism enoxaparin sodium alone Low molecular weight heparin Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) Johns Hopkins All Children's Hospital US 2020-05-15 2022-10-15 COVAC-TP, COVAC-TP, NCT04354155 Phase 2 Clinical Not yet recruiting 0 29 Months 38 Anthony Sochet, MD, Frances L Hamblin, MSHS, Laurel McDevitt, MS, Neil Goldenberg 2020-04-23
SevCov: Sevoflurane in COVID-19 ARDS Coronavirus disease 19 infection, Lung injury, Respiratory distress syndrome sevoflurane alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Zurich Switzerland 2020-04-23 2021-03-31 2020-00719, NCT04355962, SevCov Phase 3 Clinical Recruiting 1 11 Months 64 Beatrice Beck Schimmer, Prof, Martin H Schläpfer, PD MD, Martin Schläpfer, PD 2020-04-28
STOIC: Computed Tomography for COVID-19 Diagnosis Coronavirus disease 19 infection, Viral pneumonia chest computed tomography alone, reverse-transcription polymerase chain reaction alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris GE Healthcare, INSERM, TheraPanacea France 2020-04-30 2020-07-31 APHP200434, NCT04355507, STOIC Phase Not Applicable Not yet recruiting 1 3 Months 10000 Adèle BELLINO, Marie-Pierre REVEL, MD, PhD, Marie-Pierre REVEL, MD,PhD 2020-04-23
A phase III large clinical trial of hydroxychloroquine for the treatment in hospitalized patients with COVID-19 disease Coronavirus disease 19 infection hydroxychloroquine alone, standard of care alone, azithromycin plus hydroxychloroquine Novartis AG US Phase 3 Clinical Not yet recruiting 0 440 2020-04-22
Traumax: Evolution of Facial Trauma During COVID Containment Measures Bone injury, Coronavirus disease 19 infection facial fractures reduction alone, osteosynthesis alone University Hospital, Montpellier Amiens (Dr Dapke), Clermont Ferrand (Dr Sesque), Lyon (Dr Bourlet – Croix Rousse), Marseille (Dr Foletti – La conception), Nantes (Pr Corre), Nice (Dr Savoldelli), Perpignan (Dr Llobet), Toulouse (Pr Lauwers - Purpan), Unités de CMF des CHU de Paris France 2020-04-01 2020-05-30 NCT04355442, RECHMPL20_0228, Traumax Phase Not Applicable Recruiting 1 1 Month 300 Marie de BOUTRAY, PH 2020-04-23
Administration of Chloropromazine as a Treatment for COVID-19 Coronavirus disease 19 infection, Viral pneumonia chlorpromazine (Neurazine) alone, convential treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cairo University Egypt 2020-05-31 2020-09-30 MEDICAL, NCT04354805 Phase 1/Phase 2 Clinical Not yet recruiting 1 4 Months 60 Ahmed Nasreldin Rezk, Ahmed Rezk, Noha Rezk 2020-04-23
Treatment for SARS-CoV-2 in High-Risk Adult Outpatients Asthma, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Emphysema, Lower respiratory tract infection, Lung disease, Pulmonary hypertension Variable regimens including azithromycin , folic acid , hydroxychloroquine sulfate Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Washington Bill & Melinda Gates Foundation US 2020-04-16 2020-10-31 NCT04354428, STUDY00009878 Phase 2/Phase 3 Clinical Recruiting 0 6 Months 630 Christine Johnston, MD, MPH, Hannah Leingang, Kirsten Hauge 2020-04-23
COV2ICU-DK: Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HS Hvidovre Hospital Denmark 2020-04-06 2021-04-06 COV2ICU-DK, COV2ICU-DK, H-20023159, NCT04354584, R349-2020-540 Phase Not Applicable Recruiting 1 12 Months 20 Ronni R Plovsing, MD, PhD 2020-04-23
A human trial to assess linear DNA vaccine (COVID-19), Takis Biotech/ LineaRx for COVID-19 Coronavirus disease 19 infection linear DNA vaccine (COVID-19), Takis Biotech/ LineaRx alone Applied DNA Sciences Inc Phase Not Applicable Planned 0 2020-04-22
COVISEP: Epidemiological Characteristics of COVID-19 in Patients With MS or NMO Coronavirus disease 19 infection Assistance Publique Hopitaux de Paris France 2020-04-20 2022-04-20 APHP200482, COVISEP, NCT04355611 Phase Not Applicable Not yet recruiting 1 24 Months 2000 Céline LOUAPRE, MD,PhD 2020-04-23
A randomized, double-blind, placebo-controlled, phase II trial to assess the efficacy and safety of MRx-4DP0004 in patients hospitalized with symptoms indicative of COVID-19 Coronavirus disease 19 infection MRx-0004 alone 4D pharma plc UK Phase 2 Clinical Not yet recruiting 1 90 Dr. Dinesh Saralaya 2020-04-22
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 Coronavirus disease 19 infection convalescent plasma alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) HILTON PHARMA (PVT) LTD Pakistan 2020-04-30 2021-04-30 NCT04352751, PIPK- 0000 /NIBD-0000/2020 Phase 4 Clinical Not yet recruiting 1 12 Months 2000 Dr. Arshi Naz, PhD,Diplab, Dr. Neeta Maheshwary, Dr. Neeta Maheshwary, MBBS M.Phil, Dr. Tahir Shamsi, FRCP MRCPath, Professor Bikha Ram, Professor Ikram Din Ujjan, Professor Javed Akram, Professor Nadeem Samad Sheikh, Professor Nisar Ahmed, Professor Shahtaj Masood, Saba Fatima 2020-04-23
UKMSRCV19: The United Kingdom Multiple Sclerosis Register Covid-19 Substudy Coronavirus disease 19 infection, Multiple sclerosis Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Swansea University, Wales UK 2020-03-14 2022-07-14 16SW0194, NCT04354519, UKMSRCV19 Phase Not Applicable Recruiting 1 28 Months 3000 Katie A Tuite-Dalton, BSc, Nikos Evangelou, Richard S Nicholas, Rod M Middleton, MBA 2020-04-23
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel Coronavirus disease 19 infection antibody test alone, enzyme-linked immunosorbent assay alone, reverse transcription polymerase chain reaction alone Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) AUVA-Allgemeine Unfallversicherungsanstalt Paracelsus Medical University Austria 2020-04-30 2020-10-31 AUVA SARS-COV-2 STUDIE, NCT04354779 Phase Not Applicable Not yet recruiting 1 6 Months 4000 Wolfgang Schaden, MD, Wolfgang Schadenc 2020-04-24
Effect of ppd on recovery of covid disease 19 Coronavirus disease 19 infection CT scan alone, Corona testing alone, purified protein derivative skin test alone, chloroquine plus lopinavir + ritonavir HIV protease inhibitor Fasa University of Medical Sciences Iran 2020-05-04 IR.FUMS.REC.1399.004, IRCT20200414047070N1 Phase 3 Clinical Not yet recruiting 1 50 Abdolah Azizi, Dr.Jalal Karimi, Dr.Mojtaba Farjam, Dr.jalal karimi 2020-04-24
AiM COVID for Covid 19 Tracking and Prediction Coronavirus disease 19 infection AiM COVID alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Aarogyam UK Clickmedix, The National Technical University of Ukraine "Igor Sikorsky Kyiv Polytechnic Institute" (NTUU "KPI"), Warwick University UK 2020-03-28 2020-04-17 AU12, NCT04354753 Phase Not Applicable Completed 1 80 Vishwesh Kulkarni 2020-04-23
Telmisartan for Treatment of COVID-19 Patients Coronavirus disease 19 infection, Respiratory distress syndrome Bertel, Laboratorio Elea Phoenix alone, Standard care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Laboratorio Elea Argentina 2020-04-01 2020-10-01 2020-001, NCT04355936 Phase 2 Clinical Recruiting 1 6 Months 400 Mariano Duarte, MD, Rodolfo P Rothlin, MD 2020-04-23
A final phase trial to evaluate ChAdOx1 nCoV-19 for the treatment of patients with covid-19 infection Coronavirus disease 19 infection ChAdOx1 nCoV-19 alone University of Oxford Phase Not Applicable Planned 0 5000 2020-04-22
An Expanded Access Program (EAP) to evaluate the efficacy and safety of ruxolitinib in COVID-19 for patients with severe COVID-19 associated cytokine storm Coronavirus disease 19 infection ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Incyte Corp US Phase Not Applicable Recruiting 0 2020-04-28
Topical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure rates Coronavirus disease 19 infection Chloroquine alone, Standard Treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) All India Institute of Medical Sciences India 2020-04-21 CTRI/2020/04/024729 Phase 2 Clinical Not yet recruiting 1 60 Alok Thakar 2020-04-24
A phase I/IIa, randomized, placebo-controlled study of COV-ENT-1 for the treatment in hospitalized patients with COVID-19 infection Coronavirus disease 19 infection, Viral pneumonia COV-ENT-1 alone Enterin Inc US 2020-07-31 Phase 1/Phase 2 Clinical Planned 0 80 2020-04-24
CONFINE: Birth Experience During COVID-19 Confinement Coronavirus disease 19 infection, Postnatal depression Self-administered questionnaires alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Central Hospital, Nancy, France France 2020-04-16 2021-11-01 2020-A00881-38, CONFINE, NCT04348929 Phase Not Applicable Recruiting 1 18 Months 600 Charline BERTHOLDT 2020-04-23
VT4COVID: Ultraprotective Ventilation Without Extracorporeal Circulation During COVID-19 Pneumonia Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure, Viral pneumonia ultraprotective ventilation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospices Civils De Lyon France 2020-04-14 2022-04-14 69HCL20_0322, NCT04349618, VT4COVID Phase Not Applicable Not yet recruiting 11 24 Months 200 Arnaud FRIGGERI, Dr, Bertrand DELANNOY, Dr, Christian POMMIER, Dr, Claire DUPUIS, Dr, Frédéric AUBRUN, Pr, Guillaume THIERY, Pr, Hodane YONIS, Dr, Jean-Christophe RICHARD, Pr, Laurent ARGAUD, Pr, Loredana BABOI, Michel MULLER, Dr, Nicolas TERZI, Pr, Thomas RIMMELE, Pr 2020-04-23
COVI-PRONE: Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial Coronavirus disease 19 infection, Respiratory failure Awake Proning alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) St Josephs Healthcare Hamilton Canada 2020-04-20 2020-10-31 2154, COVI-PRONE, NCT04350723 Phase Not Applicable Not yet recruiting 1 6 Months 350 Sarah Culgin, Waleed Alhazzani, Zainab Al Duhalib 2020-04-23
RASCOVID-19: Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19 Coronavirus disease 19 infection ACEi alone, ARB alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Gentofte Novo Nordisk Foundation Denmark 2020-04-30 2020-12-31 2020-001544-26, H-20026205, NCT04351581, RASCOVID-19 Phase Not Applicable Recruiting 1 8 Months 215 Filip K Knop, MD, PhD 2020-04-27
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge Anxiety disorder, Cancer, Cardiac failure, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Depression, Diabetes mellitus, End stage renal disease, Liver cirrhosis, Liver disease Medically Tailored Meals alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kaiser Permanente US 2020-04-15 2021-07-31 IRB-1556587, Meals MATTER, NCT04351880 Phase Not Applicable Not yet recruiting 0 15 Months 640 John Steiner, MD, MPH, Melanie L Drace, MPH, Rebecca S Boxer, MD, MS 2020-04-26
Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients Coronavirus disease 19 infection, Lung disease Variable regimens including herbal medicine , hydroxychloroquine , lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mazandaran University of Medical Sciences Iran 2020-04-18 IR.MAZUMS.REC.1398.1457, IRCT20200404046935N1 Phase 3 Clinical Recruiting 1 40 Farhang Babamahmoodi 2020-04-23
HEROES: The COVID-19 Health Care Workers Study Coronavirus disease 19 infection, Psychiatric disorder Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chile US, Spain, Italy, Chile 2020-04-15 2021-04-14 HEROES, HEROES COVID-19, NCT04352634 Phase Not Applicable Not yet recruiting 3 12 Months 2000 Eduardo Fernández-Jiménez, PhD, Eric Tapia, MPH, Francesca Moro, MD, Gonzalo Martínez-Alés, MD, Maria-Fe Bravo-Ortiz, MD, PhD, Mauro Carta, MD, Roberto Mediavilla, PhD, Ruben Alvarado, PhD, Rubén Alvarado, PhD, Sara Schilling, MPH 2020-04-23
Echocardiographic Manifestation in Patient With Coronavirus Disease 2019 (COVID-19) Coronavirus disease 19 infection GE Logiq E portable color ultrasound diagnostic machine (GE Healthcare) alone, doppler echocardiography alone, two-dimensional echocardiography alone Renji Hospital China 2020-02-19 2020-04-06 COVID19-ECHOCARDIOGRAPHY, NCT04352842 Phase Not Applicable Completed 1 1 Month 55 Jun Pu, M.D 2020-04-24
Assessment of Objective clinical scoring system to rule out COVID-19 with high sensitivity Coronavirus disease 19 infection Outbreak of Respiratory Tract Infection Score (ORTIS) sytstem alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) Dr Atul's Child Hospital India 2020-05-01 CTRI/2020/04/024636 Phase Not Applicable Not yet recruiting 1 1000 Varnit Shanker 2020-04-23
PROLIFIC: Chemoprophylaxis Trial (COVID-19) Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Cambridge University Hospitals NHS Foundation Trust UK 2020-04-30 2021-04-30 NCT04352933, PROLIFIC, PROLIFIC2020 (A095583) Phase 3 Clinical Not yet recruiting 1 12 Months 1000 Ella James, PhD, Heike Templin, Joseph Cheriyan, MBCHB, FRCP 2020-04-21
COVID-19-hematological Malignancies: the Italian Hematology Alliance Acute leukemia, Coronavirus disease 19 infection, Lymphoma, Multiple myeloma, Myelodysplastic syndrome, Myeloproliferative disorder Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ospedale di Circolo - Fondazione Macchi Italy 2020-04-07 2021-04-30 HM-COVID19-ITALY, NCT04352556 Phase Not Applicable Recruiting 69 12 Months 250 Adriano Venditti, MD, Alberto Bosi, MD, Alessandro Busca, MD, Alessandro Corso, MD, Alessandro Inzoli, MD, Alfredo Molteni, MD, Anna Conconi, MD, Antonio Cuneo, MD, Antonio Pinto, MD, Antonio Spadano, MD, Attilio Guarini, MD, Attilio Olivieri, MD, Atto Billio, MD, Augusto Federici, MD, Benedetto Bruno, MD, Brunangelo Falini, MD, Bruno Martino, MD, Carlo Gambacorti Passerini, MD, Carlo Visco, MD, Carmen Fava, MD, Carmine Selleri, MD, Caterina Musolino, MD, Celestino Ferrandina, MD, Chiara Cattaneo, MD, Corrado Tarella, MD, Daniela Cilloni, MD, Daniele Vallisa, MD, Domenico Russo, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, Fabrizio Ciambelli, MD, Fabrizio Pane, MD, Felicetto Ferrara, MD, Filippo Gherlinzoni, MD, Francesco Di Raimondo, MD, Francesco Lanza, MD, Francesco Merli, MD, Francesco Passamonti, MD, Francesco Zaja, MD, Giampietro Semenzato, MD, Gianluca Gaidano, MD, Giorgio La Nasa, MD, Giuseppe Avvisati, MD, Giuseppe Visani, MD, Livio Pagano, MD, Luca Arcaini, MD, Luigi Rigacci, MD, Marco Ladetto, MD, Marco Ruggeri, MD, Marco Salvini, MD, Mario Luppi, MD, Massimo Gentile, MD, Massimo Massaia, MD, Matteo Della Porta, MD, Maurizio Martelli, MD, Mauro Krampera, MD, Mauro Turrini, MD, Michele Cavo, MD, Michele Spina, MD, Monica Bocchia, MD, Nicola Di Renzo, MD, Nicola Fracchiolla, MD, Nicola Giuliani, MD, Paolo Corradini, MD, Patrizia Tosi, MD, Patrizio Mazza, MD, Pellegrino Musto, MD, Piero Galieni, MD, Renato Bassan, MD, Renato Fanin, MD, Roberto Cairoli, MD, Roberto Lemoli, MD, Sara Galimberti, MD, Sergio Siragusa, MD, Valerio De Stefano, MD 2020-04-21
HERO: Health Care Worker Prophylaxis Against COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) GeoSentinel Foundation US 2020-04-24 2020-08-24 GFICOVID-19-1, HERO, NCT04352946 Phase 3 Clinical Not yet recruiting 0 4 Months 374 Bradley A Connor, MD, Kevin Kain, MD, Marina Rogova, RN, Megan Landes, MD, Robert S Brown, Jr, MD, William MacLeod, ScD 2020-04-23
The effect of PHR spray on patients with coronavirus-19 Coronavirus disease 19 infection, Lung disease PHR160 Inhaler Spray alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Bagheiat-allah University of Medical Sciences Iran 2020-03-10 2020-03-24 IR.BMSU.REC.1398.387, IRCT20160131026298N2 Phase 2/Phase 3 Clinical Completed 1 64 Ahmad Reza Sharifi Olounabadi, REZAMOHTASHAMI, AHMAD REZA SHARIFI OLOUNABADI, Reza Mohtashami 2020-04-22
The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases Coronavirus disease 19 infection standard treatment alone, Rucoldup, Ghaem Daru plus Vomigone, Dineh Pharmaceutical Company Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Saveh University of Medical Sciences Iran 2020-04-18 IR.SAVEHUMS.REC.1399.004, IRCT20200415047089N1 Phase 3 Clinical Recruiting 1 100 hamidreza koohestani, mehdi mesri 2020-04-22
The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable Coronavirus disease 19 infection Hudson face mask alone, sedation therapy alone, simplified negative pressure cuirass style ventilator alone, supplemental oxygen therapy alone Healthy volunteers accepted, Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Perth Anaesthetic Group St John of God Murdoch Hospital, Australia Australia 2020-04-20 2020-04-20 ACTRN12620000477921p Phase Not Applicable Not yet recruiting 1 1 Dr Michael Soares 2020-04-22
Phase II, open-label, randomized clinical trial with the primary objective to assess the safety and efficacy of the convalescent plasma to limit complications in Covid-19 patients Coronavirus disease 19 infection convalescent plasma alone Indian Council of Medical Research Phase 2 Clinical Not yet recruiting 0 2020-04-22
Phase II, randomized trial of Brukinsa to treat in later-stage COVID-19 patients Coronavirus disease 19 infection mechanical ventilation alone, zanubrutinib alone Btk tyrosine kinase inhibitor BeiGene Co Ltd US Phase 2 Clinical Planned 0 42 Treon 2020-04-22
Thalidomide in COVID19 Coronavirus disease 19 infection, Viral pneumonia Variable regimens including Talidex. Alan pharmaceuticals , acetaminophen + codeine , azithromycin , ceftriaxone , diphenhydramine , enoxaparin sodium , hydroxychloroquine , methylprednisolone , vancomycin Low molecular weight heparin, Peptidoglycan recognition protein inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Isfahan University of medical Sciences Deputy minister of technology research Iran 2020-04-15 IRCT20170207032444N3, http://ethics.research.ac.ir/IR.MUI.MED.REC.1399.027 Phase 3 Clinical Recruiting 1 60 Farzane Ashrafi, Mehrzad Salmasi, Ramin Sami, Shaghayegh Haghjooy Javanmard, farzane ashrafi 2020-04-22
Cord Blood Therapy to prevent progression of COVID-19 related pneumonia Coronavirus disease 19 infection, Viral pneumonia cord blood therapy alone, standard supportive management alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Monash Health Australia 2020-06-01 2020-12-31 ACTRN12620000478910, CBC-19 Phase 2 Clinical Not yet recruiting 1 7 Months 24 Dr Atul Malhotra 2020-04-22
FEELIV COVID: An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease Coronavirus disease 19 infection, Liver disease Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Institute of Liver and Biliary Sciences, India India 2020-04-22 2020-04-30 FEELIV COVID, ILBS-COVID-03, NCT04352491 Phase Not Applicable Recruiting 1 1500 Dr Mohit Varshney, DM, Dr Mohit Varshney, MD, Dr Shiv Kumar Sarin, DM 2020-04-23
A clinical trial to investigate the role of Pegylated Interferon alpha-2b for COVID 19 Coronavirus disease 19 infection peginterferon alfa-2b follow-on-biologic, Zydus-Cadila alone Interferon alpha 2 ligand Zydus-Cadila Group Phase Not Applicable Planned 0 2020-04-22
The IMSOMNIA study: Mental health and wellbeing on general population during the COVID-19 outbreak Anxiety disorder, Coronavirus disease 19 infection, Depression, Insomnia Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The George Institute for Global Health US, Australia, China, Italy, Spain, Germany 2020-05-01 ACTRN12620000479909p, The IMSOMNIA study Phase Not Applicable Not yet recruiting 5 3000 Dr Amanda Y Wang, Dr Qi Mei 2020-04-22
BBCovid: COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses Coronavirus disease 19 infection Citrox plus beta-cyclodextrin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universite Claude Bernard Hospices Civils De Lyon, University Hospital, Montpellier, University Hospital, Tours France 2020-04-27 2020-06-20 BBCOVID, BBCovid, NCT04352959 Phase 2 Clinical Not yet recruiting 1 1 Month 178 Carrouel Florence 2020-04-27
SpectrOVID19: Prospective gas chromatographic and spectrometric analysis of the exhalation of healthy test persons and of SARS-CoV2 infected patients as well as of patients suffering from COVID-19 at the Klinikum Dortmund Coronavirus disease 19 infection gas chromatography alone, ionic motility spectrometry alone Healthy volunteers accepted, Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum Dortmund GgmbH Germany 2020-04-12 176/2020, DRKS00021399, SpectrOVID19 Phase Not Applicable Recruiting 1 450 Oliver Müller 2020-04-23
Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients Coronavirus disease 19 infection, Respiratory distress syndrome methotrexate loaded nanoparticle alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azidus Brasil Hospital Santa Marcelina, InCor Heart Institute 2020-05-01 2020-11-30 LDE-MTX_COVID19, NCT04352465 Phase 1/Phase 2 Clinical Not yet recruiting 0 7 Months 42 Luciana Ferrara, Rodrido Esper, MD, PhD 2020-04-23
Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers (SUPPORT COVID-19 Healthcare Workers) Acute stress disorder, Coronavirus disease 19 infection Lactobacillus rhamnosus HN001 alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) University of Auckland New Zealand 2020-06-01 2020-07-16 ACTRN12620000480987p Phase Not Applicable Not yet recruiting 1 1 Month 507 Dr Rebecca Slykerman 2020-04-23
The RAPID COVID TRIAGE Algorithm Coronavirus disease 19 infection Spartan Cube point-of-care Covid-19 test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ottawa Heart Institute Research Corp 2020-04-15 2021-02-28 20200228-01H, NCT04353154 Phase Not Applicable Not yet recruiting 0 10 Months 20 Dr. Derek So, Poppy MacPhee 2020-04-23
RACONA: Efficacy of Nafamostat in Covid-19 Patients Coronavirus disease 19 infection nafamostat mesylate alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Padova University of Zurich, Yokohama City University Italy 2020-04-30 2021-12-31 NCT04352400, RACONA, RACONA NAFAMOSTAT Phase 2/Phase 3 Clinical Not yet recruiting 2 20 Months 256 Gian Paolo Rossi, Gian Paolo Rossi, Prof. 2020-04-22
VACAT: COVID-19 and Vaccination Attitudes Coronavirus disease 19 infection Healthy volunteers accepted Hopitaux Universitaires De Geneve University of Lausanne, University of Zurich UK 2020-04-14 2020-04-30 NCT04352582, VACAT, VACAT Phase Not Applicable Recruiting 1 1000 Dominic Rohner, PhD, Geraldine Blanchard-Rohner, Geraldine Blanchard-Rohner, MD-PhD 2020-04-22
Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression high intensity interval training alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universidad de Extremadura Spain 2020-03-17 2020-04-26 ACTRN12620000482965 Phase Not Applicable No longer recruiting 1 1 Month 77 Dr Juan Pedro Fuente-García, Mr Santos Villafaina 2020-04-22
Effects of digital home exercise programs on physical and mental well-being during the COVID-19 pandemic: a multicenter trial Coronavirus disease 19 infection digital home exercise programs alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Johann Wolfgang Goethe-Universitat Frankfurt am Main Foro Italico University of Rome, Spaulding Rehabilitation Network, The University Children’s Hospital Basel, Universidade Cidade de Sao Paulo, Universite Jean Monnet, University of Cadiz Brazil, Austria, France, US, Chile, Spain, Switzerland, Germany 2020-04-22 2020-25, DRKS00021273 Phase Not Applicable Not yet recruiting 7 544 Mr Dr Jan Wilke, Mr Prof Luiz Hespanhol, Mr. Dr Christoph Heidt, Mr. Prof David Jiménez-Pavón, Mr. Prof Pascal Edouard, Ms. Dr Chiara Fossati 2020-04-22
Effect of Ozone Therapy in Treatment of COVID-19 Coronavirus disease 19 infection conventional treatment alone, oxygen/ozone alone, ozone major autohemotherapy alone Bagheiat-allah University of Medical Sciences Iran 2020-04-23 IR.BMSU.REC.1399.060, IRCT20191125045492N2 Phase 2 Clinical Recruiting 1 80 Ali Sarrafzadeh, Dr. Gholamhosein Alishiri, Morteza Izadi 2020-04-23
Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All? Coronavirus disease 19 infection, Urinary tract tumor surgery alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Nice France 2020-03-15 2020-05-01 20UROCOVID.03, NCT04352699 Phase Not Applicable Recruiting 1 1 Month 120 Aysha SHAIKH, Matthieu DURAND, Matthieu DURAND, MD, PhD 2020-04-22
AUS-COVID: Australian cardiovascular COVID-19 registry Coronavirus disease 19 infection, Heart injury, Myocardial disease, Myocarditis Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Paul Ramsay Foundation Australia 2020-04-20 2020-08-19 ACTRN12620000486921, AUS-COVID Phase Not Applicable Not yet recruiting 20 4 Months 865 Prof Ravinay Bhindi 2020-04-22
PATCH 2 and 3: Prevention and Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) UnitedHealth Group Inc Perelman School of Medicine, Prohealth Care Associates US 2020-04-07 2021-06-15 2020-0003, NCT04353037, PATCH 2 and 3 Phase 2 Clinical Recruiting 0 14 Months 850 Daniel Griffin, MD PhD, Daniel Griffin, MD, PhD, Deneen Vojta, MD, Ravi Amaravadi, MD 2020-04-27
COVID-19 associated brainstem encephalitis - is SARS-CoV-2 a neurotropic agent? Ageusia, Coronavirus disease 19 infection, Dysomia, Encephalitis, Taste disorder Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Neurosurgical University Clinic Freiburg Germany 2020-04-20 211/20, DRKS00021439 Phase Not Applicable Recruiting 1 70 Jonas Hosp 2020-04-22
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 Coronavirus disease 19 infection, Septic shock Toraymyxin PMX-20R cartridge alone, hemoperfusion alone, standard medical care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Spectral Diagnostics (US) Inc NCT04352985, SDI-PMX-013 Phase Not Applicable Recruiting 0 Debra Foster 2020-04-22
DolPsyCOVID: Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak Anxiety disorder, Coronavirus disease 19 infection, Depression, Pain questionnaire assesment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-12-31 2020-A00912-37, DolPsyCOVID, EQ_2020_02, NCT04353011 Phase Not Applicable Not yet recruiting 1 8 Months 50 Anne BERA, MD 2020-04-22
Antibody-based Tests for SARS-CoV-2 COVID-19: Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings Coronavirus disease 19 infection CoronaCide COVID-19 IgM/IgG rapid test alone, Premier Biotech COVID-19 IgM/IgG rapid test alone Healthy volunteers accepted Texas Cardiac Arrhythmia US 2020-03-27 2021-01-31 NCT04352764, TCAI_COVID-19 Phase Not Applicable Recruiting 0 10 Months 5000 Andrea Natale, MD, Andrea Natale, MD FACC FHRS, Deb Cardinal, RN 2020-04-28
Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19) Coronavirus disease 19 infection Inactivated vaccine (COVID-19), Sinovac Biotech alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Sinovac Research & Development Co Ltd Sinovac Biotech Ltd China 2020-04-16 2020-12-13 NCT04352608, PRO-NCOV-1001 Phase 1/Phase 2 Clinical Recruiting 2 7 Months 744 Congbing Jiang, Bachelor, Fengcai Zhu, Doctor, Hongxing Pan, Doctor 2020-04-28
Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease Adult respiratory distress syndrome, Coronavirus disease 19 infection, Viral pneumonia autologous adipose derived mesenchymal cells alone, conventional treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Regeneris Medical 2020-04-30 2026-04-30 COVID-MSCIV, NCT04352803 Phase 1 Clinical Not yet recruiting 0 72 Months 20 Ryan Welter, MD PhD 2020-04-23
Influence Physical Activity Psychological Responses COVID-19 Pandemic Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression Google Forms online survey alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universidad de Extremadura Brazil, Uruguay, Chile 2020-03-16 2020-09-30 3.954.038, NCT04352517 Phase Not Applicable Recruiting 3 6 Months 3500 Alba Dr Camacho-Cardenosa, Doctor, Atila Alexandre Trapé, Dr, Eugenio Narciso Merellano Navarro, Javier Dr Brazo-Sayavera, Doctor, Marta Dr Camacho-Cardenosa, Doctor 2020-04-23
Pirfenidine in SARS-COV2 Coronavirus disease 19 infection, Pulmonary fibrosis, Respiratory distress syndrome Variable regimens including chloroquine , lopinavir + ritonavir , oseltamivir , pirfenidone , ribavirin Exo-alpha sialidase inhibitor, HIV protease inhibitor, PDGF receptor antagonist, TGF beta receptor antagonist, p38 MAP kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kermanshah University of Medical Sciences Iran 2020-04-26 IR.KUMS.REC.1399.017, IRCT20200314046764N1 Phase 3 Clinical Not yet recruiting 1 40 Bahareh Baghchi, Mohammad Nazarian Pirdoosti 2020-04-24
Atorvastatin effect on COVID-19 Coronavirus disease 19 infection atorvastatin alone HMG CoA reductase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Mazandaran University of Medical Sciences Iran 2020-04-05 IR.MAZUMS.REC.1399.042, IRCT20190727044343N2 Phase 2/Phase 3 Clinical No longer recruiting 1 100 Lotfollah Davoodi 2020-04-22
ILUSA: International Lung UltraSound Analysis (ILUSA) Study Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Respiratory disease, Respiratory tract infection Lung ultrasound examination alone Female Katholieke Universiteit Leuven UK, Italy, Belgium 2020-04-20 2020-12-31 COVID-19: ILUSA (S63988), ILUSA, NCT04353141 Phase Not Applicable Not yet recruiting 8 8 Months 1850 Antonia Testa, PhD, Antonio Lanzone, PhD, Dirk Timmerman, PhD, Federico Prefumo, Francesca Moro, Francesca Moro, MD, Francesco D'Antonio, Giovanni Scambia, PhD, Hannes Van der Merwe, MD, Hannes Van der Merwe, PhD, Irene Cetin, Jan Deprest, PhD, Tiziana Frusca, Tom Bourne, PhD, Wouter Froyman, MD 2020-04-22
A clinical study to assess antiviral efficacy of DWRX-2003 for the potential treatment of COVID-19 Coronavirus disease 19 infection repositioned niclosamide (refractory lung disease/COVID-19), Daewoong Pharmaceutical/Institut Pasteur Korea alone Daewoong Pharmaceutical Co Ltd, Institut Pasteur Korea South Korea Phase Not Applicable Planned 1 2020-04-23
Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad Coronavirus disease 19 infection, Viral pneumonia SinaCurcumin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-05-19 IR.MUMS.REC.1399.054, IRCT20200408046990N1 Phase 3 Clinical Not yet recruiting 1 60 Mohsen Tafaghodi, Sepideh Elyasi 2020-04-23
The effect of azithromycin in treatment of COVID19 Coronavirus disease 19 infection, Viral pneumonia Variable regimens including atazanavir , azithromycin , hydroxychloroquine , lopinavir + ritonavir , oseltamivir Exo-alpha sialidase inhibitor, HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-04-24 IR.TUMS.VCR.REC.1399.165, IRCT20200415047092N1 Phase 3 Clinical Recruiting 1 110 Ehsan Sekhavati Moghadam, Fereshte Ghiasvand, Mohammad Ali Sahraian 2020-04-28
Treatment of COVID-19-induced cytokine storm by hemoperfusion Coronavirus disease 19 infection hemodialysis alone, hemoperfusion HA330 filter (JAFRON BIOMEDICAL.CO.LTD, China) alone, heparin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tabriz University of Medical Sciences Iran 2020-04-20 IR.TBZMED.REC.1399.024, IRCT20200317046797N5 Phase 2 Clinical Recruiting 1 10 Ali Taghizadieh, Dr Bahram Niknafs, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed 2020-04-23
The effect of melatonin on the quality of sleep in COVID-19 patients Coronavirus disease 19 infection Variable regimens including azithromycin , hydroxychloroquine , melatonin Mazandaran University of Medical Sciences Iran 2020-04-14 IR.MAZUMS.REC.1399.056, IRCT20200411047030N1 Phase 3 Clinical Recruiting 1 82 Prof. Majid Saeedi, Reza Alizadeh-Navaei, Seyyed Abbas Mousavi 2020-04-22
COCON: Control of COVID-19 in hospitals Coronavirus disease 19 infection Universitair Medisch Centrum Utrecht The Netherlands Organisation for Health Research and Development Netherlands 2020-04-22 2020-08-31 COCON, NL8528 Phase Not Applicable Not yet recruiting 1 4 Months 2000 Marjolein Kluytmans 2020-04-22
A clinical study of CRISPR-based DETECTR assay for the diagnosis of patients with COVID-19 infection and patients with other viral respiratory infections Coronavirus disease 19 infection, Viral respiratory tract infection CRISPR-based DETECTR assay alone Mammoth Biosciences US Phase Not Applicable Status not specified 0 78 Dr Charles Chiu, Dr James Broughton, Dr Janice Chen 2020-04-24
General practice cooperative COVID-19 centre Urmond Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) MCC Omnes Netherlands 2020-05-01 2022-01-03 METCZ20200068, NL8529 Phase Not Applicable Not yet recruiting 1 20 Months 2000 Luc Gidding 2020-04-22
An expanded access compassionate use program to assess remestemcel-L in patients with COVID-19 acute respiratory distress syndrome (ARDS) Coronavirus disease 19 infection, Respiratory distress syndrome remestemcel-L alone Mesoblast Ltd Phase Not Applicable Planned 0 2020-04-21
CPAP-Covid: Continuous positive airway pressure in severe Covid-19 pneumonia Coronavirus disease 19 infection, Viral pneumonia continuous positive airway pressure (CPAP) alone, face mask alone, non-rebreathing mask alone, oxygen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Academic Medical Center, University of Amsterdam Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose Netherlands 2020-04-18 2020-07-18 CPAP-Covid, NL8521 Phase 1 Clinical Not yet recruiting 1 3 Months 13 Joost van den Aardweg 2020-04-22
Effect of Arbidol in treatment of COVID-19 Coronavirus disease 19 infection arbidol plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Iran University of Medical Sciences Iran 2020-04-29 IR.IUMS.REC.1399.090, IRCT20180725040596N2 Phase 3 Clinical Not yet recruiting 1 100 Dr Abbas Motevalian, Dr. Marzieh Nojomi, Dr. Mitra ranjbar, ِDr. Mitra Ranjbar 2020-04-22
SOS COVID: SARS-CoV-2 Observational Study Coronavirus disease 19 infection, Respiratory tract infection Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitair Medisch Centrum Utrecht European Commission Europe, Netherlands 2020-04-14 2022-02-01 NL73596.041.20, NL8520, SOS COVID Phase Not Applicable Not yet recruiting 1 21 Months 600 Alike van der Velden 2020-04-23
Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19 Coronavirus disease 19 infection common national protocol alone, convalescent plasma alone, immunoglobulin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Birjand University of Medical Sciences Iran 2020-04-18 IR.BUMS.REC.1399.008, IRCT20200413047056N1 Phase 3 Clinical Recruiting 1 15 Malihe Zangoue, Mohammad Fereidouni, Tooba Kazemi 2020-04-22
Assessment the Activity Value of 13- Cis-Retinoic Acid(Isotretinoin) in the Treatment of COVID-19 (Isotretinoin) Coronavirus disease 19 infection standard therapy alone, Variable regimens including ascorbic acid , azithromycin , cis-retinoic acid , clarithromycin , cyanocobalamin , hydroxychloroquine , lopinavir , oseltamivir , paracetamol , ritonavir Cytochrome P450 3A4 inhibitor, Exo-alpha sialidase inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kafrelsheikh University Egypt 2020-04-30 2020-06-30 , PROPOSED BY MAHMOUD ELKAZZAZ, NCT04353180 Phase 3 Clinical Recruiting 1 2 Months 45 Dr.Tamer Hydara, Doctor of internal medicine, M.Sc. Mahmoud Elkazzaz, M.Sc.Biochemistry, M.Sc.Mahmoud Elkazzaz, M.Sc.Biochemistry, Mahmoud Elkazzaz, M.Sc.of Biochemistry, Mahmoud Ramadan mohamed Elkazzaz 2020-04-27
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia anti-SARS-CoV-2 convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cedars-Sinai Medical Center Johns Hopkins University, University of Pittsburgh Medical Center US 2020-05-31 2021-05-31 ACUTE CARE CP CONSORTIUM TRIAL, NCT04353206 Phase 0 Clinical Not yet recruiting 0 12 Months 90 Akil Merchant, MD, Anders Berg, MD PhD, Catherine Le, MD, David Hager, MD PhD, David N Hager, MD PhD, Daving NG, MD, Ellen Klapper, MD, Eric Vail, MD, Jenny Van Eyk, PhD, Jillian Oft, MD, John F McDyer, MD, John McDyer, MD, Justin Darrah, MD, Noah Merin, MD PhD, Peter Chen, MD, Philip Cheng, MD, Rachel Zabner, MD 2020-04-22
A Phase II trial to evaluate the efficacy of Ryanodex in patients infected with SARS-CoV-2 Coronavirus disease 19 infection dantrolene sodium (heat stroke/malignant hyperthermia), Eagle Pharmaceuticals alone Calcium channel modulator Eagle Pharmaceuticals Inc Hackensack University Medical Center Phase 2 Clinical Planned 0 2020-04-21
PostCOVID19: Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System Coronavirus disease 19 infection, Heart disease, Respiratory disease, Viral pneumonia azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo Brazil 2020-06-01 2021-09-30 NCT04353245, PostCOVID19, UAP107 Phase Not Applicable Not yet recruiting 1 16 Months 130 Carlos Vicente Serrano 2020-04-22
Investigate the Aerosol Particle Distribution During Aerosol Generating Procedures Coronavirus disease 19 infection High-flow nasal cannula alone, Surgical mask alone, bronchoscopy examination alone, intubation alone, nebulization alone, tracheostomy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rush University Medical Center US 2020-04-20 2020-05-30 COVID19-AEROSOL, NCT04353531 Phase Not Applicable Not yet recruiting 0 1 Month 40 Jie Li, PhD 2020-04-22
Renal Outcome in Patients With COVID-19 Coronavirus disease 19 infection, End stage renal disease, Renal injury Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Giessen Germany 2020-04-30 2020-07-31 AZ 58/20, NCT04353583 Phase Not Applicable Not yet recruiting 1 3 Months 40 Faeq Husain-Syed, MD, Horst-Walter Birk, MD, Werner Seeger, MD 2020-04-25
ACEI-COVID: Stopping ACE-inhibitors in COVID-19 Coronavirus disease 19 infection ACE inhibitor/angiotensin receptor blocker alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medizinische Universität Innsbruck Ludwig-Maximilians University of Munich Austria, Germany 2020-04-15 2022-05-15 2020-001206-35, ACEI-COVID, ACEI-COVID, NCT04353596 Phase 4 Clinical Recruiting 18 25 Months 208 Andreas Knez, MD, Andreas May, MD, August Zabernigg, MD, Axel Bauer, MD, Clemens Wendnter, Dominik Wolf, MD, Florian Straube, MD, Gert Mayer, MD, Graziadei Ivo, MD, Günter Weiss, MD, Hannes Alber, MD, Hannes Gänzer, MD, Herbert Tilg, MD, Heribert Schunkert, MD, Julia Mayerle, MD, Karl-Ludwig Laugwitz, MD, Konstantinos Rizas, MD, Lorenz Bott-Flügerl, MD, Martin Reincke, Mathias Pauschinger, MD, Michael Bergwelt von, MD, Michael Joannidis, MD, Michael Schreinlechner, MD, Nikolay Vdovin, MD, Norbert Kaiser, MD, Peter Trenkwalder, MD, Steffen Massberg, MD, Ulrich Kreider-Stempfle, MD, Wöll Ewald, MD 2020-04-27
covid19 fai2r: Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases Autoinflammatory disease, Coronavirus disease 19 infection, Inflammatory disease, Rare immune disease Centre Hospitalier Regional Universitaire de Lille FAI²R (Auto-immune and auto-inflammatory rare diseases French network) France 2020-04-18 2020-12-31 NCT04353609, NI_2020_03, covid19 fai2r Phase Not Applicable Recruiting 2 8 Months 13770 Eric Hachulla, MD,PhD, Samira Plassart 2020-04-27
Modulation of Hyperinflammation in COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome leucocyte modulatory device (L-MOD) alone, slow low-efficiency daily dialysis alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Lawson Health Research Institute UK 2020-04-20 2021-01-01 115785, NCT04353674 Phase 1 Clinical Not yet recruiting 1 8 Months 40 Christopher W McIntyre, MD, Sandrine Lemoine, MD 2020-04-23
THICK: Trial of Hydroxychloroquine In Covid-19 Kinetics Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of South Alabama US 2020-04-17 2020-12-01 NCT04353271, THICK, [1582736-1] Phase 2/Phase 3 Clinical Recruiting 0 7 Months 58 Kate Ledbetter, RN, Wendy Blount, RN, MSN, William O Richards, MD 2020-04-23
Camostat Mesylate in COVID-19 Outpatients Coronavirus disease 19 infection camostat mesylate alone Serine protease inhibitor, Trypsin inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Yale University US 2020-04-30 2021-05-31 2000027971, NCT04353284 Phase 2a Clinical Not yet recruiting 0 13 Months 114 Joseph Vinetz, M.D. 2020-04-22
A multicenter, phase II, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of Vicromax in the treatment of patients with advanced COVID-19 Coronavirus disease 19 infection merimepodib alone Inosine monophosphate dehydrogenase inhibitor Biosig Technologies Inc US 2020-06-30 Phase 2 Clinical Planned 0 20 Andrew D. Badley 2020-04-28
CoSigS: COVID 19-Caregivers IGg Seroconversion Coronavirus disease 19 infection Blood sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Limoges France 2020-04-25 2020-12-25 87RI20_0016/COSIGS, CoSigS, NCT04353323 Phase Not Applicable Not yet recruiting 1 8 Months 130 Laurent FOURCADE, MD, Laurent Fourcade, MD, laurent.fourcade@unilim.fr 2020-04-22
Efficacy of Chloroquine in COVID-19 Treatment Coronavirus disease 19 infection chloroquine alone Tanta University Egypt 2020-04-17 2030-12-01 CHLOROQUINE COVID, NCT04353336 Phase 2/Phase 3 Clinical Not yet recruiting 1 127 Months 40 Sherief Abd-Elsalam, ass. prof., sherief Abd-Elsalam, Ass. Prof. 2020-04-22
CALYPSO: WGS Analysis Of SARS-COV-2 Positive Patients Coronavirus disease 19 infection whole genome sequencing alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Vanda Pharmaceuticals Inc Washington University School of Medicine, US US 2020-04-30 2020-12-31 CALYPSO, NCT04353401, VP-01-01 CALYPSO Phase Not Applicable Recruiting 0 8 Months 5000 2020-04-23
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19 Coronavirus disease 19 infection Mycobacterium w alone Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cadila Pharmaceuticals Ltd Council of Scientific and Industrial Research (India) 2020-04-30 2021-05-30 CRSC20005, NCT04353518 Phase 3 Clinical Not yet recruiting 0 13 Months 4000 Anil Avhad, MBBS, Sanjay Patel, MBBS 2020-04-23
Retrospective Study on surgical outcomes among surgical patients during the COVID-19 (SARS-CoV-2) Pandemic Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopital Tenon France 2020-04-22 ACTRN12620000498998 Phase Not Applicable Not yet recruiting 1 700 Dr Julien BUREY, Prof Christophe QUESNEL 2020-04-22
COVIDCONVERT: Study evaluating Coronavirus (COVID-19) nasal/oral swab results compared to blood antibody results in COVID-19 clinic patients Coronavirus disease 19 infection analysis of SARS-CoV-2 IgG, IgA and IgM antibody serum sample alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Albury Wodonga Health, Border Medical Oncology Australia 2020-04-07 ACTRN12620000487910, COVIDCONVERT Phase Not Applicable Recruiting 2 500 Dr Justin Jackson, Mrs Jacqui McBurnie 2020-04-22
A Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic Coronavirus disease 19 infection facebook delivered physical activity focused group lifestyle intervention alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of New South Wales Australia 2020-05-21 ACTRN12620000492954p Phase Not Applicable Not yet recruiting 8 20 A/Prof Simon Rosenbaum, Miss Grace McKeon 2020-04-21
COVIDCONVERT: Study evaluating Front-line health care workers serial blood COVID-19 antibody results in relation to symptom presentation Coronavirus disease 19 infection analysis of SARS-CoV-2 IgG, IgA and IgM antibody serum sample alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Albury Wodonga Health, Border Medical Oncology Australia 2020-04-07 ACTRN12620000493943, COVIDCONVERT Phase Not Applicable Recruiting 2 50 Dr Justin Jackson, Mrs Jacqui McBurnie 2020-04-22
COVIDSurgRCT-v1.0-20200330: Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 Coronavirus disease 19 infection Plaquenil plus lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University of Birmingham UK 2020-04-15 2020-001448-24, COVIDSurgRCT-v1.0-20200330, RG-20-029COVID-19 Phase 3 Clinical Recruiting 1 6400 Donna Smith 2020-04-22
COVID65plus: Test and Treat COVID65plus Coronavirus disease 19 infection, Respiratory tract infection hydroxychloroquine alone Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Tubingen Germany 2020-04-21 2021-05-01 COVID65PLUS, COVID65plus, NCT04351516 Phase 2/Phase 3 Clinical Recruiting 2 12 Months 350 Lukas Perkhofer, MD, Manola Zago, PhD, Michael Bitzer, MD, Siri Göpel, MD, Thomas Seufferlein, MD 2020-04-27
ReCovER: Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room Coronavirus disease 19 infection University of Cologne Germany 2020-04-20 2026-08-31 NCT04351854, RECOVER, ReCovER Phase Not Applicable Not yet recruiting 1 76 Months 500 Victor Suarez, MD, Volker Burst, Volker Burst, MD 2020-04-23
PRECISE: Prophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using Choloroquine Compounds Coronavirus disease 19 infection hydroxychloroquine sulfate alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Specialized Healthcare and Medical Education Department Beth Israel Deaconess Medical Center, Mayo Hospital, Pakistan Kidney and Liver Institute, Services Hospital, Lahore US 2020-04-15 2020-05-30 NBC-COVID1902, NCT04351191, PRECISE Phase 4 Clinical Not yet recruiting 0 1 Month 400 Ammar Sarwar 2020-04-20
ACTICOV-2: Immunological Profiling of Patients With COVID-19 in Respiratory Distress Coronavirus disease 19 infection, Respiratory distress syndrome immunological profiling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Nimes Institute of Human Genetics France 2020-04-30 2020-10-31 ACTICOV-2, NCT04351711, NIMAO/2020-01/PC-01 Phase Not Applicable Not yet recruiting 1 6 Months 60 Albert Sotto, Anissa Megzari, Jean-Yves Lefrant, Laurent Muller, Monsef Benkirane, Pierre Corbeau, Tu Anh Tran 2020-04-21
DARTS: Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak) Coronavirus disease 19 infection ELISA assay alone, RT-PCR alone, lateral flow assay alone, point-of-care test alone, point-of-need test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) St Georges University of London UK 2020-04-15 2022-04-15 2020.0075, DARTS, NCT04351646 Phase Not Applicable Not yet recruiting 1 24 Months 500 Timothy D Planche, Dr. 2020-04-21
OsPsyCOVID: Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak Coronavirus disease 19 infection, Osteoporosis Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-12-31 2020-A00911-38, EQ_2020_03, NCT04351633, OsPsyCOVID Phase Not Applicable Not yet recruiting 1 8 Months 50 Bernard Cortet, MD,PhD 2020-04-24
Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics Coronavirus disease 19 infection social media usage alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Assiut University Egypt 2020-04-30 2020-08-31 2020A20, NCT04351568 Phase Not Applicable Not yet recruiting 1 4 Months 874 Noha Esmael Ebrahem 2020-04-20
Phase III Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia lenzilumab alone, standard of care alone GM-CSF ligand inhibitor, Immunoglobulin G1 modulator, Immunoglobulin kappa modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Humanigen Inc 2020-05-31 2020-09-30 HGEN003-06, NCT04351152 Phase 3 Clinical Not yet recruiting 0 4 Months 238 CTI Clinical Trial & Consulting Services (CRO), Cameron Durrant, MD, Omar Ahmed, PharmD 2020-04-20
A phase I/II clinical trial to examine an oral solution of nafamostat in preventing or reducing the lethal outcome of COVID-19 infection Coronavirus disease 19 infection nafamostat mesylate (oral/MPAR/abuse-resistant/repurposed, COVID-19), Ensysce Biosciences alone Serine protease inhibitor Ensysce Biosciences Inc US Phase 1/Phase 2 Clinical Planned 0 2020-04-21
ReCOVery-SIRIO: Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms Coronavirus disease 19 infection amiodarone alone, verapamil alone Calcium channel inhibitor, Potassium channel inhibitor, Sodium channel inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Nicolaus Copernicus University Poland 2020-04-27 2021-04-10 NCT04351763, NCU-COVID19, ReCOVery-SIRIO Phase 2/Phase 3 Clinical Recruiting 1 11 Months 804 Eliano Pio Navarese, Jacek Kubica, MD, PhD, Prof. Eliano P Navarese, MD, PhD, Prof. Jacek Kubica, MD, PhD 2020-04-20
Efficacy of Favipiravir in COVID-19 Treatment Coronavirus disease 19 infection favipiravir alone RNA polymerase inhibitor Tanta University Egypt 2020-04-17 2030-12-01 FAVIPREVIR COVID, NCT04351295 Phase 2/Phase 3 Clinical Not yet recruiting 1 127 Months 40 Sherief Abd-Elsalam, ass. prof., sherief Abd-Elsalam, Ass. Prof. 2020-04-22
Multicenter, prospective, cohort study evaluating outcome of COVID-19 in patients with hepatobiliary-pancreatic disease Cholangiocarcinoma, Coronavirus disease 19 infection, Hepatobiliary disease, Liver cirrhosis, Liver disease, Liver tumor, Pancreas disease, Pancreas tumor School of Medicine, Keio University Japan 2020-04-17 UMIN000040185 Phase Not Applicable Recruiting 1 600 Nobuhiro Nakamoto, Nobuhito Taniki 2020-04-22
A case-series study to assess the effect of Intravenous Immunoglobulin in treating COVID-19 infection Coronavirus disease 19 infection intravenous immunoglobulin alone Wuhan Jinyintan Hospital China Phase Not Applicable Status not specified 1 3 2020-04-22
COVERAGE: Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) Coronavirus disease 19 infection favipiravir alone, home treatment alone, hydroxychloroquine alone, imatinib alone, telmisartan alone Abl tyrosine kinase inhibitor, Angiotensin II receptor antagonist, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, RNA polymerase inhibitor, Signal transduction inhibitor Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Bordeaux Universite de Bordeaux France 2020-04-15 2020-08-15 2020-001435-27, CHUBX 2020/12, COVERAGE, NCT04356495 Phase 3 Clinical Not yet recruiting 2 4 Months 1057 Denis MALVY, Pr, Laura RICHERT, Dr, Xavier ANGLARET, Dr 2020-04-23
A case-study to assess the effect of Intravenous Immunoglobulin (IVIG) for the treament of COVID-19 infection Coronavirus disease 19 infection Intravenous Immunoglobulin alone Sharp Memorial Hospital US Phase Not Applicable Status not specified 0 1 George Sakoulas, M.D 2020-04-23
CounterCovid: Countering Lung Damage in COVID-19 infection Coronavirus disease 19 infection imatinib alone Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Amsterdam UMC Netherlands 2020-03-31 2020-001236-10, COVID-19, CounterCovid Phase 2 Clinical No longer recruiting 1 304 Jurjan Aman 2020-04-23
Double Therapy With IFN-beta 1b and Hydroxychloroquine Coronavirus disease 19 infection standard care alone, hydroxychloroquine plus interferon beta-1b Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University of Hong Kong Hong Kong 2020-04-09 2022-07-31 NCT04350281, UW 20-211 Phase 2 Clinical Recruiting 1 27 Months 80 Ivan FN Hung, MD FRCP, Kelvin KW To, MD FRCPath, Kelvin To, MD MRCP 2020-04-21
An Investigator-initiated, Randomized, Open-Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection Coronavirus disease 19 infection intravenous immunoglobulin alone, standard of care alone Sharp Memorial Hospital Octapharma AG US Phase Not Applicable Status not specified 0 20 George Sakoulas, M.D. 2020-04-22
Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multicenter Clinical Research Coronavirus disease 19 infection, Viral pneumonia COVID-19 Intelligent Assistant Analysis System alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Union Hospital Tongji Medical School Huazhong University Of Science & Technology China 2020-05-01 2022-04-30 ChiCTR2000032010 Phase Not Applicable Not yet recruiting 1 24 Months Fan Yang, Wenliang Fan 2020-04-22
Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease Coronavirus disease 19 infection, Liver disease, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Renji Hospital China 2020-04-17 2020-04-23 ChiCTR2000032009 Phase Not Applicable Not yet recruiting 1 30 Xiao Xiao, Xiong Ma 2020-04-22
Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19 Coronavirus disease 19 infection Copenhagen Bacillus Calmette-Guerin vaccine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ain Shams University Egypt 2020-04-20 2020-12-01 FMASU P19A/ 2020, NCT04350931 Phase 3 Clinical Not yet recruiting 2 7 Months 900 Adel Khattab, Fatma Soliman E Ebeid, Fatma Soliman E Ebeid, MD, Iman Hassan, MD 2020-04-23
Efficacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Hypoxia, Viral pneumonia hyperbaric oxygen therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Navy General Hospital, Wuhan Huoshenshan Hospital China 2020-04-17 2020-05-17 ChiCTR2000032011 Phase 0 Clinical Not yet recruiting 1 1 Month 45 Dazhi Guo, Shuyi Pan 2020-04-22
Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia deep sedation therapy alone, neuromuscular blocker therapy alone, tidal volume therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-03-18 2020-12-31 2030/31, NCT04350710 Phase Not Applicable Recruiting 1 9 Months 50 Francois BELONCLE, MCU-PH, François BELONCLE, MCU PH 2020-04-21
DARE-19: Dapagliflozin in Respiratory Failure in Patients With COVID-19 Coronavirus disease 19 infection, Respiratory failure dapagliflozin propanediol alone Sodium glucose transporter-2 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Saint Luke's Health System AstraZeneca plc, George Clinical Pty Ltd Europe, US 2020-04-15 2020-12-31 D1690C00081, DARE-19, ESR-20-20653, NCT04350593 Phase 3 Clinical Recruiting 0 8 Months 900 Mikhail Kosiborod, MD, Mikhail N Kosiborod, Sheryl Windsor, Study Coordinator 2020-04-27
COR-DLUS: Coronavirus (COVID-19) Diagnostic Lung Ultrasound Study Coronavirus disease 19 infection, Lung disease PCR testing alone, blood tests alone, chest x-ray alone, lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Plymouth NHS Trust UK 2020-04-20 2021-01-20 282661, COR-DLUS, NCT04351802 Phase Not Applicable Not yet recruiting 1 9 Months 180 John P Corcoran, BMBCh MRCP, UHPNT Research & Development Office 2020-04-21
IB1aIC: Interferon Beta-1a in Hospitalized COVID-19 Patients Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , interferon beta-1a , lopinavir + ritonavir HIV protease inhibitor Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-15 2020-04-24 IB1aIC, INTERFERON BETA 1A IN COVID-19, NCT04350671 Phase 4 Clinical Recruiting 1 40 Ilad Alavi Darazam, MD, Minoosh Shabani, MD, Mohammadreza Haji Esmaelie, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA, Shervin Shokouhi, MD 2020-04-21
UAIIC: Umifenovir in Hospitalized COVID-19 Patients Coronavirus disease 19 infection standards of care alone, Variable regimens including hydroxychloroquine , interferon-beta 1a , lopinavir + ritonavir , umifenovir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-15 2020-04-24 NCT04350684, UAIIC, UMIFENOVIR IN COVID-19 Phase 4 Clinical Recruiting 1 40 Ilad Alavi Darazam, MD, Latif Gachkar, MD, Mahdi Amirdosara, MD, Masoud Mardani, MD, Minoosh Shabani, MD, Mohammadreza Haji Esmaelie, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA, Shervin Shokouhi, MD 2020-04-21
COVID-GYN: Impact of the COVID-19 Pandemic in Gynecological Oncology Breast tumor, Coronavirus disease 19 infection, Ovary tumor, Uterine cervix tumor, Uterus tumor, Vaginal cancer, Vulva disease modification of planned therapeutic management alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospices Civils De Lyon France 2020-04-30 2020-05-31 2020-A01036-33, 69HCL20_0346, COVID-GYN, NCT04351139 Phase Not Applicable Not yet recruiting 3 1 Month 400 François Golfier, MD, Gil Dubernard, MD, Géry LAMBLIN, Géry LAMBLIN, MD, Marion Cortet, MD 2020-04-27
Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) DRK-Blutspendedienst Baden-Wurttemberg-Hessen GmbH German Ministry of Health Germany 2020-04-06 2020-001310-38, CAPSID2020-DRK-BSD Phase 2 Clinical Recruiting 1 120 Sixten Körper 2020-04-27
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome Coronavirus disease 19 infection, Renal injury, Respiratory distress syndrome extracorporeal CO2 removal (ECCO2R) therapy alone, multiFiltrate device alone, renal replacement therapy (RRT) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Giessen Germany 2020-04-30 2020-05-31 AZ 63/20, NCT04351906 Phase Not Applicable Not yet recruiting 1 1 Month 20 Faeq Husain-Syed, MD, Istvan Vadasz, MD, Werner Seeger, MD 2020-04-28
The effects of the COVID-19 pandemic on mental health Acute stress disorder, Coronavirus disease 19 infection, Psychiatric disorder interview alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum der Albert-Ludwigs Universitaet Freiburg Germany 2020-04-20 174/20, DRKS00021395 Phase Not Applicable Not yet recruiting 1 60 Prisca Bauer 2020-04-21
PRPsyCOVID: Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak Coronavirus disease 19 infection, Rheumatoid arthritis questionnaire assesment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-12-31 2020-A00907-32, EQ_2020_01, NCT04351399, PRPsyCOVID Phase Not Applicable Not yet recruiting 1 8 Months 100 René-Marc FLIPO, MD,PhD 2020-04-22
Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Montefiore Medical Center US 2020-04-30 2020-08-31 2020-11445, NCT04350450 Phase 2 Clinical Not yet recruiting 0 4 Months 100 Priya Nori, MD, Yi Guo, PharmD 2020-04-22
PROLIFIC Trial (COVID-19): Preventative Drug Treatment For COVID-19 Infectious Disease Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cambridge University Hospitals NHS Foundation Trust Evolution Education Trust UK 2020-04-14 2020-001331-26, NCT00000000, PROLIFIC Trial (COVID-19), PROLIFIC2020 Phase 3 Clinical Recruiting 1 1000 Carrie Bayliss 2020-04-21
COL-COVID: Randomized, Open-blind, Controlled Trial to Study the Benefit of Colchicine in Patients With COVID-19 Coronavirus disease 19 infection colchicine alone, standard therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) Spain 2020-04-20 2020-11-20 COL-COVID, IMIB-COLVID-2020-03, NCT04350320 Phase 3 Clinical Not yet recruiting 1 7 Months 102 Domingo A Pascual Figal, MD, Elisa García Vazquez 2020-04-21
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment Coronavirus disease 19 infection chloroquine alone, Variable regimens including chloroquine , ivermectin , nitazoxanide Chloride channel modulator Tanta University Egypt 2020-04-17 2030-12-01 IVERMECIN COVID, NCT04351347 Phase 2/Phase 3 Clinical Not yet recruiting 1 127 Months 60 Sherief Abd-Elsalam, ass. prof., sherief Abd-Elsalam, Ass. Prof. 2020-04-21
ZnD3-Cov-Vici: Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome 25-OH cholecalciferol plus zinc gluconate Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-07-31 2020-A00873-36, 2020_30, NCT04351490, ZnD3-Cov-Vici Phase Not Applicable Not yet recruiting 1 3 Months 3140 David SEGUY, MD,PhD 2020-04-22
The effect of MCT Oil on COVID-19 Coronavirus disease 19 infection advice base on traditional medicine instructions alone, medium-chain triglyceride therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Kerman University of Medical Sciences Iran 2020-04-02 IR.KMU.REC.1399.019, IRCT20160313027033N2 Phase Not Applicable Recruiting 1 120 Alireza Zahedi Neyestani, Mahdiyehsadat Eftekharafzali, Mohammad Setayesh 2020-04-23
ACOVACT: Austrian Coronavirus Adaptive Clinical Trial Coronavirus disease 19 infection candesartan alone, chloroquine alone, clazakizumab alone, lopinavir + ritonavir alone, rivaroxaban alone, chloroquine plus hydroxychloroquine Angiotensin II receptor antagonist, Factor Xa antagonist, HIV protease inhibitor, IL-6 receptor antagonist Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Vienna Donauspital, Hospital Hietzing Hanuschkrankenhaus, Kaiser Franz Josef Spital, Medizinische Universität Innsbruck, Otto Wagner Hospital, Wilhelminenspital Vienna Austria 2020-04-16 2020-12-31 ACOVACT, ACOVACT, NCT04351724 Phase 2/Phase 3 Clinical Recruiting 6 8 Months 500 Alexander Zoufaly, MD, Bernd Jilma, MD, Brigitte Schmied, MD, Christian Schörgenhofer, MD, PHD, Georg-Christian Funk, MD, Günter Weiss, MD, Kurt Redlich, MD, Thomas Stefenelli, MD 2020-04-21
A trial to evaluate XAV-19 for the treatment of patients with COVID-19 infection Coronavirus disease 19 infection XAV-19 alone Xenothera Phase Not Applicable Planned 0 2020-04-20
ICAR: Polyvalent Immunoglobulin in COVID-19 Related ARDS Coronavirus disease 19 infection, Respiratory distress syndrome Clairyg alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Centre Hospitalier Sainte Anne IFSI Virginia Olivier Sainte-Anne Hospital, LFB SA, Ministry of Social Affairs and Health, France France 2020-04-11 2020-08-31 2020-001570-30, D20-P013, ICAR, NCT04350580 Phase 3 Clinical Recruiting 1 4 Months 138 AWASSI, Aurélien Mazeraud, MD PHD, Aurélien Mazeraud, MD, PHD, Tarek Sharshar, MD, PHD 2020-04-28
Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized, controlled trial Coronavirus disease 19 infection Variable regimens including azithromycin , chloroquine , hydroxychloroquine Yokohama City University North America, Japan 2020-04-17 UMIN000040188 Phase Not Applicable Not yet recruiting 1 Nobuyuki Horita 2020-04-21
A Phase III trial of mRNA-1273 for Coronavirus disease 19 infection Coronavirus disease 19 infection mRNA-1273 alone Moesin modulator ModeRNA Therapeutics Phase 3 Clinical Planned 0 2020-04-20
COVID+PA: Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID-19(+) Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Abderrahmane Mami Hospital Dacima Consulting, Eshmoun Clinical Research Centre Tunisia 2020-04-15 2020-07-15 COVID+PA, ECC2020-04, NCT04351919 Phase 4 Clinical Not yet recruiting 1 3 Months 400 Chokri Jeribi, Dr, Dr Jalila Ben Khelil, Eshmoun team 2020-04-22
Austrian COVID-19 Registry Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Arbeitsgemeinschaft Medikamentoese Tumortherapie Austria 2020-04-01 2021-12-31 AGMT_COVID-19, NCT04351529 Phase Not Applicable Recruiting 1 21 Months 1000 Daniela Wolkersdorfer, Dr., Richard Greil, MD, Stephanie Esmaeilzadeh-Leithner, MSc. 2020-04-21
Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T-Cells in Patients With Severe COVID-19 Coronavirus disease 19 infection SARS-CoV-2 specific T-cells alone, convalescent donor blood donation alone, leukapheresis alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) KK Women's and Children's Hospital National University Hospital (Singapore) Pte Ltd, Singapore General Hospital Pte Ltd Singapore 2020-04-30 2020-08-31 COVID-T 1.0, NCT04351659 Phase Not Applicable Recruiting 2 4 Months 8 Lip Kun Tan, Michaela Seng, Wing Hang Leung, Yeh Ching Linn 2020-04-21
BREATHE: A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome gimsilumab alone GM-CSF ligand inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Kinevant Sciences GmbH, Roivant Sciences Ltd US 2020-04-30 2020-10-31 BREATHE, KIN-1901-2001, NCT04351243 Phase 2 Clinical Recruiting 0 6 Months 270 Arnaud Bastien, MD, Dr. Gerard Criner, Mathews, MD, Puja Dubal 2020-04-22
High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 Asthma, Bronchiectasis, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Cough, Cystic fibrosis, Fatigue, Headache, Interstitial lung disease, Lung tumor, Myalgia, Nasal congestion, Pharyngitis, Pulmonary hypertension, Sleep apnea, Upper respiratory tract infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-30 2020-06-30 IRB20-0572, NCT04351620 Phase 1 Clinical Recruiting 0 2 Months 20 Iazsmin Ventura, MD, Reem Jan, Reem Jan, MBBS BSc 2020-04-21
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19 Coronavirus disease 19 infection bioolgical sampling alone, whole genome sequencing alone Healthy volunteers accepted University Hospital Basel Leonhard Med IT ETH Zurich, Swiss Institute Of Bioinformatics, sciCORE University of Basel Switzerland 2020-04-09 2022-04-30 2020-00769, NCT04351503, QU20EGLI2 Phase Not Applicable Recruiting 6 24 Months 10000 Adrian Egli, Prof. Dr. med, Adrian Egli, Prof. Dr. med., Aitana Lebrand, Dr. med., Andreas Buser, Prof. Dr. med, Bram Stieltjes, Dr. med, Diana Ciardo, Dr. med, Hans Hirsch, Prof. Dr. med., Hans Pargger, Prof. Dr. med, Karsten Borgwardt, Prof.Dr. med, Richard Neher, Prof. Dr. med, Roland Bingisser, Prof. Dr. med, Sarah Tschudin- Sutter, Prof. Dr. med., Stefano Bassetti, Prof. Dr. med., Thierry Sengstag, Dr., Valérie Barbié, Dr. med, Valérie Barbié, Dr. med. 2020-04-28
A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Variable regimens including Ma-Xing-Shi-Gan tang , Yin-Qiao powder , thymosin a1 Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) The Affiliated Hospital of Guangdong Medical College Zhanjiang municipal bureau of science and technology China 2020-03-01 2020-08-01 ChiCTR2000032040, ChiMCTR2000003220 Phase Not Applicable Recruiting 1 5 Months 30 Huang Jianan, Zhang Yuanli 2020-04-21
Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Danggui Shaoyao Powder alone, western medicine therapy alone Union Hospital Tongji Medical School Huazhong University Of Science & Technology China 2020-01-20 2020-07-31 ChiCTR2000032098, ChiMCTR2000003225 Phase Not Applicable Recruiting 1 6 Months 300 Liu yuhan, Yang shenglan 2020-04-21
The effect of hydroxychloroquine to prevent coronavirus disease Coronavirus disease 19 infection Quarantine alone, hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Iran University of Medical Sciences Iran 2020-04-20 IR.IUMS.REC.1399.076, IRCT20190122042450N4 Phase 3 Clinical Recruiting 1 1000 Dr. Abbas Motavallian, Fereshteh Abdolmaleki, Mohammad Ebrahim Khamseh 2020-04-21
A retrospective, observational study to assess neurological manifestations of hospitalized patients With COVID-19 in Wuhan, China Coronavirus disease 19 infection Wuhan Union Hospital, China China Phase Not Applicable Status not specified 1 214 2020-04-20
A clinical study to assess itanapraced in the treatment of COVID-19 patients showing evidence of brain infection Brain disease, Coronavirus disease 19 infection itanapraced alone Amyloid protein deposition inhibitor, Gamma-secretase inhibitor CereSpir Inc Phase Not Applicable Planned 0 2020-04-20
An open-label clinical study to assess inhaled nitric oxide (NO) delivered through LungFit system in the treatment of patients with COVID-19 Coronavirus disease 19 infection LungFit system alone, nitric oxide (inhalant formulation, cystic fibrosis/COVID-19/bronchiolitis/NTM/COPD/pulmonary hypertension), Beyond Air alone Beyond Air Inc Israel Phase Not Applicable Planned 1 2020-04-20
An open-label clinical study to assess inhaled nitric oxide (NO) delivered using LungFit system in the treatment of patients with COVID-19 Coronavirus disease 19 infection LungFit system alone, nitric oxide (inhalant formulation, cystic fibrosis/COVID-19/bronchiolitis/NTM/COPD/pulmonary hypertension), Beyond Air alone Beyond Air Inc Canada Phase Not Applicable Planned 1 2020-04-20
COVID-19 Remote Monitoring Coronavirus disease 19 infection, Heart arrhythmia VitalConnect Vital Sign Patch alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mount Sinai Medical Center US 2020-04-30 2021-04-30 GCO 20-0932, NCT04350476 Phase Not Applicable Not yet recruiting 0 12 Months 1000 Betsy Ellsworth, ANP, Martin Goldman, MD, Sam Cammack, Sam Cammack, MA, MPH, Vivek Y Reddy, MD 2020-04-21
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 Acute lung injury, Coronavirus disease 19 infection TD-0903 alone JAK tyrosine kinase inhibitor Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Theravance Biopharma Inc UK 2020-04-30 2020-06-30 0183, 2020-000577-24, NCT04350736 Phase 1 Clinical Not yet recruiting 1 2 Months 54 Medical Monitor, Theravance Biopharma Call Center 2020-04-27
Lung ultrasound versus CT scan in COVID-19 disease Coronavirus disease 19 infection, Viral pneumonia Lung UltraSound alone, low-dose CT-scan alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Radboudumc Netherlands 2020-03-15 2020-06-30 2020-6372, NL8497 Phase Not Applicable Recruiting 1 3 Months 200 Frank Bosch 2020-04-20
BADAS: BCG Vaccine for Health Care Workers as Defense Against COVID 19 Coronavirus disease 19 infection BCG vaccine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Texas A&M University System Baylor College of Medicine, Cedars-Sinai Medical Center, Harvard University, MD Anderson Cancer Center US 2020-04-20 2021-11-30 2020-0432F, BADAS, H-47454, NCT04348370 Phase 4 Clinical Recruiting 0 19 Months 1800 Andrew DiNardo, MD, Anna Mandalakas, MD, Ashish Kamat, MD, Ashish M Kamat, MD, Gabriel A Neal, MD, George Udeani, PharmD, Jeffrey D Cirillo, PhD, Marisa Lozano, Megan D Murray, MD, MPH, Megan Murray, MD, MPH, Moshe Arditi, MD, Pablo Avalos, MD, Seth Lerner, MD 2020-04-28
CounterCovid19: Countering Lung Damage in COVID-19 infection (CounterCovid) studyCountering Lung Damage in COVID-19 infection study Coronavirus disease 19 infection, Lung injury imatinib alone Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Amsterdam UMC Netherlands 2020-03-31 2020-06-30 2020.158, CounterCovid19, NL8491 Phase 3 Clinical Recruiting 1 3 Months 386 Harm Jan Bogaard 2020-04-17
PVC-RAM: Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial Coronavirus disease 19 infection Virtual Care and Remote Automated Monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Population Health Research Institute Hamilton Health Sciences Corp, McMaster University Canada 2020-04-30 2020-09-30 NCT04344665, PVC-RAM, V1.0, 2020.04.06 Phase Not Applicable Not yet recruiting 2 5 Months 900 Michael McGillion, PhD, PJ Devereaux, PhD, Valerie Harvey, BSc 2020-04-17
LUS-CC: Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients Coronavirus disease 19 infection, Viral pneumonia Lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Radboudumc Netherlands 2020-03-15 2020-05-31 2020-6371, LUS-CC, NL8498 Phase Not Applicable Recruiting 1 2 Months 20 Frank Bosch 2020-04-22
Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak Coronavirus disease 19 infection Ayurveda Self-Management alone, Yoga breathing alone, paracetamol alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Aarogyam UK UK 2020-02-26 2020-03-30 AU08, NCT04345549 Phase Not Applicable Completed 1 1 Month 18 Jaydeep Joshi, Neha Sharma 2020-04-17
CATNAP: COVID-19 smartphone-based Trial of Non-ICU Admission Prone Positioning Coronavirus disease 19 infection Self-prone position recommendation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Boston University US 2020-04-30 2020-07-31 CATNAP, H-40070, NCT04344587 Phase Not Applicable Recruiting 0 3 Months 380 Allan J Walkey, MD 2020-04-27
LEEP-COVID: Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 Coronavirus disease 19 infection, Respiratory failure Multifrequency Bioimpedance Spectroscopy alone, Q-NRG metabolic cart device alone, muscle sound ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University US 2020-04-20 2020-12-01 LEEP-COVID, NCT04350073, PRO00105221 Phase Not Applicable Recruiting 0 7 Months 120 Jeroen Molinger, Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM, Paul Wischmeyer, MD, EDIC, FASPEN, FCCM 2020-04-23
ReportAge-COVID: Clinical and Biological Predictors of COVID-19 Disease in Older Patients Coronavirus disease 19 infection Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istituto Nazionale di Ricovero e Cura per Anziani Italy 2020-04-30 2020-12-31 INRCA_01_2020, NCT04348396, ReportAge-COVID Phase Not Applicable Not yet recruiting 1 8 Months 300 Antonio Cherubini, MD, Silvia Bustacchini, MD 2020-04-20
UPSAT: Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation Coronavirus disease 19 infection, Hypoxia, Respiratory failure postural positioning alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Johns Hopkins University US 2020-04-20 2021-05-31 IRB00246834, NCT04344561, UPSAT Phase Not Applicable Not yet recruiting 0 13 Months 70 Luu Pham, MD, Trishul Siddharthan, MD 2020-04-17
COVIDIMMUNE: Evaluating the Immune Response for COVID-19 Coronavirus disease 19 infection 2019-NCoV IgM/IgG (MAGLUMI) alone, Anti-SARS-CoV-2 (EuroImmun) alone, COVID-19 IgM/IgG (DIA PRO) alone, Coronavirus COVID-19 IgG ELISA (IBL) alone, Immunocomb (BioGal) alone, NADAL COVID-19 IgG/Igm (Nal Von Minden) alone, Rt-PCR kit alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assaf-Harofeh Medical Center Israel 2020-04-20 2020-12-31 105-20-ASF, COVIDIMMUNE, NCT04348422 Phase Not Applicable Not yet recruiting 1 8 Months 1000 Amir Hadanny, MD, Prof. Shay Efrati, Shai Efrati, MD 2020-04-22
Saved From COVID-19 Coronavirus disease 19 infection chloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Columbia University US 2020-04-30 2021-04-30 AAAS9992, NCT04349371 Phase 2 Clinical Recruiting 0 12 Months 350 Anca Askanase, MD, MPH, Anca D. Askanase, MD, MPH, Deborah A Theodore, MD, Tommy Chen, Yevgeniya Gartshyten, MD 2020-04-22
PRODEX: Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection Coronavirus disease 19 infection, Respiratory failure dexmedetomidine alone Alpha 2 adrenoceptor agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Limoges France 2020-04-20 2020-11-20 87RI20_0011 (PRODEX), NCT04350086, PRODEX Phase 4 Clinical Not yet recruiting 1 7 Months 10 Paul-Antoine QUESNEL, MD 2020-04-21
Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Renal injury, Viral pneumonia Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Shanghai Jiao Tong University China 2020-03-10 2022-12-31 ChiCTR2000031705 Phase Not Applicable Recruiting 1 33 Months 200 Ying Fan 2020-04-22
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc Hope Biosciences Stem Cell Research Foundation US 2020-04-23 2021-04-30 ALLOGENEIC COVID-19 PROTECTION, NCT04348435 Phase 2 Clinical Recruiting 0 12 Months 100 Thanh Cheng, MD 2020-04-27
Telerehabilitation for Patients Diagnosed With Coronavirus Coronavirus disease 19 infection Telerehabilitation alone, exercise brochure alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Istinye Universitesi 2020-04-10 2020-07-31 009, NCT04346927 Phase Not Applicable Not yet recruiting 0 3 Months 30 Yasemin Çırak 2020-04-20
Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Shanghai East Hospital China 2020-03-01 2020-04-30 ChiCTR2000031707 Phase Not Applicable Recruiting 1 2 Months 47 Chen Li 2020-04-20
Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine Coronavirus disease 19 infection, Viral pneumonia Traditional Chinese medicine sachet alone, general basic epidemic prevention measures alone, oral and nasal spray alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Beijing institute of Traditional Chinese Medicine China 2020-04-01 2020-12-31 ChiCTR2000031955 Phase 0 Clinical Recruiting 1 9 Months 3808 Lingru Li 2020-04-20
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azidus Brasil Brazil 2020-04-20 2020-07-31 HIAPRE0420OR, NCT04348474 Phase 0 Clinical Suspended 1 3 Months 200 2020-04-23
Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people Coronavirus disease 19 infection, Viral pneumonia Ke-Gan-Li-Yan oral liquid alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Fifth Affiliated Hospital, Sun Yat-Sen University China 2020-04-01 2020-08-31 ChiCTR2000031982, ChiMCTR2000003216 Phase 4 Clinical Not yet recruiting 1 5 Months 240 Hu Guanying, Huang Mingxing 2020-04-21
Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs Coronavirus disease 19 infection, Viral pneumonia Asian Ancestry Fujian Provincial Hospital China 2020-02-05 2020-02-10 ChiCTR2000031896 Phase Not Applicable No longer recruiting 1 923 Miao Xing 2020-04-21
Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community Coronavirus disease 19 infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chinese University of Hong Kong Health and Medical Research Fund, Hong Kong China 2020-04-15 2021-04-14 ChiCTR2000031928 Phase Not Applicable Not yet recruiting 1 12 Months 3000 Peter Choi Ching Lam, Prof. KS Chan Paul 2020-04-21
POINT-C: ICU Trial in Critical Ill COVID-19 Patients Cardiovascular disease, Coronavirus disease 19 infection blood sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Graz Austria 2020-04-08 2020-07-31 250320, NCT04349982, POINT-C Phase Not Applicable Recruiting 1 3 Months 50 Christoph Klivinyi, Dr., Martin Rief, Dr, Martin Rief, Dr. 2020-04-21
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc Hope Biosciences Stem Cell Research Foundation US 2020-04-16 2020-12-31 NCT04349631, PROTECTION AGAINST COVID-19 Phase 2 Clinical Recruiting 0 8 Months 56 Thanh Cheng, MD 2020-04-27
Resi-CoV: Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort Coronavirus disease 19 infection CD-RISC 25 questionnaire alone Healthy volunteers accepted University Hospital, Angers 2020-04-15 2020-05-25 2020-A00831-39, NCT04349163, Resi-CoV Phase Not Applicable Not yet recruiting 0 1 Month 280 Delphine Douillet, Delphine Douillet, MD 2020-04-21
A COVID-19 Symptom, Exposure and Immune Response Registry Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) ObvioHealth 2020-04-20 2021-05-01 NCT04348942, OBVIO-OBV-001 Phase Not Applicable Not yet recruiting 0 12 Months 10000 Jalisa Watson, MHA, Parth Shah, MD 2020-04-25
Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National Institute of Dental and Craniofacial Research National Institutes of Health Clinical Center US 2020-04-16 2020-07-01 20-D-0094, 200094, NCT04348240 Phase Not Applicable Recruiting 0 2 Months 60 Blake M Warner, D.D.S., Eileen M Pelayo 2020-04-28
APPROVE-CARE: Awake Prone Positioning to Reduce Invasive Ventilation in COVID-19 Induced Acute Respiratory failure Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure Prone positioning alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University College Galway Ireland 2020-04-11 2021-05-11 APPROVE-CARE, APPROVE-CARE-2020, NCT04347941 Phase Not Applicable Not yet recruiting 1 13 Months 200 Bairbre A McNicholas, MB BCh PhD, David Cosgrave, MB BCh FARSI 2020-04-24
Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 Coronavirus disease 19 infection nitazoxanide alone, standard care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azidus Brasil Centro De Genomas, Emilio Ribas Infectious Diseases Institute, Farmoquimica SA, Hospital Vera Cruz Brazil 2020-04-12 2020-06-30 NCT04348409, NITFQM0320OR Phase 2 Clinical Not yet recruiting 3 2 Months 50 Florentino de Araujo Cardoso Filho, Florentino de Araujo Cardoso Filho, MD, PhD, Luciana Ferrara, Ricardo Diaz, MD, PhD, Sérgio Cimerman, MD, PhD 2020-04-23
CoPE It: An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection CoPE It training alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinik für Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen, Universität Duisburg-Essen Germany 2020-04-23 20-9243-BO, CoPE It, DRKS00021301 Phase Not Applicable Not yet recruiting 2 90 Alexander Bäuerle, Martin Teufel 2020-04-27
Analysis of clinical characteristics and therapeutic effect of nine cases of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Affiliated Hospital of Zunyi Medical College National Natural Science Foundation of China China 2019-12-31 2020-03-01 ChiCTR2000031930 Phase Not Applicable No longer recruiting 1 2 Months 9 Chen Hongjun, Chen Miao 2020-04-21
An Open, Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19 Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome Variable regimens including Dalargin , azithromycin , hydroxychloroquine , tocilizumab Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Burnasyan Federal Medical Biophysical Center Russian Federation 2020-04-08 2020-12-31 DAL-05-04-2020, NCT04346693 Phase 3 Clinical Recruiting 1 8 Months 320 Tatyana Astrelina 2020-04-18
Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection Coronavirus disease 19 infection triiodothyronine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories Sa Attikon Hospital Greece 2020-05-02 2021-05-31 NCT04348513, T3INJ-02/THYSUPPORT, Thy-Support Phase 2 Clinical Not yet recruiting 1 12 Months 60 Apostolos Armaganidis, MD, Georgia Kostopanagiotou, MD 2020-04-18
Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Saint Etienne France 2020-03-30 2020-001281-11, 20CH065 Phase 4 Clinical Recruiting 1 50 project manager 2020-04-21
A potential clinical trial of SARS-CoV-2 3C-like (3CL) protease inhibitors for the potential iv treatment of COVID-19 caused by SARS-CoV-2 (2019-nCoV) Coronavirus disease 19 infection SARS-CoV-2 3C-like (3CL) protease inhibitors (Coronavirus disease 19 infection), Pfizer alone Protease inhibitor Pfizer Inc 2020-09-30 Phase Not Applicable Planned 0 2020-04-17
CORIPLASM: Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris Etablissement Francais du Sang France 2020-04-14 2020-06-01 2020-001246-18, APHP200375-10, CORIPLASM, NCT04345991 Phase 2 Clinical Not yet recruiting 1 1 Month 120 Karine LACOMBE 2020-04-21
Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): A Randomized Controlled Trial Coronavirus disease 19 infection, Viral pneumonia Chinese herbal tea alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) China Academy of Chinese Medical Sciences China 2020-04-16 2020-12-31 ChiCTR2000031944, ChiMCTR2000003212 Phase Not Applicable Recruiting 1 8 Months 2000 Liu Bin, Lu Cheng 2020-04-21